

APPENDIX

SELECTED WORLD WIDE WEB SITES

The following is a list of Web sites that readers may find useful. The sites have been visited at various times by one of the authors (RKM). Most are located in the USA, but many provide extensive links to international sites and to databases (eg, for protein and nucleic acid sequences) and online journals. RKM would be grateful if readers who find other useful sites would notify him of their URLs by e-mail (rmurray6745@rogers.com) so that they may be considered for inclusion in future editions of this text.

Readers should note that URLs may change or cease to exist.

ACCESS TO THE BIOMEDICAL LITERATURE

HighWire Press: <http://highwire.stanford.edu>

(Extensive lists of various classes of journals—biology, medicine, etc.—and offers also the most extensive list of journals with free online access.)

National Library of Medicine: <http://www.nlm.nih.gov/>

(Free access to Medline via PubMed.)

GENERAL RESOURCE SITES

The Biology Project (from the University of Arizona): <http://www.biology.arizona.edu/default.html>

Harvard Department of Molecular & Cellular Biology Links: <http://mcb.harvard.edu/BioLinks.html>

SITES ON SPECIFIC TOPICS

American Heart Association: <http://www.americanheart.org>

(Useful information on nutrition, on the role of various biomolecules—eg, cholesterol, lipoproteins—in heart disease, and on the major cardiovascular diseases.)

Cancer Genome Anatomy Project (CGAP): <http://www.ncbi.nlm.nih.gov/ncicgap>

(An interdisciplinary program to generate the information and technical tools needed to decipher the molecular anatomy of the cancer cell.)

European Bioinformatics Institute: http://www.ebi.ac.uk/ebi_home.html

(Maintains the EMBL Nucleotide and SWISS-PROT databases as well as other databases.)

GeneCards: <http://bioinformatics.weizmann.ac.il/cards/>

(A database of human genes, their products, and their involvements in diseases. From the Weizmann Institute of Science.)

GeneTestsGeneClinics: <http://www.geneclinics.org/>

(A medical genetics information resource with comprehensive articles on many genetic diseases.)

Genes and Disease: <http://www.ncbi.nlm.nih.gov/disease/>

(Coverage of the genetic basis of many different types of diseases.)

The Glycoscience Network (TGN): http://www.vei.co.uk/TGN/tgn_side.htm

(TGN is an informal worldwide grouping of scientists who share an interest in carbohydrates. The site contains considerable information on carbohydrates and an extensive list of links to other sites dealing with sugar-containing molecules.)

Howard Hughes Medical Institute: <http://www.hhmi.org/>

(An excellent site for following current biomedical research. Contains a comprehensive Research News Archive.)

The Human Gene Mutation Database: <http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html>

(An extensive tabulation of mutations in human genes from the Institute of Medical Genetics in Cardiff, Wales.)

Human Genome Project Information: <http://www.ornl.gov/hgmis/>

(From the Human Genome Program of the United States Department of Energy.)

The Institute for Genetic Research: <http://www.tigr.org/>

(Sequences of various bacterial genomes and other information.)

Karolinska Institute Nutritional and Metabolic Diseases: <http://www.mic.ki.se/Diseases/c18.html>

(Access to information on many nutritional and metabolic disorders.)

MITOMAP: <http://www.mitomap.org/>

(A human mitochondrial genome database.)

National Center for Biotechnology Information: <http://ncbi.nlm.nih.gov/>

(Information on molecular biology and how molecular processes affect human health and disease.)

National Human Genome Research Institute: <http://www.genome.gov/>

(Extensive information about the Human Genome Project.)

National Institutes of Health (NIH): <http://www.nih.gov/>

(Includes links to the separate Institutes and Centers that constitute NIH, covering a wide range of biomedical research.)

Neuroscience (Biosciences): <http://neuro.med.cornell.edu/VL/>

(A comprehensive list of neuroscience resources; part of the World-Wide Web Virtual Library.)

Office of Rare Diseases: http://rarediseases.info.nih.gov/index_main.html

(Access to information on more than 7000 rare diseases, including current research.)

OMIM Home Page—Online Mendelian Inheritance in Man: <http://www.ncbi.nlm.nih.gov/omim/>

(An extensive catalog of human genetic disorders, updated daily. Lists access to various allied resources.)

Protein Data Bank (PDB): <http://www.rcsb.org/pdb/>

(A worldwide repository for the processing and distribution of three-dimensional biologic macromolecular structure data.)

The Protein Kinase Resource: <http://pkr.sdsc.edu/html/index.shtml>

(Information on the protein kinase family of enzymes.)

The Protein Society: <http://www.faseb.org/protein/index.html>

(An extensive list of Web resources for protein scientists.)

Signaling Update: <http://www.signaling-update.org/>

(A one-stop overview for the specialist or nonspecialist of what is happening in cell signaling.)

Society for Endocrinology: <http://www.endocrinology.org>

(Aims to promote advancement of public education in endocrinology. Contains a number of articles on endocrinology and a list of links to other relevant sites.)

tbase—the Transgenic/Targeted Mutation Database at the Jackson Laboratory, Bar Harbor, Maine: <http://tbase.jax.org/>

(An attempt to organize information on transgenic animals and targeted mutations generated and analyzed worldwide.)

The Wellcome Trust Sanger Institute: <http://www.sanger.ac.uk>

(A genome research center whose purpose it is to increase knowledge of genomes, particularly through large-scale sequencing and analysis.)

Whitehead Institute/MIT Center for Genome Research: <http://www.genome.wi.mit.edu/>

(Access to various databases and articles entitled "What's New in Genome Research.")

Chapter 2

<http://www.geocities.com/bioelectrochemistry/sorensen.htm>

Chapter 3

<http://www.bio.cmu.edu/Courses/03231>

<http://www.bcbp.gu.se/~orjan/bmstruct/>

Chapter 4

<http://www.lundberg.bcbp.gu.se/~orjan/bmstruct/>

Chapter 5

<http://www.umass.edu/microbio/chime/explorer/>

<http://molvis.sdsc.edu/protexpl/index.htm>

<http://www.umass.edu/microbio/rasmol/>

<http://www.cryst.bbk.ac.uk/PPS2/course/section10/membrane.html>

<http://molbio.info.nih.gov/cgi-bin/pdb/>

<http://www.mc.vanderbilt.edu/peds/pidl/genetic/chlers.htm>

Chapter 6

<http://sickle.bwh.harvard.edu/>

<http://globin.cse.psu.edu/>

Chapter 7

<http://s02.middlebury.edu/CH441A/EnzymeTutorials.html>

<http://www.i-a-s.de/IAS/botanik/e18/18.htm>

Chapter 8

<http://www.indstate.edu/thcme/mwking/enzyme-kinetics.html>

<http://ntri.tamuk.edu/cell/kinetics.html>

Chapter 9

<http://users.wmin.ac.uk/~mellerj/physiology/bernard.htm>

<http://www.cm.utexas.edu/academic/courses/Fall2001/CH369/LEC06/Lec6.htm>

<http://www.cellularsignaling.org>

<http://arethusa.unh.edu/bchm752/ppthtml/JJan27/sld015.htm>

Chapter 22

<http://www.auhs.edu/netbiochem/NetWelco.htm>

Chapter 28

<http://www.people.virginia.edu/~rjh9u/scurvy.html>

<http://www.mc.vanderbilt.edu/biolib/hc/journeys/scurvy.html>

<http://opbs.okstate.edu/~melcher/MG/MGW2/MG2411.html>

Chapter 29

<http://www.nucdf.org/whatis.htm>

Chapter 30

<http://www.pkunetwork.org/>

<http://www.rarediseases.org/search/rdblast.html>

<http://www.msud-support.org/overv.htm>

Chapter 34

<http://www.rarediseases.org/search/rdblast.html>

<http://www.rheumatology.org/patients/factsheet/gout.html>

<http://www.merck.com/pubs/mmanual/section5/chapter55/55a.htm>

<http://www.nlm.nih.gov/medlineplus/goutandpseudogout.html>

http://www.amg.gda.pl/~cssppmm/ppd/ppd_py_umps.html

BIOCHEMICAL JOURNALS AND REVIEWS

The following is a partial list of biochemistry journals and review series and of some biomedical journals that contain biochemical articles. Biochemistry and biology journals now usually have Web sites, often with useful links, and some journals are fully accessible without charge. The reader can obtain the URLs for the following by using a search engine.

Annual Reviews of Biochemistry, Cell and Developmental Biology, Genetics, Genomics and Human Genetics

Archives of Biochemistry and Biophysics (Arch Biochem Biophys)

Biochemical and Biophysical Research Communications (Biochem Biophys Res Commun)

Biochemical Journal (Biochem J)

Biochemistry (Biochemistry)

Biochemistry (Moscow) (Biochemistry [Mosc])

Biochimica et Biophysica Acta (Biochim Biophys Acta)

Biochimie (Biochimie)

European Journal of Biochemistry (Eur J Biochem)

Indian Journal of Biochemistry and Biophysics (Indian J Biochem Biophys)

Journal of Biochemistry (Tokyo) (J Biochem [Tokyo])

Journal of Biological Chemistry (J Biol Chem)

Journal of Clinical Investigation (J Clin Invest)

Journal of Lipid Research (J Lipid Res)

Nature (Nature)

Nature Genetics (Nat Genet)

Proceedings of the National Academy of Sciences USA (Proc Natl Acad Sci USA)

Science (Science)

Trends in Biochemical Sciences (Trends Biochem Sci)

Index

Note: Page numbers in bold face type indicate a major discussion. A *t* following a page number indicates tabular material and an *f* following a page number indicates a figure.

- A bands, 556, 557*f*, 558*f*
 A blood group substance, 618, 619*f*
 A cyclins, 333, 334*f*, 335*t*
 A gene, GalNAc transferase encoded by, 618–619
 A (aminoacyl/acceptor) site, aminoacyl-tRNA binding to, in protein synthesis, 368, 368*f*
 ABC-1. *See* ATP-binding cassette transporter-1
 Abetalipoproteinemia, 207, 228*t*
 ABO blood group system, biochemical basis of, 617–619, 619*f*
 Absorption, 474–480
 Absorption chromatography, for protein/peptide purification, 22
 Absorption spectra, of porphyrins, 273–274, 277*f*
 Absorptive pinocytosis, 430
 ACAT (acyl-CoA:cholesterol acyltransferase), 223
 Accelerator (Ac-) globulin (factor V), 600*t*, 601, 602*f*
 Acceptor (A/aminoacyl) site, aminoacyl-tRNA binding to, in protein synthesis, 368, 368*f*
 Acceptor arm, of tRNA, 310, 312*f*, 360, 361*f*
 Aceruloplasminemia, 589
 ACEs. *See* Angiotensin-converting enzyme inhibitors
 Acetal links, 105–106
 Acetic acid, 112*t*
 pK_a value of, 12*t*
 Acetoacetate, 183–184, 184*f*
 in tyrosine catabolism, 254*f*, 255
 Acetoacetyl-CoA synthetase, in mevalonate synthesis, 219, 220*f*
 Acetone, 183
 Acetone bodies. *See* Ketone bodies
 Acetylation
 in covalent modification, mass increases and, 27*t*
 of xenobiotics, 630
 Acetyl-CoA, 122, 122*f*
 carbohydrate metabolism and, 122, 122*f*, 123*f*
 catabolism of, 130–135, 131*f*, 132*f*. *See also* Citric acid cycle
 cholesterol synthesis and, 219–220, 220*f*, 221*f*, 222*f*
 fatty acid oxidation to, 123–124, 123*f*, 181–183, 181*f*, 182*f*
 formation of, 254*f*, 255–259, 255*f*, 256*f*, 257*f*, 258*f*, 259*f*
 lipogenesis and, 173–177, 174*f*, 175*f*
 as fatty acid building block, 176–177
 pyruvate dehydrogenase regulated by, 141–142, 142*f*, 178
 pyruvate oxidation to, 134, 135*f*, 140–142, 141*f*, 142*f*, 143*t*
 xenobiotic metabolism and, 630
 Acetyl-CoA carboxylase, 156*t*, 179
 in lipogenesis regulation, 156*t*, 173, 174*f*, 178, 178*f*, 179
 N-Acetylgalactosamine (GalNAc), in glycoproteins, 515, 516*t*
 N-Acetylglucosamine (GlcNAc), in glycoproteins, 516*t*
 N-Acetylglucosamine phosphotransferase (GlcNAc phosphotransferase)
 in I-cell disease, 532
 in pseudo-Hurler polydystrophy, 532
 N-Acetylglutamate, in urea biosynthesis, 245, 246*f*
 Acetyl hexosamines, in glycoproteins, 109*t*
 N-Acetyl lactosamines, on N-linked glycan chains, 521
 Acetyl (acyl)-malonyl enzyme, 173, 175*f*
 N-Acetyl neuraminic acid, 169, 171*f*
 in gangliosides, 201, 203*f*
 in glycoproteins, 169, 171*f*, 515, 516*t*
 in mucins, 519*f*, 520
 Acetyl transacylase, 173, 174*f*, 175*f*
 Acetyltransferases, xenobiotic metabolism and, 630
 Acholuric jaundice, 282
 Achondroplasia, 432*t*, 551*t*, 553–554, 554*f*
 Acid anhydride bonds, 287
 Acid anhydrides, group transfer potential for, 289–290, 289*f*, 290*f*, 290*t*
 Acid-base balance, ammonia metabolism in, 245
 Acid-base catalysis, 51–52
 HIV protease in, 52, 53*f*
 α-Acid glycoprotein (orosomucoid), 583*t*
 Acid hydrolysis, for polypeptide cleavage, 26*t*
 Acid phosphatase, diagnostic significance of, 57*t*
 Acidemia, isovaleric, 259, 259–262
 Acidosis
 lactic. *See* Lactic acidosis
 metabolic, ammonia in, 245
 Acids
 conjugate, 10
 molecular structure affecting strength of, 12, 12*t*
 polyfunctional, nucleotides as, 290
 as proton donors, 9
 strong, 9
 weak. *See* Weak acids
 Aciduria
 dicarboxylic, 188
 methylmalonic, 155
 orotic, 300, 301
 urocanic, 250
 Aconitase (aconitate hydratase), 130
 ACP. *See* Acyl carrier protein
 Acrosomal reaction, glycoproteins in, 528
 ACTH. *See* Adrenocorticotropic hormone
 Actin, 557, 559, 560
 decoration of, 561, 561*f*
 fibronectin receptor interacting with, 540, 541*f*
 in muscle contraction, 557–559, 558*f*, 561–562, 561*f*, 562*f*
 regulation of striated muscle and, 562–563
 in nonmuscle cells, 576–577
 in red cell membranes, 615*f*, 616*f*, 616*t*, 617
 in striated vs. smooth muscle, 572*t*
 β-Actin, 577
 F-Actin, 559, 559*f*, 561
 in nonmuscle cells, 576, 577
 G-Actin, 559, 559*f*
 in nonmuscle cells, 576
 γ-Actin, 577
 Actin-filament capping protein, 540, 541*f*
 Actin (thin) filaments, 557, 558*f*, 559*f*
 α-Actinin, 540, 566*t*
 Activated protein C, in blood coagulation, 603
 Activation energy, 61, 63
 Activation energy barrier, enzymes affecting, 63
 Activation function 1, 460
 Activation function 2, 460
 Activation reaction, 456, 458*f*
 Activator-recruited cofactor (ARC), 472*t*, 473
 Activators
 in regulation of gene expression, 374, 376. *See also* Enhancers
 transcription, 351, 351*t*
 Active chromatin, 316–318, 318*f*, 383
 Active site, 51, 51*f*. *See also* Catalytic site
 Δ*G_f* and, 63

- Active sulfate (adenosine 3'-phosphate-5'-phosphosulfate), 289, 289f, 629
- Active transport, 423, 423t, 424f, 426-427, 427-428, 428f
- in bilirubin secretion, 280, 281f
- Activity (physical), energy expenditure and, 478
- Actomyosin, 560
- ACTR coactivator, 472, 472t
- Acute fatty liver of pregnancy, 188
- Acute inflammatory response, neutrophils in, 620
- Acute phase proteins, 583, 583t
- negative, vitamin A as, 483-484
- Acylcarnitine, 180-181, 181f
- Acyl carrier protein (ACP), 173, 174f
- synthesis of, from pantothenic acid, 173, 495
- Acyl-CoA:cholesterol acyltransferase (ACAT), 223
- Acyl-CoA dehydrogenase, 87, 181, 182f
- medium-chain, deficiency of, 188
- Acyl-CoA synthetase (thiokinase)
- in fatty acid activation, 180, 181f
- in triacylglycerol synthesis, 199, 214f, 215
- Acylglycerols, 197
- metabolism of, **197-201**
- catabolism, **197**
- clinical aspects of, 202
- synthesis, **197-201**, 197f, 198f
- in endoplasmic reticulum, 126, 127f
- Adapter proteins, in absorptive pinocytosis, 430
- Adenine, 288f, 288t
- Adenosine, 287f, 288t
- base pairing of in DNA, 303, 304, 305f
- in uric acid formation, 299, 299f
- Adenosine deaminase
- deficiency of, 300
- localization of gene for, 407t
- Adenosine diphosphate. *See* ADP
- Adenosine monophosphate. *See* AMP
- Adenosine 3'-phosphate-5'-phosphosulfate, 289, 289f, 629
- Adenosine triphosphate. *See* ATP
- S-Adenosylmethionine, 258f, 259, 264, 266f, 289, 290f, 290t
- Adenylic acid, as second messenger, 457
- Adenyl cyclase
- in cAMP-dependent signal transduction, 458-459, 460t
- cAMP derived from, 147
- in lipolysis, 215, 216f
- Adenyl kinase (myokinase), 84
- deficiencies of, 151-152
- in gluconeogenesis regulation, 157
- as source of ATP in muscle, 573, 575f
- Adhesion molecules, 529, 529t. *See also* Cell adhesion
- Adipose tissue, 111, **214-215**, 214f
- brown, **217**, 217f
- metabolism in, **214-215**, 214f, 235t
- control of, 216-217
- ADP, 287f
- free energy of hydrolysis of, 82t
- mitochondrial respiratory rate and, 94-95, 97t, 98f
- myosin, muscle contraction and, 561, 561f
- in platelet activation, 606f, 607
- in respiratory control, 94-95, 97, 97t, 98f, 134-135
- structure of, 83f
- ADP/ATP transporter, 95, 98f
- ADPase, 607, 607t
- ADP-chaperone complex, 508. *See also* Chaperones
- ADP-ribose, NAD as source of, 490
- ADP-ribosylation, 490
- Adrenal cortical hormones. *See also specific hormone and* Glucocorticoids; Mineralocorticoids
- synthesis of, 438-442, 440f, 441f
- Adrenal gland, cytochrome P450 isoforms in, 627
- Adrenal medulla, catecholamines produced in, 445
- Adrenergic receptors, in glycogenolysis, 148
- Adrenocorticotrophic hormone (ACTH), 437, 438, 439f, 453, 453f
- Adrenodoxin, 627
- Adrenodoxin reductase, 627
- Adrenogenital syndrome, 442
- Adrenoleukodystrophy, neonatal, 503, 503t
- Aerobic glycolysis, 139
- as muscle ATP source, 575, 575f, 575t
- Aerobic respiration
- citric acid cycle and, 130
- AF-1. *See* Activation function 1
- AF-2. *See* Activation function 2
- AF-2 domain, 470
- Affinity chromatography
- for protein/peptide purification, 23
- in recombinant fusion protein purification, 58, 59f
- AFP. *See* Alpha-fetoprotein
- Agammaglobulinemia, 595
- Age, xenobiotic-metabolizing enzymes affected by, 630
- Aggrecan, 542, 551t, 553, 553f
- Aggregates, formation of after denaturation, 36
- Aging, glycosaminoglycans and, 549
- Aglycone, 105, 106
- AHG. *See* Antihemophilic factor A/globulin
- AIB1 coactivator, 472, 472t
- ALA. *See* Aminolevulinic acid
- Alanine, 15t
- pl of, 17
- in pyruvate formation, 250, 252f
- synthesis of, 237, 238f
- β -Alanine, 264, 300, 301f
- Alanine (alanine-pyruvate) aminotransferase (ALT/SGPT)
- diagnostic significance of, 57t
- in urea synthesis, 243-244, 244f
- β -Alanine dipeptides, 264, 265f
- Albumin, 580, 581f, 583-584, 583t
- conjugated bilirubin binding to, 283
- free fatty acids in combination with, 180, 206, 206t, 584
- glomerular membrane permeability to, 540-541
- Albuminuria, 542
- Alcohol, ethyl. *See* Ethanol
- Alcohol dehydrogenase, in fatty liver, 212
- Alcoholism
- cirrhosis and, 212
- fatty liver and, 212-214
- Aldehyde dehydrogenase, 87
- in fatty liver, 212
- Aldolase A, deficiency of, 143
- Aldolase B, 167, 168f
- deficiency of, 171
- Aldolases, in glycolysis, 137, 138f
- Aldose-ketose isomerism, 103f, 104, 104f
- Aldose reductase, 167, 169f, 172
- Aldoses, 102, 102t, 104t
- ring structure of, 104
- Aldosterone
- binding of, 455
- synthesis of, 438-440, 441f
- angiotensin affecting, 451, 452
- Aldosterone synthase (18-hydroxylase), in steroid synthesis, 440, 441f
- Alkaline phosphatase
- in bone mineralization, 550
- isozymes of, diagnostic significance of, 57t
- in recombinant DNA technology, 400t
- Alkalosis, metabolic, ammonia in, 245
- Alkaptonuria, 255
- Allergic reactions, peptide absorption causing, 474
- Allopurinol, 290, 297
- Allosteric activators, 157
- Allosteric effectors/modifiers, 129
- in gluconeogenesis regulation, 157
- negative, 74. *See also* Feedback inhibition
- second messengers as, **76**
- Allosteric enzymes, 75, 129
- aspartate transcarbamoylase as model of, 75
- Allosteric properties of hemoglobin, **42-46**
- Allosteric regulation, of enzymatic catalysis, 74, **74-76**, 75f, 128f, **129**
- gluconeogenesis regulation and, 157
- Allosteric site, 74, 75
- Alpha-adrenergic receptors, in glycogenolysis, 148
- Alpha-amino acids. *See also* Amino acids
- genetic code specifying, 14, 15-16t
- in proteins, 14

- Alpha-amino nitrogen. *See* Amino acid nitrogen
- Alpha anomers, 104
- Alpha₂ antitrypsin/antitrypsin. *See* α_1 -Antitrypsinase
- Alpha- (α) carotene, 482
- Alpha-fetoprotein, 583*t*
- Alpha-globin gene, localization of, 407*t*
- Alpha (α) helix, 31–32, 32*f*, 33*f*
amphipathic, 31–32
in myoglobin, 40, 41*f*
- Alpha (α) ketoglutarate. *See* α -Ketoglutarate
- Alpha-lipoproteins, 205. *See also* High-density lipoproteins
familial deficiency of, 228*t*
- Alpha-R groups, amino acid properties affected by, 18
- Alpha (α) thalassemia, 47
- Alpha-tocopherol. *See* Tocopherol
- Alport syndrome, 538, 538*t*
- ALT. *See* Alanine aminotransferase
- Alteplase (tissue plasminogen activator/t-PA), 604–605, 605*f*, 606*t*, 607*t*
- Alternative pathway, of complement activation, 596
- Altitude, high, adaptation to, 46
- Alu family, 321–322
- Alzheimer disease, amyloid in, 37, 590
- α -Amanitin, RNA polymerases affected by, 343
- Ambiguity, genetic code and, 359
- Amino acid carbon skeletons, catabolism of, 249–263
acetyl-CoA formation and, 254*f*, 255–259, 255*f*, 256*f*, 257*f*, 258*f*, 259*f*
branched-chain, 259, 260*f*, 261*f*, 262*f*
disorders of, 259–262
pyruvate formation and, 250–255, 252*f*, 253*f*
transamination in initiation of, 249–250, 249*f*, 250*f*, 251*f*
- Amino acid nitrogen
catabolism of, 242–248
in amino acid carbon skeleton catabolism, 249, 249*f*
end products of, 242–243
urea as, 245–247, 246*f*
L-glutamate dehydrogenase in, 244–245, 244*f*, 245*f*
transamination of, 243–244, 243*f*
- L-Amino acid oxidase, 86–87
in nitrogen metabolism, 244, 244*f*
- Amino acid sequences. *See also* Protein sequencing
determination of, for glycoproteins, 515*t*
primary structure determined by, 18–19
repeating, in mucins, 519, 520*f*
- Amino acids, 2, 14–20, 15–16*t*. *See also* Peptides
absorption of, 477
analysis/identification of, 20
blood glucose and, 159
branched chain, catabolism of, 259, 260*f*, 261*f*, 262*f*
disorders of, 259–262
in catalysis, conservation of, 54, 55*t*
chemical reactions of, functional groups dictating, 18–20
deamination of. *See* Deamination
deficiency of, 237, 480
excitatory. *See also* Aspartate; Glutamate
glucogenic, 231–232
in gluconeogenesis, 133–134, 134*f*
interconvertibility of, 231–232
keto acid replacement of in diet, 240
ketogenic, 232
melting point of, 18
metabolism of, 122*f*, 124, 124*f*, 125*f*. *See also* Amino acid carbon skeletons, catabolism of; Amino acid nitrogen, catabolism of
pyridoxal phosphate in, 491
net charge of, 16–17, 17*f*
nutritionally essential, 124
nutritionally nonessential, 124
synthesis of, 237–241
in peptides, 14, 19, 19*f*
p*K*_a values of, 15–16*t*, 17, 17*f*
environment affecting, 18, 18*t*
products derived from, 264–269. *See also* specific product
properties of, 14–18
 α -R group determining, 18
protein degradation and, 242, 243*f*
in proteins, 14
removal of ammonia from, 244, 244*f*
requirements for, 480
sequence of, primary structure determined by, 18–19
solubility point of, 18
substitutions of, missense mutations caused by, 362–363, 362*f*
synthesis of, 237–241
in carbohydrate metabolism, 123
citric acid cycle in, 133, 134*f*
transamination of. *See* Transamination
transporter/carrier systems for, 99
glutathione and, 629–630
hormones affecting, 427
- Aminoacyl residues, 18–19
peptide structure and, 19
- Aminoacyl (A/acceptor) site, aminoacyl-tRNA binding to, in protein synthesis, 368, 368*f*
- Aminoacyl-tRNA, in protein synthesis, 368
- Aminoacyl-tRNA synthetases, 360, 360*f*
- γ -Aminobutyrate, 267, 268*f*
- β -Aminoisobutyrate, 300, 301*f*
- Aminolevulinic (ALA), 270, 273*f*
in porphyria, 278
- Aminolevulinic dehydratase, 270, 273*f*
in porphyria, 274, 277*t*
- Aminolevulinic synthase, 270, 272–273, 273*f*, 276*f*
in porphyria, 274, 277*f*, 278
- Aminopeptidases, 477
- Aminophospholipids, membrane asymmetry and, 420
- Aminoproteinase, procollagen, 537
- Amino sugars (hexosamines), 106, 106*f*
glucose as precursor of, 169, 171*f*
in glycosaminoglycans, 109, 169, 171*f*
in glycosphingolipids, 169, 171*f*
interrelationships in metabolism of, 171*f*
- Aminotransferases (transaminases), 133–134, 134*f*
diagnostic significance of, 57*t*
in urea biosynthesis, 243–244, 244*f*
- Ammonia
in acid-base balance, 245
detoxification of, 242
excess of, 247
glutamine synthase fixing, 245, 245*f*
nitrogen removed as, 244, 244*f*
- Ammonia intoxication, 244
- Ammonium ion, p*K*_a value of, 12*t*
- Amobarbital, oxidative phosphorylation/respiratory chain affected by, 92, 95, 96*f*
- AMP, 287*f*, 288*f*, 288*t*, 297*f*
coenzyme derivatives of, 290*t*
cyclic. *See* Cyclic AMP
free energy of hydrolysis of, 82*t*
IMP conversion to, 293, 296*f*
feedback-regulation of, 294, 296*f*
PRPP glutamyl amidotransferase regulated by, 294
structure of, 83*f*, 288*f*
- Amp resistance genes, 402, 403*f*
- Amphibolic pathways/processes, 122
citric acid cycle and, 133
- Amphipathic α -helix, 31–32
- Amphipathic lipids, 119–121, 120*f*
in lipoproteins, 205, 207*f*
in membranes, 119, 120*f*, 417–418, 417*f*
- Amphipathic molecules, folding and, 6
- Ampicillin resistance genes, 402, 403*f*
- Amplification, gene, in gene expression regulation, 392–393, 393*f*
- Amylases
diagnostic significance of, 57*t*
in hydrolysis of starch, 474
- β -Amyloid, in Alzheimer disease, 37, 590
- Amyloid-associated protein, 590
- Amyloid precursor proteins, 590
in Alzheimer disease, 37, 590
- Amyloidosis, 590–591
- Amylopectin, 107, 108*f*
- Amylopectinosis, 152*t*
- Amylose, 107, 108*f*

- Anabolic pathways/anabolism, 81, 122. *See also* Endergonic reaction; Metabolism
- Anaerobic glycolysis, 136, 137f, 139
as muscle ATP source, 574–576, 575f, 575t
- Analbuminemia, 584
- Anaphylaxis, slow-reacting substance of, 196
- Anaplerotic reactions, in citric acid cycle, 133
- Anchorin, in cartilage, 551t
- Andersen's disease, 152t
- Androgen response element, 459t
- Androgens
estrogens produced from, 442–445, 444f
receptors for, 471
synthesis of, 440–442, 441f, 443f
- Androstenedione
estrone produced from, 444f, 445
synthesis of, 442, 443f
- Anemias, 47
Fanconi's, 338
hemolytic, 136, 143, 609, 619, 620t
glucose-6-phosphate dehydrogenase deficiency causing, 163, 169–170, 613, 614f, 619
haptoglobin levels in, 584
hyperbilirubinemia/jaundice in, 282, 284, 284t
pentose phosphate pathway/
glutathione peroxidase and, 166, 167f, 169–170
primaquine-sensitive, 613
red cell membrane abnormalities causing, 619
iron deficiency, 478, 497, 586, 610t
megaloblastic
folate deficiency causing, 482t, 492, 494
vitamin B₁₂ deficiency causing, 482t, 492, 610t
pernicious, 482t, 492
recombinant erythropoietin for, 526, 610
sickle cell. *See* Sickle cell disease
- Angiotensin II, 437, 451, 452f
synthesis of, 451–452, 452f
- Angiotensin III, 452, 452f
- Angiotensin-converting enzyme, 451–452, 452f
- Angiotensin-converting enzyme inhibitors, 451–452
- Angiotensinogen, 451, 452f
- Anion exchange protein, 615, 615f, 616t
- Ankyrin, 615f, 616f, 616t, 617
- Anomeric carbon atom, 104
- Anomers, α and β , 104
- Anserine, 264, 265, 265f
- Antennae (oligosaccharide branches), 521
- Anterior pituitary gland hormones, blood glucose affected by, 161
- Anti conformers, 287, 287f
- Antibiotics
amino sugars in, 106
bacterial protein synthesis affected by, 371–372
folate inhibitors as, 494
- Antibodies, 580, 581. *See also* Immunoglobulins
monoclonal, hybridomas in production of, 595–596, 596f
in xenobiotic cell injury, 631, 631f
- Antibody diversity, 591
- DNA/gene rearrangement and, 593–594
- Antichymotrypsin, 583t
- Anticoagulants, coumarin, 604
- Anticodon region, of tRNA, 359, 360, 360f
- Antifolate drugs, purine nucleotide synthesis affected by, 293
- Antigenic determinant (epitope), 33, 591
- Antigenicity, xenobiotics altering, cell injury and, 631, 631f
- Antigens, 591
- Antihemophilic factor A/globulin (factor VIII), 599f, 600, 600t
deficiency of, 604
- Antihemophilic factor B (factor IX), 599f, 600, 600t
coumarin drugs affecting, 604
deficiency of, 604
- Antimalarial drugs, folate inhibitors as, 494
- Antimycin A, respiratory chain affected by, 95, 96f
- Antioxidants, 91, 119, 611–613, 613t
retinoids and carotenoids as, 119, 482t
vitamin C as, 119
vitamin E as, 91, 119, 486, 487f
- Antiparallel loops, mRNA and tRNA, 360
- Antiparallel β sheet, 32, 33f
- Antiparallel strands, DNA, 303
- Antiport systems, 426, 426f
for nucleotide sugars, 517
- α_1 -Antiproteinase (α_1 -antitrypsin), 583t, 589
deficiency of, 589–590, 589f, 590f, 623
as thrombin inhibitor, 603
- Antiproteinases, 623, 624t
- Antithrombin/antithrombin III, 583t, 603–604
heparin binding to, 547, 603–604
- α_1 -Antitrypsin (α_1 -antiproteinase), 583t, 589
deficiency of, 589–590, 589f, 590f, 623–624
as thrombin inhibitor, 603
- APC. *See* Activated protein C
- Apo A-I, 206, 206t, 224
deficiencies of, 228t
- Apo A-II, 206t
lipoprotein lipase affected by, 207–208
- Apo A-IV, 206, 206t
- Apo B-48, 206, 206t
- Apo B-100, 206, 206t
in LDL metabolism, 209, 210f
regulation of, 223
- Apo C-I, 206, 206t
- Apo C-II, 206, 206t
in lipoprotein lipase activity, 207–208
- Apo C-III, 206, 206t
lipoprotein lipase affected by, 208
- Apo D, 206, 206t
- Apo E, 206, 206t
receptors for
in chylomicron remnant uptake, 208–209, 209f
in LDL metabolism, 209, 210f
- Apo ferritin, 586
- Apolipoproteins/apoproteins, 205, 205–206
distribution of, 205–206, 206t
hemoglobin; oxygenation affecting, 42
- Apomyoglobin, hindered environment for heme iron and, 41, 41f
- Apoproteins. *See* Apolipoproteins/apoproteins
- Apoptosis, 201
p53 and, 339
- Apo-transketolase, activation of, in thiamin nutritional status assessment, 489
- APP. *See* Amyloid precursor protein
- Apurinic endonuclease, in base excision-repair, 337
- Apyrimidinic endonuclease, in base excision-repair, 337
- Aquaporins, 424–426
- D-Arabinose, 104f, 105t
- Arabinosyl cytosine (cytarabine), 290
- Arachidonic acid/arachidonate, 113t, 190, 190f
eicosanoid formation and, 192, 193f, 194, 194f, 195f
for essential fatty acid deficiency, 191–192
- ARC, 472t, 473
- ARE. *See* Androgen response element
- Argentaffinoma (carcinoid), serotonin in, 266–267
- Arginase
in periodic hyperlysinemia, 258
in urea synthesis, 246f, 247
- Arginine, 16t, 265, 266f
catabolism of, 250, 251f
in urea synthesis, 246f, 247
- Arginosuccinase
deficiency of, 248
in urea synthesis, 246f, 247
- Arginosuccinate, in urea synthesis, 245, 246f, 247
- Arginosuccinate synthase, 246f, 247
deficiency of, 247
- Arginosuccinic aciduria, 248

- Aromatase enzyme complex, 442, 444f, 445
- ARS (autonomously replicating sequences), 326, 413
- Arsenate, oxidation and phosphorylation affected by, 137, 142
- Arterial wall, intima of, proteoglycans in, 548
- Arthritis
gouty, **299**
proteoglycans in, 548
rheumatoid, glycosylation alterations in, 533
- Artificial membranes, **421–422**
- Ascorbate, 167, 168f
- Ascorbic acid (vitamin C), 163, 482t, **495–496**, 496f
as antioxidant, 119
in collagen synthesis, 38, 496, 535
deficiency of, 482t, 496
collagen affected in, 38–39, 496, 538–539
iron absorption and, 478, 496
supplemental, 496
- Asialoglycoprotein receptors
in cotranslational insertion, 506, 506f
in glycoprotein clearance, **517**
- Asn-GlcNAc linkage
in glycoproteins, 521
in glycosaminoglycans, 543
- Asparaginase, in amino acid nitrogen catabolism, 245, 245f
- Asparagine, 15t
in amino acid nitrogen catabolism, 245
catabolism of, 249, 250f
synthesis of, 237–238, 238f
- Asparagine synthetase, 238, 238f
- Aspartate
catabolism of, 249, 250f
synthesis of, 237–238, 238f
in urea synthesis, 246f, 247
- Aspartate 102, in covalent catalysis, 53–54, 54f
- Aspartate aminotransferase (AST/SGOT), diagnostic significance of, 57t
- Aspartate transcarbamoylase, 75
in pyrimidine synthesis, 298f, 299
- Aspartic acid, 15t
pI of, 17
- Aspartic protease family, in acid-base catalysis, 52, 53f
- Aspartylglycosaminuria, 532–533, 533t
- Aspirin
antiplatelet actions of, 607–608
cyclooxygenase affected by, 193
prostaglandins affected by, 190
- Assembly particles, in absorptive pinocytosis, 430
- AST. *See* Aspartate aminotransferase
- Asthma, leukotrienes in, 112
- Asymmetric substitution, in porphyrins, 270, 271f
- Asymmetry
importin binding and, 501
lipid and protein, membrane assembly and, 511, 512f
in membranes, 416, 419–420
- Ataxia-telangiectasia, 338
- ATCase. *See* Aspartate transcarbamoylase
- Atherosclerosis, 205, 607
cholesterol and, 117, 219, 227
HDL and, 210–211
hyperhomocysteinemia and, folic acid supplements in prevention of, 494
LDL receptor deficiency in, 209
lysophosphatidylcholine (lysocitinin) and, 116
- Atorvastatin, 229
- ATP, 82, **82–85**, 287f, 289
in active transport, 427–428, 428f
in coupling, 82, 84
fatty acid oxidation producing, 182
free energy of hydrolysis of, 82–83, 82t
in free energy transfer from exergonic to endergonic processes, **82–83**, 82f
hydrolysis of
in muscle contraction, 561–562, 561f
by NSF, 509, 510f
inorganic pyrophosphate production and, 85
in mitochondrial protein synthesis and import, 499
in muscle/muscle contraction, 556, 561–562, 561f
decrease in availability of, 564
sources of, **573–574**, 574–576, 575f, 575t
in purine synthesis, **293–294**, 295f
respiratory control in maintenance of supply of, 94–95, 97, 97t, 98f, 134–135
structure of, 83f
synthesis of
ATP synthase in, 96, 97f, 98f
in citric acid cycle, 131f, **133**, 142, 143t
glucose oxidation yielding, 142, 143t
respiratory chain in, 93–95, 98f
- ATP/ADP cycle, 83, 84f
- ATPase
in active transport, 427–428, 428f
chaperones exhibiting activity of, 508
copper-binding P-type, mutations in gene for
Menkes diseases caused by, 588
Wilson disease caused by, 588–589
- ATP-binding cassette transporter-1, 210, 211f
- ATP-chaperone complex, 508. *See also* Chaperones
- ATP-citrate lyase, 134, 135f, 156t, 157
acetyl-CoA for lipogenesis and, 177
- ATP synthase, membrane-located, 96, 97f, 98f
- Attractylolide, respiratory chain affected by, 95
- Attachment proteins, 540, 541f
- Autoantibodies, in myasthenia gravis, 431
- Autonomously replicating sequences (ARS), 326, 413
- Auto-oxidation. *See* Peroxidation
- Autoradiography, definition of, 413
- Autotrophic organisms, 82
- Avidin, biotin deficiency caused by, 494
- Axial ratios, 30
- Axonemal dyneins, 577
- 5- or 6-Azacytidine, 290
- 8-Azaguanine, 290, 291f
- Azathioprine, 290
- 5- or 6-Azauridine, 290, 291f
- B blood group substance, 618, 619f
- B (β) cells, pancreatic, insulin produced by, 160
- B cyclins, 333, 334f, 335t
- B gene, Gal transferase encoded by, 618–619
- B lymphocytes, 591
in hybridoma production, 595–596, 596f
- B vitamins. *See* Vitamin B complex
- BAC vector. *See* Bacterial artificial chromosome (BAC) vector
- Bacteria
intestinal, in bilirubin deconjugation, 281
transcription cycle in, 342–343, 342f
- Bacterial artificial chromosome (BAC) vector, 401–402, 402t
for cloning in gene isolation, 635t
in Human Genome project, 634
- Bacterial gyrase, 306
- Bacterial promoters, in transcription, 345–346, 345f
- Bacteriophage, definition of, 413
- Bacteriophage lambda (λ), 378–383, 379f, 380f, 381f, 382f
- BAL. *See* Dimeric caprol
- BAL 31 nuclease, in recombinant DNA technology, 400t
- Balanced chemical equations, **60**
- BamHI, 398, 399t
- Barbiturates, respiratory chain affected by, 95, 96f
- Basal lamina, laminin as component of, **540–542**
- Basal metabolic rate, 478
- Base excision-repair of DNA, 336t, 337, 337f
- Base pairing in DNA, 7, 303, 304, 305f
matching of for renaturation, 305–306
recombinant DNA technology and, 396–397
replication/synthesis and, 328–330, 330f

- Base substitution, mutations occurring by, 361, 361f, 362
- Basement membranes, collagen in, 537
- Bases
- conjugate, 10
 - as proton acceptors, 9
 - strong, 9
 - weak, 9
- Bence Jones protein, 595
- Bends (protein conformation), 32–33, 34f
- Beriberi, 482t, 489
- Beta-alanine. *See* β -Alanine
- Beta anomers, 104
- Beta- (β) carotene, 482, 482t, 483, 483f
- See also* Vitamin A
 - as antioxidant, 119, 482t
- Beta-endorphins, 453, 453f
- Beta-globin gene
- localization of, 407t
 - recombinant DNA technology in
 - detection of variations in, 407–408, 408f, 409t
- Beta-lipoproteins, 205. *See also* low density lipoproteins
- Beta-oxidation of fatty acids, **181–183**, 181f, 182f
- ketogenesis regulation and, 186–187, 187f, 188f
 - modified, **183**, 183f
- Beta (β) sheet, 32, 33f
- Beta subunits of hemoglobin, myoglobin and, 42
- Beta (β) thalassemia, 47
- Beta (β) turn, 32, 34f
- BFU-E. *See* Burst-forming unit-erythroid
- BgIII, 399t
- BHA. *See* Butylated hydroxyanisole
- BHT. *See* Butylated hydroxytoluene
- Bi-Bi reactions, 69–70, 69f, 70f
- Michaelis-Menten kinetics and, 70, 70f
- Bicarbonate, in extracellular and intracellular fluid, 416t
- Biglycan
- in bone, 548t
 - in cartilage, 551t
- Bilayers, lipid, 418–419, 418f, 419f
- membrane proteins and, 419
- Bile, bilirubin secretion into, 280, 281f
- Bile acids (salts), **225–227**
- enterohepatic circulation of, 227
 - in lipid digestion and absorption, 475, 476f
 - secondary, 226f, 227
 - synthesis of, 225–227, 226f
 - regulation of, 226, 226f, 227
- Bile pigments, **278–284**, 282f. *See also* Bilirubin
- Biliary obstruction,
- hyperbilirubinemia/jaundice caused by, 283, 284, 284t
- Bilirubin
- accumulation of (hyperbilirubinemia), **281–284**, 284t
 - conjugated
 - binding to albumin and, 283
 - reduction of to urobilinogen, 281, 282f - conjugation of, 280, 280f, 281f
 - fecal, in jaundice, 284t
 - heme catabolism producing, **278–280**, 279f
 - liver uptake of, **280–281**, 280f, 281f, 282f
 - normal values for, 284t
 - secretion of into bile, 280, 281f
 - unconjugated, disorders occurring in, 282–283
 - urine, in jaundice, 284, 284t
- Biliverdin, 278, 279f
- Biliverdin reductase, 278
- Bimolecular membrane layer, 418–419. *See also* Lipid bilayer
- Binding constant, Michaelis constant (K_m)
- approximating, 66
- Binding proteins, 454–455, 454t, 455t, 583t
- Biochemistry
- as basis of health/disease, **2–4**, 3t
 - definition of, 1
 - Human Genome Project and, 3–4
 - methods and preparations used in, 1, 2t
 - relationship of to medicine, **1–4**, 3f
- Biocytin, 494, 495f
- Bioenergetics, **80–85**. *See also* ATP
- Bioinformatics, 412, 638
- protein function and, 28–29
- Biologic oxidation. *See also* Oxidation
- Biomolecules. *See also specific type*
- stabilization of, 7
 - water affecting structure of, **6–7**, 6t
- Biotechnology, Human Genome Project affecting, 638
- Biotin, 482t, **494–495**, 495f
- deficiency of, 482t, 494
 - in malonyl-CoA synthesis, 173, 174f
 - as prosthetic group, 50
- BiP. *See* Immunoglobulin heavy chain
- binding protein
- 1,3-Bisphosphoglycerate (BPG), free energy of hydrolysis of, 82t
- 2,3-Bisphosphoglycerate (BPG), T structure of hemoglobin stabilized by, 45, 45f
- Bisphosphoglycerate mutase, in glycolysis in erythrocytes, 140, 140f
- 2,3-Bisphosphoglycerate phosphatase, in erythrocytes, 140, 140f
- Blindness, vitamin A deficiency causing, 483
- Blood
- coagulation of, **598–608**. *See also* Coagulation; Coagulation factors
 - functions of, **580**, 581t
- Blood cells, **609–625**. *See also* Erythrocytes; Neutrophils; Platelets
- Blood clotting. *See* Coagulation
- Blood glucose
- normal, 145
 - regulation of
 - clinical aspects of, **161–162**, 161f
 - diet/gluconeogenesis/glycogenolysis in, **158–161**, 159f, 160f
 - glucagon in, 160–161
 - glucokinase in, 159–160, 160f
 - glycogen in, 145
 - insulin in, 160
 - limits of, **158**
 - metabolic and hormonal mechanisms in, 159, 160t, 161
- Blood group substances, 618, 619f
- glycoproteins as, 514, 618
- Blood group systems, 617–619, 619f
- Blood plasma. *See* Plasma
- Blood type, 617–618
- Blood vessels, nitric oxide affecting, 571–573, 573f, 574t
- Blot transfer techniques, 403, 404f
- Blunt end ligation/blunt-ended DNA, 398, 399–400, 400f, 413
- BMR. *See* Basal metabolic rate
- Body mass index, 478
- Body water. *See* Water
- Bohr effect, 44, 45f
- in hemoglobin M, 46
- Bone, **549–550**, 549f, 550f
- metabolic and genetic disorders involving, **551–552**, 551t
 - proteins in, 548t, 549
- Bone Gla protein, 548t
- Bone marrow, heme synthesis in, 272
- Bone matrix Gla protein, 488
- Bone morphogenetic proteins, 548t
- Bone sialoprotein, 548t
- Bone SPARC protein, 548t
- Borulinum B toxin, 511
- Bovine spongiform encephalopathy, 37
- BPG. *See* 1,3-Bisphosphoglycerate; 2,3-Bisphosphoglycerate
- Bradykinin, in inflammation, 621
- Brain, metabolism in, 235t
- glucose as necessity for, 232
- Branched chain amino acids, catabolism of, **259**, 260f, 261f, 262f
- disorders of, **259–262**
- Branched-chain α -keto acid dehydrogenase, 259
- Branched chain ketonuria (maple syrup urine disease), 259
- Branching enzymes
- absence of, 152t
 - in glycogen biosynthesis, 145, 147f
- Brefeldin A, 510–511
- Brittle bones (osteogenesis imperfecta), 551t
- Broad beta disease, 228t

- Bronze diabetes, 587
- Brown adipose tissue, **217**, 217f
- Brush border enzymes, 475
- BSE. *See* Bovine spongiform encephalopathy
- Buffers
- Henderson-Hasselbalch equation
 - describing behavior of, 11, 12f
 - weak acids and their salts as, 11–12, 12f
 - "Bulk flow," of membrane proteins, 507
- Burst-forming unit-cyathoid, 610, 611f
- Butylated hydroxyanisole (BHA), as
 - antioxidant/food preservative, 119
- Butylated hydroxytoluene (BHT), as
 - antioxidant/food preservative, 119
- Butyric acid, 112t
- C1–9 (complement proteins), 596
- C-peptide, 449, 450f
- C₂₀ polyunsaturated acids, eicosanoids
 - formed from, 190, **192**, 193f, 194f
- C-reactive protein, 583, 583t
- C regions/segments. *See* Constant regions/segments
- Ca²⁺ ATPase, 463
- Ca²⁺-Na⁺ exchanger, 463, 567–568
- Cachexia, cancer, 136, 479
- Caffeine, 289, 289f
 - hormonal regulation of lipolysis and, 215
- Calbindin, 477
- Calcidiol (25-hydroxycholecalciferol), in
 - vitamin D metabolism, 484, 485f
- Calciferol. *See* Vitamin D
- Calcineurin, 566t
- Calcinosis, 486
- Calcitonin, 437
- Calcitriol (1,25(OH)₂-D₃), 437, 439f, 485
 - calcium concentration regulated by, 485
 - storage/secretion of, 453, 454t
 - synthesis of, 445, 446f, 484, 485f
- Calcium, 496t
 - absorption of, 477
 - vitamin D metabolism and, 477, 484, 484–485
 - in blood coagulation, 599f, 600, 600t, 601
 - in bone, 549
 - in extracellular fluid, 416, 416t
 - in intracellular fluid, 416, 416t
 - iron absorption affected by, 478
 - in malignant hyperthermia, 564–565, 565f
 - metabolism of, 463
 - vitamin D metabolism and, 484–485
 - in muscle contraction, 562
 - in cardiac muscle, 566–568
 - phosphorylation and, 148
 - sarcoplasmic reticulum and, 563–564, 563f, 564f
 - in smooth muscle, 570, 571
 - in platelet activation, 606f, 607
 - as second messenger, 436–437, 437t, 457, 463–465, 463t
 - phosphatidylinositol metabolism affecting, 464–465, 464f, 465f
 - vitamin D metabolism affected by, 485–486
- Calcium ATPase, 463, 568
- Calcium-binding proteins, vitamin K and
 - glutamate carboxylation and
 - postsynthetic modification and, 487–488, 488f
 - synthesis and, 488, 604
- Calcium/calmodulin, 463
- Calcium/calmodulin-sensitive phosphorylase kinase, in glycogenolysis, 148
- Calcium channels, 463. *See also* Calcium release channel
 - in cardiac muscle, 566–567
- Calcium-induced calcium release, in cardiac muscle, 567
- Calcium pump, 463, 568
- Calcium release channel
 - dihydropyridine receptor and, 563–564, 563f
 - mutations in gene for, malignant hyperthermia caused by, 564–565, 565f, 630t
- Calcium release channel, 563, 564f
- Calcium-sodium exchanger, 463
- Caldesmon, 571
- Calmodulin, 463, 463t, 562
 - muscle phosphorylase and, 148, 149f
- Calmodulin-4Ca²⁺, in smooth muscle contraction, 570–571, 571f
- Calnexin, 508, 526
- Calreticulin, 508, 526
- Calsequestrin, 563, 563f
- cAMP. *See* Cyclic AMP
- Cancer/cancer cells. *See also*
 - Carcinogenesis/carcinogens
- cyclins and, 334
 - glycoproteins and, 514, 526, 530t, 531
 - hormone-dependent, vitamin B₆
 - deficiency and, 491
 - membrane abnormalities and, 432t
 - mucins produced by, 520
- Cancer cachexia, 136, 479
- Cancer chemotherapy
 - folate inhibitors in, 494
 - neutropenia caused by, 610
 - synthetic nucleotide analogs in, **290–291**, 291f
- Cancer phototherapy, porphyrins in, 273
- CAP. *See* Catabolite gene activator protein
- Caproic acid, 112t
- Carbamates, hemoglobin, 44
- Carbamoyl phosphate
 - excess, 301
 - free energy of hydrolysis of, 82t
 - in urea synthesis, 245, 246–247, 246f, 247
- Carbamoyl phosphate synthase I
 - deficiency of, 247
 - in urea synthesis, 245–246, 246f
- Carbamoyl phosphate synthase II, in pyrimidine synthesis, 296, 298f, 299
- Carbohydrates, **102–110**. *See also specific type and* Glucose; Sugars
 - in cell membranes, **110**
 - cell surface, glycolipids and, 116
 - classification of, 102, 102t
 - complex (glycoconjugate), glycoproteins as, 514
 - digestion and absorption of, **474–475**, 475f
 - interconvertibility of, 231
 - isomerism of, 102–104, 103f
 - in lipoproteins, **110**
 - metabolism of, 122–123, 122f, 123f, 124–125, 125f
 - diseases associated with, 102
 - vitamin B₁ (thiamin) in, **488–489**, 489f
 - in proteoglycans, 542, 543, 543f
- Carbon dioxide
 - citric acid cycle in production of, **130–133**, 132f
 - transport of, by hemoglobin, 44, 45f
- Carbon monoxide
 - heme catabolism producing, 278
 - oxidative phosphorylation/respiratory chain affected by, 92, 95, 96f
- Carbon skeleton, amino acid. *See* Amino acid carbon skeletons
- Carbonic acid, pK_a value of, 12t
- Carbonic anhydrase, in osteopetrosis, 552
- Carboxybiotin, 494, 495f
- γ-Carboxyglutamate, vitamin K in synthesis of, 487, 488f
- Carboxyl terminal repeat domain, 350
- Carboxylase enzymes, biotin as coenzyme of, 494–495
- Carboxypeptidases, 477
- Carboxypeptinase, procollagen, 537
- Carcinogenesis/carcinogens, 631
 - chemical, 631
 - cytochrome P450 induction and, 628
 - indirect, 631
- Carcinoid (argentaffinoma), serotonin in, 266–267
- Carcinoid syndrome, 490
- Cardiac developmental defects, 570
- Cardiac glycosides, 106
- Cardiac muscle, 556, **566–570**, 568t, 569t
- Cardiolipin, 115, 115f
 - synthesis of, 197, 197f, 199, 199f
- Cardiomyopathies, 556, 569–570, 569t
- Cargo proteins/molecules, 510
 - in export, 503
 - in import, 501, 502f

- Carnitine
 deficiency of, 180, 187
 in fatty acid transport, 180–181, 181f
- Carnitine-acylcarnitine translocase, 180, 181f
- Carnitine palmitoyltransferase, deficiency of, 180
- Carnitine palmitoyltransferase-I, 180, 181f
 deficiency of, 187
 in ketogenesis regulation, 186–187, 187f, 188f
- Carnitine palmitoyltransferase-II, 181, 181f
 deficiency of, 187–188
- Carnosinase deficiency, 264
- Carnosine, 264, 265, 265f
- Carnosinuria, 264
- β -Carotene, 482, 482t, 483, 483f. *See also* Vitamin A
 as antioxidant, 119, 482t
- Carotene dioxygenase, 482–483, 483f
- Carotenoids, 482–484, 483f, 484f. *See also* Vitamin A
- Carrier proteins/systems, 426, 426f
 for nucleotide sugars, 517
- Cartilage, 543, 551t, 552–553, 553f
 chondrodysplasia affecting, 553–554
- Catabolic pathways/catabolism, 81, 122.
See also Exergonic reaction; Metabolism
- Catabolite gene activator protein (cyclic AMP regulatory protein), 376, 378
- Catabolite regulatory protein, 460
- Catalase, 88–89
 as antioxidant, 119, 611–613, 613t
 in nitrogen metabolism, 244, 244f
- Catalysis/catalytic reactions (enzymatic). *See also* Metabolism
 acid-base, 51–52
 HIV protease in, 52, 53f
 at active site, 51, 51f
 Bi-Bi, 69–70, 69f, 70f
 Michaelis-Menten kinetics and, 70, 70f
 coenzymes/cofactors in, 50–51, 51f
 conservation of residues and, 54, 55t
 covalent, 52, 52f, 63
 chymotrypsin in, 52–54, 54f, 63
 fructose-2,6-bisphosphatase in, 54, 55f
 double displacement, 69–70, 69f
 enzyme detection facilitated by, 55–56, 56f
 equilibrium constant and, 63
 isozymes and, 54–55
 kinetics of, 63–70
 activation energy and, 61, 63
 balanced equations and, 60
 competitive versus noncompetitive inhibition and, 67–69, 67f, 68f, 69f
 factors affecting rates of, 61–63, 62f, 63–64, 64f
 free energy changes and, 60–61
 initial velocity and, 64
 multiple substrates and, 69–70, 69f, 70f
 substrate concentration and, 64, 64f, 65f
 models of, 65–67, 66f, 67f
 transition states and, 61
 mechanisms of, 51–52, 52f
 prosthetic groups/cofactors/coenzymes in, 50–51, 51f
 site-directed mutagenesis in study of, 58
 oxaloacetate and, 130
 ping-pong, 69–70, 69f
 prosthetic groups in, 50–51, 51f
 by proximity, 51
 regulation of, 72–79, 128f, 129
 active and passive processes in, 72, 73f
 allosteric, 74, 74–76, 75f, 128f, 129
 compartmentation in, 72–73
 covalent, 74, 76, 77–78, 78f
 enzyme quantity and, 73–74
 feedback inhibition and, 74–76, 75f, 76, 129
 feedback regulation and, 76, 129
 metabolite flow and, 72, 73f
 Michaelis constant (K_m) in, 72, 73f
 phosphorylation-dephosphorylation in, 78–79, 78t
 proteolysis in, 76–77, 77f
 second messengers in, 76
 RNA and, 356
 sequential (single) displacement, 69, 69f
 specificity of, 49, 50f
 by strain, 52
 substrate concentration affecting rate of, 64, 64f, 65f
 Hill model of, 66–67, 67f
 Michaelis-Menten model of, 65–66, 66f
- Catalytic residues, conserved, 54, 55t
- Catalytic site, 75. *See also* Active site
- Cataracts, diabetic, 172
- Catecholamines. *See also* specific type
 receptors for, 436
 storage/secretion of, 453, 454t
 synthesis of, 445–447, 447f
- Catepsins, in acid-base catalysis, 52
- Cavolac, 422
- Caveolin-1, 422
- CBG. *See* Corticosteroid-binding globulin
- CBP/CBP/p300 (CREB-binding protein), 461, 468, 469, 469f, 471–472, 472t
- CD11a-c/CD18, in neutrophils, 621, 621t
- CD18, 620–621
- CD49a/e/f, 622t
- CD59, 531
- CDK-cyclin inhibitor/CDKI, DNA/chromosome integrity and, 339
- CDKs. *See* Cyclin-dependent protein kinases
- cDNA, 413
 sequencing, in glycoprotein analysis, 515t
- cDNA library, 402, 413
- CDRs. *See* Complementarity-determining regions
- Celiac disease, 474
- Cell, 1
 injury to
 oxygen species causing, 611–613, 613t
 xenobiotics causing, 631, 631f
 lysis of, complement in, 596
 in macromolecule transport, 428–431, 429f, 430f
- Cell adhesion
 fibronectin in, 540, 541f
 glycosphingolipids in, 202
 integrins in, 620–621, 622t
 selectins in, 528–529, 529t, 530f
- Cell biology, 1
- Cell-cell interactions, 415
 mucins in, 520
- Cell cycle, S phase of, DNA synthesis during, 333–335, 334f, 335t
- Cell death, 201
- Cell-free systems, vesicles studied in, 509
- Cell fusion, 595
- Cell-mediated immunity, 591
- Cell membrane. *See* Plasma membrane
- Cell migration, fibronectin in, 540
- Cell recognition, glycosphingolipids in, 202
- Cell sap. *See* Cytosol
- Cell surface carbohydrates, glycolipids and, 116
- Cell surfaces, heparan sulfate on, 545
- Cellulose, 109
- Cellulose acetate zone electrophoresis, 580, 582f
- Central core disease, 565, 569t
- Central nervous system, glucose as metabolic necessity for, 232
- Centromere, 318, 319f
- Cephalin (phosphatidylethanolamine), 115, 115f
 membrane asymmetry and, 420
 synthesis of, 197, 197f
- Ceramide, 116, 116f, 201–202, 202f, 203f
 synthesis of, 201–202, 202f
- Cerebrohepato-renal (Zellweger) syndrome, 188, 503, 503t
- Cerebrosides, 201
- Ceruloplasmin, 583t, 587, 588
 deficiency of, 589
 diagnostic significance of, 57t, 587
- Cervonic acid, 113t
- CFTR. *See* Cystic fibrosis transmembrane regulator

- CFU-E. *See* Colony-forming unit-erythroid
- Chain elongation. *See also* Elongation by DNA polymerase, 328
in glycosaminoglycan synthesis, 543
in transcription cycle, 342, 342f
- Chain initiation. *See also* Initiation in transcription cycle, 342, 342f
- Chain termination. *See also* Termination in glycosaminoglycan synthesis, 543
in transcription cycle, 342, 342f
- Channeling, in citric acid cycle, 130
- Channelopathies, 568, 569t
- Chaperones, 36–37, 507–508, 508t
ATPase activity of, 508
ATP-dependent protein binding to, 499, 508
histone, 315
in protein sorting, 499, 508t
- Chaperonins, 36–37
- Charging, in protein synthesis, 360, 360f
- Checkpoint controls, 339
- Chédiak-Higashi syndrome, 512t
- Chemical carcinogenesis/carcinogens, 631
- Chemiosmotic theory, 92, 95–97, 97f
experimental findings in support of, 96
respiratory control and uncouplers and, 97
- Chemotactic factors, 620
- Chemotherapy, cancer
folate inhibitors in, 494
neutropenia caused by, 610
synthetic nucleotide analogs in, 290–291, 291f
- Chenodeoxycholic acid, 225, 226f
- Chenodeoxychyl CoA, 226, 226f
- Chimeric gene approach, 385–386, 387f, 388f
- Chimeric molecules, 397–406, 413
restriction enzymes and DNA ligase in preparation of, 399–400, 401f
- Chips, gene array, protein expression and, 28
- Chirin, 109, 109f
- Chloride
in extracellular and intracellular fluid, 416, 416t
permeability coefficient of, 419f
- Chlorophyll, 270
- Cholecalciferol (vitamin D₃)
synthesis of in skin, 445, 446f, 484, 485f
in vitamin D metabolism, 484, 485f
- Cholestatic jaundice, 283
- Cholesterol, 117, 118, 119f, 205, 219–230
in bile acid synthesis, 225–227, 226f
in calcitriol (1,25(OH)₂-D₃) synthesis, 445, 446f
dietary, 219
excess of. *See* Hypercholesterolemia
excretion of, 225–227, 226f
in hormone synthesis, 438, 438–445, 439t, 440f
in lipoprotein, 205, 207f
in membranes, 417
fluid mosaic model and, 422
metabolism of, 123–124, 123f
clinical aspects of, 227–229, 228t
diurnal variations in, 220
high-density lipoproteins in, 209–211, 211f
plasma levels of
atherosclerosis and coronary heart disease and, 227
dietary changes affecting, 227
drug therapy affecting, 229
lifestyle changes affecting, 227–229
normal, 223
synthesis of, 219–220, 220f, 221f, 222f
acetyl-CoA in, 123f, 124, 219–220, 220f, 221f, 222f
carbohydrate metabolism and, 123
HMG-CoA reductase in regulation of, 220, 223f
in tissues, 118, 119f
factors affecting balance of, 220–223, 224f
transport of, 223–224, 225f
reverse, 210, 211f, 219, 224
cholesteryl ester hydrolase, 223
cholesteryl ester transfer protein, 224, 225f
cholesteryl esters, 118, 205, 224
in lipoprotein core, 205, 207f
cholestyramine resins, for hypercholesterolemia, 229
Cholic acid, 225
Choline, 114–115, 115f
deficiency of, fatty liver and, 212
in glycine synthesis, 238, 239f
membrane asymmetry and, 420
Cholinesterase. *See* Acetylcholinesterase
Choluric jaundice, 282
Cholyl CoA, in bile acid synthesis, 226, 226f
Chondrodysplasias, 551t, 553–554, 554f
Chondroitin sulfates, 109, 109f, 538, 543–545, 544f, 544t
functions of, 547
Chondroectin, 551t, 553
Chorionic gonadotropin, human (hCG), 438
Christmas factor (factor IX), 599f, 600, 600t
coumarin drugs affecting, 604
deficiency of, 604
Chromatids
nucleoprotein packing in, 318, 319t, 320f
sister, 318, 319f
exchanges between, 325, 325f
Chromatin, 314–316, 315f, 315t
active vs. inactive regions of, 316–318, 318f
higher order structure/compaction of, 316, 317f
reconstitution of, in DNA replication, 333
remodeling of in gene expression, 383–384
Chromatography. *See also* specific type
affinity
for protein/peptide purification, 23
for recombinant fusion protein purification, 58, 59f
for protein/peptide purification, 21–24
Sephacrose-lectin column, for glycoprotein analysis, 515t
Chromium, 496t
Chromosomal integration, 324, 324f
Chromosomal recombination, 323–324, 323f, 324f
Chromosomal transposition, 324–325
Chromosome jumping, 635t
Chromosome walking, 411, 411f, 635t
Chromosomes, 318–319, 319f, 319t, 320f, 321f
integrity of, monitoring, 339
interphase, chromatin fibers in, 316
metaphase, 317f, 318, 319t
polytene, 318, 318f
variations in, 636
Chronic granulomatous disease, 623, 623f
Chyle, 207
Chylomicron remnants, 206t, 208, 209f
liver uptake of, 208–209
Chylomicrons, 125, 205, 206t
apolipoproteins of, 206, 206t
metabolism of, 125, 126f, 207–209, 209f
in triacylglycerol transport, 207, 208f, 209f
Chymotrypsin, 477
conserved residues and, 55t
in covalent catalysis, 52–54, 54f
in digestion, 477
for polypeptide cleavage, 26t
Chymotrypsinogen, 477
cl repressor protein/cl repressor gene, 379–383, 380f, 381f, 382f
CICR. *See* Calcium-induced calcium release
Cirrhosis of liver, 130, 212
in α_1 -antitrypsin deficiency, 590
Cistron, 375–376
Citrate
in citric acid cycle, 130, 131f
in lipogenesis regulation, 178
Citrate synthase, 130, 132f
Citric acid, pK_a/pK_s value of, 12t
Citric acid cycle (Krebs/tricarboxylic acid cycle), 83, 130–135, 131f, 132f
ATP generated by, 131f, 133, 142, 143t
carbon dioxide liberated by, 130–133, 132f
deamination and, 133–134
gluconeogenesis and, 133, 134f, 153–155, 154f

- Citric acid cycle (*cont.*)
 in metabolism, 122, 122f, 123f, 124f,
 126, 127f, 130, **133–135**, 134f
 amino acid, 122f, 124f
 carbohydrate, 122–123, 122f, 123f,
 133–134, 134f
 lipid/fatty acid, 122f, 123, 123f, 134,
 135f
 at subcellular level, 126, 127f
 in mitochondria, 126, 127f
 reducing equivalents liberated by,
130–133, 132f
 regulation of, 134–135
 respiratory chain substrates provided by,
130, 131f
 transamination and, 133–134, 134f
 vitamins in, **133**
- Citrulline, in urea synthesis, 245, 246–247,
 246f, 247
- Citrullinemia, 247
- CJD. *See* Creutzfeldt-Jakob disease
- Cl. *See* Chloride
- Class B scavenger receptor B1, 210, 211f
- Class (isotype) switching, 594
- Classic pathway, of complement activation,
 596
- Clathrin, 429f, 430
- Clathrin-coated vesicles, 510
- Cleavage, in protein sequencing, 25, 26f
- CLIP, 453, 453f
- Clofibrate, 229
- Clones
 definition of, 413
 library of, 402, 413
 in monoclonal antibody production, 596
- Cloning, 400–402, 401f, 402t, 403f
 in gene isolation, 635t
- Cloning vectors, 400–402, 401f, 402t,
 403f, 414
- Closed complex, 345
- Clotting factors, 600t. *See also specific type*
under Factor
 vitamin K in synthesis of, **486–488**, 488f
- CMP, 288t
- CMP-NeuAc, 516t, 517
- CNBr. *See* Cyanogen bromide
- CO. *See* Carbon monoxide
- CO₂. *See* Carbon dioxide
- CoA. *See* Coenzyme A
- Coactivators, transcription, 351, 351t
- Coagulation (blood), **598–608**
 endothelial cell products in, 607, 607t
 extrinsic pathway of, 598, 599f, 601
 fibrin formation in, 598–601, 599f
 final common pathway in, 598, 599,
 601, 602f
 intrinsic pathway of, 598, 599f, 600–601
 laboratory tests in evaluation of, 608
 prostaglandins in, 190
 proteins involved in, 599–600, 600t. *See*
also Coagulation factors
 vitamin K in, **486–488**, 488f
 coumarin anticoagulants affecting, 604
 Coagulation factors, 600t. *See also specific*
type under Factor
 vitamin K in synthesis of, **486–488**, 488f
- Coat proteins, recruitment of, 509, 510f
- Coated pits, in absorptive pinocytosis, 429f,
 430
- Coating, vesicle, 509, 510f
 brefeldin A affecting, 510–511
- Cobalamin (vitamin B₁₂), 482t, **491–492**,
 492f
 absorption of, 491–492
 intrinsic factor in, 477, 491–492
 deficiency of, 482t, 492
 functional folate deficiency and, 492,
 494
 in methylmalonic aciduria, 155
- Cobalophilin, 492
- Cobalt, 496t
 in vitamin B₁₂
- Cobamide, coenzymes derived from, 51
- Coding regions, 319, 321f, 637
 in recombinant DNA technology, 397,
 398f
- Coding strand, 304
 in RNA synthesis, 341
- Codon usage tables, 359–360
- Codons, 358, 359t
 amino acid sequence of encoded protein
 specified by, **358**
 nonsense, 359
- Coenzyme A, synthesis of from pantothenic
 acid, 495, 495f
- Coenzyme Q (Q/ubiquinone), 92, 95f
- Coenzymes, 50
 in catalysis, **50–51**, 51f
 nucleotide derivatives, 290, 290t
- Cofactors, 50
 in blood coagulation, 600, 600t, 603
 in catalysis, **50–51**, 51f
 in citric acid cycle regulation, 134–135
- Colipase, 475
- Collagen, **37–39**, 371, **535–539**, 536t
 in bone, 548t, 549
 in cartilage, 551t, 552, 553f
 classification of, 535, 536t
 elastin differentiated from, 539t
 fibril formation by, **535–539**, 536f, 537t
 genes for, 535, 536t
 diseases caused by mutations in, 39,
 538–539, 538t
 chondrodysplasias, 551t, 553
 osteogenesis imperfecta, 551
 maturation/synthesis of, 38–39
 ascorbic acid (vitamin C) in, 38, 496
 disorders of, 38–39
 O-glycosidic linkage in, 518
 in platelet activation, 605, 606f, 607
 posttranslational modification of,
 537–538, 537t
- secretion of, 537
 triple helix structure of, 38, 38f,
535–539, 536f
 types of, 535, 536t
- Collision-induced dissociation, in mass
 spectrometry, 27
- Collision (kinetic) theory, 61
- Colon cancer. *See* Colorectal cancer
- Colony-forming unit-erythroid, 610, 611f
- Colony hybridization, 403–404. *See also*
Hybridization
- Colorectal cancer, mismatch repair genes in,
 336
- Coltranslational glycosylation, 504
- Column chromatography, for protein/
 peptide purification, 21, 22f
- Combinatorial diversity, 592
- Compartmentation, **72–73**
- Competitive inhibition, noncompetitive
 inhibition differentiated from,
67–69, 67f, 68f, 69f
- Complement, 583t, 596–597
 in inflammation, 596, 621t
- Complementarity
 of DNA, 306, 307f
 recombinant DNA technology and,
 396–397
 of RNA, 306, 309f
- Complementarity-determining regions,
 591–592, 594f
- Complementary DNA (cDNA), 413
- Complementary DNA (cDNA) library,
 402, 413
- Complex (glycoconjugate) carbohydrates,
 glycoproteins as, 514
- Complex oligosaccharide chains, 521, 522f
 formation of, 521, 524
- Concanavalin A (ConA), 110, 518t
- Conformational diseases, 590
- Congenital disorders of glycosylation
 (CDG), 530t, 531
- Congenital long QT syndrome, 432t
- Congenital nonhemolytic jaundice (type I
 Crigler-Najjar syndrome), 283
- Conjugate acid, 10
- Conjugate base, 10
- Conjugation
 of bilirubin, 280, 280f, 281f
 of xenobiotics, 626, **628–630**
- Connective tissue, 535
 bone as, **549–550**
 keratan sulfate I in, 545
- Connexin, 431
- Consensus sequences, 353, 353f
 Kozak, 365
- Conservation of energy, 83
- Conserved residues, 54, 55t
- Constant regions/segments, 593
 gene for, 593
 DNA rearrangement and, 325–326,
 393, 593–594

- immunoglobulin heavy chain, 591, 592f
immunoglobulin light chain, 325–326, 393, 591, 592f
- Constitutive enzymes, 75
- Constitutive gene expression, 376, 378
- Constitutive heterochromatin, 316
- Constitutive mutation, 376
- Constitutive secretion, 498
- Contig map, 634f
- Contractility/contraction. *See* Muscle contraction
- Cooperative binding
hemoglobin, 42
Bohr effect and, 44, 45f
Hill equation describing, 66–67, 67f
- COP1 vesicles, 510
- COP2 vesicles, 510
- Coplanar atoms, partial double-bond character and, 19, 20f
- Copper, 496t
ceruloplasmin in binding of, 587, 588
as cofactor, 588, 588t
enzymes containing, 588t
in Menkes disease, 588
metallothioneins in regulation of, 588
in oxidases, 86
tests for disorders of metabolism of, 588, 589t
in Wilson disease, 587, 588–589
- Copper-binding P-type ATPase, mutations in gene for
Menkes disease caused by, 588
Wilson disease caused by, 588–589
- Copper toxicosis, 588. *See also* Wilson disease
- Coproporphyrinogen I, 271, 275f
- Coproporphyrinogen III, 271, 275f
- Coproporphyrinogen oxidase, 271, 275f, 276f
in porphyria, 277t
- Coproporphyrins, 272f
spectrophotometry in detection of, 273–274
- Coprostanol (coprosterol), 225
- Core proteins, 542, 543f
in glycosaminoglycan synthesis, 542–543
- Coregulator proteins, 469, 471–473, 472f
- Corepressors, 472t, 473
- Cori cycle, 159, 159f
- Cori's disease, 152t
- Cornea, keratan sulfate I in, 545, 546, 547
- Coronary (ischemic) heart disease. *See also* Atherosclerosis
cholesterol and, 227
- Corrinoids, 491. *See also* Cobalamin
- Corticosteroid-binding globulin (CBG/transcortin), 454–455, 455t, 583t
cyclooxygenases affected by, 193
- Corticosterone
binding of, 454, 455t
synthesis of, 438, 440, 441f
- Corticotropin. *See* Adrenocorticotrophic hormone
- Cortisol, 439f, 440f
binding of, 454, 455, 455t
synthesis of, 440, 441f
- Cos sites, 401
- Cosmids, 401, 402t, 413
for cloning in gene isolation, 635t
- Cotranslation (factor VII), 599f, 600t, 601
coumarin drugs affecting, 604
- Cotranslational insertion, 504, 505–506
- Cotransport systems, 426, 426f
- Coulomb's law, 5
- Coumarin, 604
- Coupling, 81–82, 81f, 82f
ATP in, 82, 84
hormone receptor-effector, 435–436
- Coupling domains, on hormone receptors, 435–436
- Covalent bonds
biologic molecules stabilized by, 6, 6t
membrane lipid-protein interaction and, 419
xenobiotic cell injury and, 631, 631f
- Covalent catalysis, 52, 52f, 63
chymotrypsin in, 52–54, 54f, 63
fructose-2,6-bisphosphatase in, 54, 55f
- Covalent cross-links, collagen, 537
- Covalent modification
mass spectrometry in detection of, 27, 27f, 27t
in protein maturation, 37–39
in regulation of enzymatic catalysis, 74, 76, 77–78, 78f. *See also* Phosphorylation; Proteolysis
gluconeogenesis regulation and, 157
irreversible, 76–77, 77f
metabolite flow and, 79
reversible, 77–79, 78f, 78t
- CPT-I. *See* Carnitine palmitoyl transferase-I
- CRE. *See* Cyclic AMP response element
- Creatine, 267, 268f
- Creatine kinase, diagnostic significance of, 57t
- Creatine phosphate, 267, 268f
free energy of hydrolysis of, 82t
in muscle, 573–574, 574–576, 575f, 575t
- Creatine phosphate shuttle, 100, 101f
- Creatinine, 267, 268f
- CREB, 461
- CREB-binding protein, 461, 469, 469f, 471
- Creutzfeldt-Jakob disease, 37
- Grigler-Najjar syndrome
type I (congenital nonhemolytic jaundice), 283
type II, 283
- Cro protein/*cro* gene, 379–383, 380f, 381f, 382f
- binding of to DNA, by helix-turn-helix motif, 389–390, 389f
- Cross-bridges, 557, 557–559, 558f, 562f
- Cross-links, covalent in collagen, 537
- Crossing-over, in chromosomal recombination, 323–324, 323f, 324f
- Crouzon syndrome, 551t
- CRP. *See* C-reactive protein; Catabolite regulatory protein; Cyclic AMP regulatory protein
- Cryoprecipitates, recombinant DNA technology in production of, 604
- Cryptoxanthin, 482
- Crystallography, x-ray, protein structure demonstrated by, 35
- CS-PG I/II/III, in bone, 548t
- CT. *See* Calcitonin
- CTD. *See* Carboxyl terminal repeat domain
- CTP, 290
in phosphorylation, 85
- CY282Y mutation, in hemochromatosis, 587
- Cyanide, oxidative phosphorylation/respiratory chain affected by, 92, 95, 96f
- Cyanogen bromide, for polypeptide cleavage, 25, 26t
- Cyclic AMP, 147, 148f, 289, 289f, 290t, 458–462, 460t, 462f
adenylyl cyclase affecting, 147, 458–459, 460t
in cardiac muscle regulation, 566
in gluconeogenesis, 158, 158f
in glycogen metabolism regulation, 147–150, 148f, 149f, 150f
as second messenger, 147, 436, 437t, 457, 458–462, 460t, 462f
smooth muscle contraction affected by, 571
- Cyclic AMP-dependent protein kinase. *See* Protein kinases
- Cyclic AMP regulatory protein (catabolite gene activator protein), 376, 378
- Cyclic AMP response element, 459t, 461
- Cyclic AMP response element binding protein, 461
- Cyclic GMP, 289f, 290
as second messenger, 290, 436, 437t, 457, 462–463
role in smooth muscle, 573f
- Cyclic 3',5'-nucleotide phosphodiesterase, in lipolysis, 215
- Cyclin-dependent protein kinases, 333, 334f, 335t
inhibition of, DNA/chromosome integrity and, 339
- Cyclins, 333–335, 334f, 335t
- Cycloheximide, 372
- Cyclooxygenase, 192
as "suicide enzyme," 194
- Cyclooxygenase pathway, 192, 192–194, 193f, 194f

- CYP nomenclature, for cytochrome P450 isoforms, 627
- CYP2A6, polymorphism of, 628, 630*t*
- CYP2C9, in warfarin-phenobarbital interaction, 628
- CYP2D6, polymorphism of, 628, 630*t*
- CYP2E1, enzyme induction and, 628
- Cysteine, 15*t*, 265
- metabolism of, 250, 252*f*, 253*f*
- abnormalities of, 250–255, 253*f*
- in pyruvate formation, 250, 252*f*
- requirements for, 480
- synthesis of, 238–239, 239*f*
- Cystic fibrosis, 431–432, 432*t*, 474, 569*t*
- Cystic fibrosis transmembrane regulator (CFTR), 431, 431*f*, 432*t*
- Cystine reductase, 250, 252*f*
- Cystinosis (cystine storage disease), 250–255
- Cystinuria (cystine-lysineuria), 250
- Cytarabine (arabinosyl cytosine), 290
- Cytidine, 287*f*, 288*t*
- Cytidine monophosphate (CMP), 288*t*
- Cytidine monophosphate
- N*-acetylneuraminic acid (CMP-NeuAc), 516*t*, 517
- Cytidine triphosphate (CTP), 290
- in phosphorylation, 85
- Cytochrome *b₅*, 89, 627
- Cytochrome *b₅₅₈*, 622
- Cytochrome *c*, 93
- Cytochrome oxidase/cytochrome *a_{a3}*, 86, 93
- Cytochrome P450-dependent microsomal ethanol oxidizing system, 212–214
- Cytochrome P450 side chain cleavage enzyme (P450_{sc}), 438, 440*f*, 442
- Cytochrome P450 system, 86, 89–90, 90*f*, 626
- ALA synthase affected by, 272, 278
- enzyme induction and, 272–273, 627–628
- genes encoding, nomenclature for, 627
- isoforms of, 627–628
- in metabolism of xenobiotics, **626–628**, 629*t*
- membrane insertion, 504
- mitochondrial, 89–90
- nomenclature system for, 627
- in xenobiotic cell injury, 631, 631*f*
- Cytochromes, as dehydrogenases, 88
- Cytogenetic abnormalities, detection of, 635*t*
- Cytogenetic map, 633, 634*f*
- Cytokines, α_2 -macroglobulin binding of, 590
- Cytosine, 288*t*
- base pairing of in DNA, 303, 304, 305*f*
- deoxyribonucleosides of, in pyrimidine synthesis, **296–297**, 298*f*
- Cytoskeleton/cytoskeletal proteins, 556, **576–578**
- red cell, 615*f*, 616–617, 616*f*, 616*t*
- Cytosol
- ALA synthesis in, 270, 273*f*
- glycolysis in, 126, 127*f*, 136
- lipogenesis in, **173–177**, 174*f*, 175*f*
- pentose phosphate pathway reactions in, **163**
- pyrimidine synthesis in, 296, 298*f*
- Cytosolic branch, for protein sorting, 498, 499*f*
- Cytosolic dynein, 577
- Cytosolic proteins, O-glycosidic linkages in, 518
- Cytotoxicity, xenobiotic, 631, 631*f*
- D-amino acids, free, 14
- D arm, of tRNA, 310, 312*f*, 360, 361*f*
- D cyclins, 333, 334*f*, 335*t*
- cancer and, 334
- D isomerism, 102–104, 103*f*
- DAF. *See* Decay accelerating factor
- dAMP, 288*f*
- Dantrolene, for malignant hyperthermia, 564
- DBD. *See* DNA-binding domain
- DBH. *See* Dopamine- β -hydroxylase
- Deamination, 124, 124*f*
- citric acid cycle in, 133–134
- liver in, 125
- Debranching enzymes
- absence of, 152*t*
- in glycogenolysis, 146–147, 148*f*
- Debrisoquin, CYP2D6 in metabolism of, 628
- Decay accelerating factor, 531
- Decorin
- in bone, 548*t*
- in cartilage, 551*t*
- Defensins, 621*t*
- Degeneracy, of genetic code, 359
- Degradation, rate of (k_{deg}), 74
- Dehydrocholesterol, in vitamin D metabolism, 484, 485*f*
- Dehydroepiandrosterone (DHEA), synthesis of, 440, 441*f*
- Dehydroepiandrosterone (Δ^5) pathway, 442, 443*f*
- Dehydrogenases, 86, **87–88**, 88*f*
- in enzyme detection, 56, 56*f*
- nicotinamide coenzyme-dependent, 87, 89*f*
- in respiratory chain, 87
- riboflavin-dependent, 87
- Deletions, DNA, recombinant DNA technology in detection of, 409, 409*t*
- Delta^{5,4} ($\Delta^{5,4}$) isomerase, 438, 441*f*, 442, 443*f*
- Delta⁴ (Δ^4) (progesterone) pathway, 442, 443*f*
- Delta⁵ (Δ^5) (dehydroepiandrosterone) pathway, 442, 443*f*
- Delta⁹ (Δ^9) desaturase
- in monounsaturated fatty acid synthesis, 191, 191*f*
- in polyunsaturated fatty acid synthesis, **191**, 191*f*
- Denaturation
- DNA structure analysis and, 304–305
- protein refolding and, 36
- temperature and, 63
- Deoxynojirimycin, 527, 527*t*
- Deoxyadenylate, 303
- Deoxycholic acid, synthesis of, 226
- Deoxycorticosterone
- binding of, 454–455
- synthesis of, 438, 441*f*
- 11-Deoxycortisol, synthesis of, 440, 441*f*
- Deoxycytidine residues, methylation of, gene expression affected by, 383
- Deoxycytidylate, 303
- Deoxyguanylate, 303
- Deoxyhemoglobin, proton binding by, 44, 45*f*
- Deoxyhemoglobin A, "sticky patch" receptor on, 46
- Deoxyhemoglobin S, "sticky patch" receptor on, 46
- Deoxynucleotides, 303–304, 304*f*, 305*f*
- Deoxyribonucleases (DNase)/DNase I, 312
- active chromatin and, 316
- Deoxyribonucleic acid. *See* DNA
- Deoxyribonucleoside diphosphates (dNDPs), reduction of NDPs to, **294**, 297*f*
- Deoxyribonucleosides, 286
- in pyrimidine synthesis, **296**
- Deoxyribose, 102, 106, 106*f*
- Deoxy sugars, 106, 106*f*
- 3-Deoxyuridine, 290
- Dephosphorylation. *See also* Phosphorylation
- in covalent modification, 78–79, 78*t*
- Depolarization, in nerve impulse transmission, 428
- Depurination, DNA, base excision-repair and, 337
- Dermatan sulfate, 544*f*, 544*t*, 545
- functions of, 547
- Δ^1 Desaturase
- in monounsaturated fatty acid synthesis, 191, 191*f*
- in polyunsaturated fatty acid synthesis, **191**, 191*f*
- Desmin, 566*t*, 577*t*
- Desmosomes, 539
- Desmosterol, in cholesterol synthesis, 220, 222*f*
- Detergents, 417–418

- Detoxification, 626
 cytochrome P450 system in, 89–90, 90f,
 626–628, 629t
- Dextrinosis, limit, 152t
- Dextrins, 109
- Dextrose, 104
- DHA. *See* Docosahexaenoic acid
- DHEA. *See* Dehydroepiandrosterone
- DHPR. *See* Dihydropyridine receptor
- DHT. *See* Dihydrotestosterone
- Diabetes mellitus, 102, 161–162
 fatty liver and, 212
 free fatty acid levels in, 206
 hemochromatosis and, 587
 insulin resistance and, 611
 ketosis/ketoacidosis in, 188
 lipid transport and storage disorders and,
 205
 lipogenesis in, 173
 as metabolic disease, 122, 231
 starvation and, 236
- Diabetic cataract, 172
- Diacylglycerol, 115, 475, 476f
 in calcium-dependent signal
 transduction, 464, 465f
 formation of, 197f, 198f
 in platelet activation, 606, 606f
 in respiratory burst, 623
- Diacylglycerol acyltransferase, 198f, 199
- Diagnostic enzymology, 57, 57t
- Dicarboxylate anions, transporter systems
 for, 98–99
- Dicarboxylic aciduria, 188
- Dicumarol (4-hydroxydicoumarin), 486
- Dielectric constant, of water, 5
- Diet. *See also* Nutrition
 blood glucose regulation and, 159–161
 cholesterol levels affected by, 227
 hepatic VLDL secretion and, 211–212,
 213f
 high-fat, fatty liver and, 212
- Diet-induced thermogenesis, 217, 478
- Diethylenetriaminepentaacetate (DTPA),
 as preventive antioxidant, 119
- Diffusion
 facilitated, 423, 423t, 424f, 426–427,
 427, 427f
 of bilirubin, 280
 of glucose. *See also* Glucose
 transporters
 insulin affecting, 427
 in red cell membrane, 611
 hormones in regulation of, 427
 "ping-pong" model of, 427, 427f
 net, 423, 424f
 passive, 423, 423t, 424f
 simple, 423, 423t, 424f
- Digestion, 474–480
- Digitalis
 Ca²⁺-Na⁺ exchanger in action of, 568
 Na⁺-K⁺ ATPase affected by, 428, 568
- Dihydrobiopterin, defect in synthesis of, 255
- Dihydrobiopterin reductase, defect in, 255
- Dihydrofolate/dihydrofolate reductase,
 methotrexate affecting, 296–297,
 494
- Dihydrolipoyl dehydrogenase, 140, 141f
- Dihydrolipoyl transacylase, 140, 141f
- Dihydropyridine receptor, 563–564, 563f,
 564f
- Dihydrotestosterone, 442, 444f
 binding of, 455t
- Dihydroxyacetone, 106f
- Dihydroxyacetone phosphate, in glycolysis,
 197, 197f, 198f
- 1,25-Dihydroxyvitamin D₃. *See* Calcitriol
- 24,25-Dihydroxyvitamin D₃ (24-hydroxy-
 calcidiol), in vitamin D
 metabolism, 484, 485f
- Diiodotyrosine (DIT), 447, 448f, 449
- Dilated cardiomyopathy, 570
- Dimercaprol (BAL), respiratory chain
 affected by, 95, 96f
- Dimeric proteins, 34
- Dimers
 Cro protein, 380, 381f
 histone, 315
 lambda repressor (cI) protein, 380, 381f
- Dimethylallyl diphosphate, in cholesterol
 synthesis, 219, 221f
- Dimethylaminoadenine, 289f
- Dinitrophenol, respiratory chain affected
 by, 95, 96f
- Dinucleotide, 291
- Dioxygenases, 89
- Dipalmitoyl lecithin, 115
- Dipeptidases, 477
- Diphosphates, nucleoside, 287, 287f
- Diphosphatidylglycerol. *See* Cardiolipin
- Diphtheria toxin, 372
- Dipoles, water forming, 5, 6f
- Disaccharidases, 102, 475
- Disaccharides, 106–107, 107f, 107t. *See also*
 specific type
- Disease
 biochemical basis of, 2, 3t
 Human Genome Project and, 3–4
 major causes of, 3t
- Displacement reactions
 double, 69–70, 69f
 sequential (single), 69, 69f
- Dissociation, of water, 8–9
- Dissociation constant, 8–9
 Michaelis constant (*K_m*) and, 66
 in pH calculation, 10
 of weak acids, 10–11, 12
- Distal histidine (histidine E7), in oxygen
 binding, 40, 41f
- Disulfide bonds, protein folding and, 37
- DIT. *See* Diiodotyrosine
- Diurnal rhythm, in cholesterol synthesis,
 220
- Diversity
 antibody, 592, 593–594
 combinatorial, 592
 in gene expression, 387, 388f
 junctional, 593–594
- Diversity segment, DNA rearrangement
 and, 593–594
- DNA, 303, 303–306, 314–340
 base excision-repair of, 336t, 337, 337f
 base pairing in, 7, 303, 304, 305f
 matching of for renaturation, 305–306
 recombinant DNA technology and,
 396–397
 replication/synthesis and, 328–330,
 330f
 binding of to regulatory proteins, motifs
 for, 387–390, 388t, 389f, 390f,
 391f
 blunt-ended, 398, 399–400, 400f, 413
 in chromatin, 314–318, 315f, 315t,
 317f, 318f
 chromosomal, 318–319, 319f, 319t,
 320f, 321f
 relationship of to mRNA, 321f
 coding regions of, 319, 321f, 637
 complementarity of, 306, 307f
 recombinant DNA technology and,
 396–397
 damage to, 335, 335t
 repair of, 335–339, 335t, 336t
 ADP-ribosylation for, 490
 deletions in, recombinant DNA technol-
 ogy in detection of, 409, 409t
 depurination of, base excision-repair and,
 337
 double-strand break repair of, 336t,
 337–338, 338f
 double-stranded, 304
 flanking sequence, 397
 genetic information contained in,
 303–306
 grooves in, 305f, 306
 insertions in, recombinant DNA
 technology in detection of, 409
 integrity of, monitoring, 339
 "jumping," 325
 mismatch repair of, 36f, 336, 336f,
 336t
 mitochondrial, 322–323, 322f, 323t
 mutations in, 314, 323–326, 323f, 324f,
 325f. *See also* Mutations
 in nucleosomes, 315–316, 316f
 nucleotide excision-repair of, 336, 337,
 338f
 rearrangements of
 in antibody diversity, 325–326, 393,
 593–594
 recombinant DNA technology in
 detection of, 409, 409t
 recombinant. *See* Recombinant DNA/
 recombinant DNA technology

DNA (cont.)

- relaxed form of, 306
 - renaturation of, base pair matching and, 305–306
 - repair of, 335–339, 335*t*, 336*t*
 - repetitive-sequence, 320–322
 - replication/synthesis of, 306, 307*f*, 326–339, 326*t*, 327*f*, 328*t*
 - DNA polymerase complex in, 328, 328*t*
 - DNA primer in, 328, 329*f*, 330*f*
 - initiation of, 328–330, 329*f*, 330*f*, 331*f*
 - origin of, 326
 - polarity of, 330–331
 - proteins involved in, 328*t*
 - reconstitution of chromatin structure and, 333
 - repair during, 335–339, 335*t*, 336*t*
 - replication bubble formation and, 331–333, 331*f*, 332*f*, 333*f*
 - replication fork formation and, 327–328, 327*f*
 - ribonucleoside diphosphate reduction and, 294, 297*f*
 - in S phase of cell cycle, 333–335, 334*f*, 335*t*
 - semiconservative nature of, 306, 307*f*
 - semidiscontinuous, 327*f*, 331, 331*f*
 - unwinding and, 326, 326–327
 - in RNA synthesis, 341–343, 342*f*, 343*t*
 - stabilization of, 7
 - structure of, 303–306, 304*f*, 305*f*
 - denaturation in analysis of, 304–305
 - double-helical, 7, 303, 304, 305*f*
 - recombinant DNA technology and, 396, 397
 - supercoiled, 306, 332, 333*f*
 - transcription of, 306
 - transposition of, 325
 - unique-sequence (nonrepetitive), 320, 320–321
 - unwinding of, 326, 326–327
 - RNA synthesis and, 344
 - xenobiotic cell injury and, 631
- DNA binding domains, 390–391, 392*f*, 470
- DNA binding motifs, 387–390, 388*t*, 389*f*, 390*f*, 391*f*
- DNA-dependent protein kinase, in double-strand break repair, 338
- DNA-dependent RNA polymerases, 342–343, 342*f*, 343*t*
- DNA elements, gene expression affected by, 384–385, 384*f*, 385*t*, 386*f*
- diversity and, 387, 388*f*
- DNA fingerprinting, 413
- DNA footprinting, 413
- DNA helicase, 326–327, 327*f*, 328, 328*t*
- DNA ligase, 328*t*, 330
- in recombinant DNA technology, 399–400, 400*t*, 401*f*

- DNA-PK. *See* DNA-dependent protein kinase
- DNA polymerases, 326, 327–328, 327*f*, 328, 328*t*
 - in recombinant DNA technology, 400*t*
- DNA primase, 327, 327*f*, 328*t*
- DNA probes, 402, 414
 - for gene isolation, 635*t*
 - library searched with, 402
 - in porphyria diagnosis, 274
- DNA-protein interactions, bacteriophage lambda as paradigm for, 378–383, 379*f*, 380*f*, 381*f*, 382*f*
- DNA sequences
 - amplification of by PCR, 405–406, 406*f*
 - determination of, 404, 405*f*
 - in gene isolation, 635*t*
 - protein sequencing and, 25–26
- DNA topoisomerases, 306, 328*t*, 332, 332*f*
- DNA transfection, identification of enhancers/regulatory elements and, 386
- DNA unwinding element, 326
- DNase (deoxyribonuclease)/DNase I, 312
- active chromatin and, 316
 - in recombinant DNA technology, 400*t*
- dNDPs. *See* Deoxyribonucleoside diphosphates
- DOC. *See* 11-Deoxycorticosterone
- Docking, in nuclear import, 501, 502*f*
- Docking protein, 504
- Docosahexaenoic acid, 191–192
- Dolichol, 118, 119*f*, 522, 523*f*
 - in cholesterol synthesis, 220, 221*f*
 - in N-glycosylation, 522
- Dolichol kinase, 522
- Dolichol-P-P-GlcNAc, 522–523
- Dolichol-P-P-oligosaccharide (dolichol-pyrophosphate-oligosaccharide), 521, 524*f*
 - in N-glycosylation, 521–524, 523*f*
- Dolichol phosphate, 522
- Domains. *See also specific type*
 - albumin, 584
 - carboxyl terminal repeat, 350
 - chromatin, 316, 318, 319*f*
 - coupling, on hormone receptors, 435–436
 - DNA binding, 390–391, 392*f*, 470
 - fibronectin, 540, 541*f*
 - protein, 33–34
 - Src homology 2 (SH2)
 - in insulin signal transmission, 465, 466*f*, 467
 - in Jak/STAT pathway, 467, 467*f*
 - trans-activation, of regulatory proteins, 390–391, 392*f*
 - transcription, 387
- L-Dopa, 446, 447*f*
- Dopa decarboxylase, 267, 267*f*, 446, 447*f*

- Dopamine, 446, 447*f*. *See also* Catecholamines
 - synthesis of, 267, 267*f*, 445–447, 447*f*
- Dopamine- β -hydroxylase, 447
- vitamin C as coenzyme for, 495–496
- Dopamine β -oxidase, 267, 267*f*
- Double displacement reactions, 69–70, 69*f*
- Double helix, of DNA structure, 7, 303, 304, 305*f*
 - recombinant DNA technology and, 396, 397
- Double reciprocal plot
 - inhibitor evaluation and, 68, 68*f*, 69*f*
 - K_m and V_{max} estimated from, 66, 66*f*
- Double-strand break repair of DNA, 336*t*, 337–338, 338*f*
- Double-stranded DNA, 304, 314
 - unwinding
 - for replication, 326, 326–327
 - RNA synthesis and, 344
- Downstream promoter element, 346–348, 347*f*
- DPE. *See* Downstream promoter element
- DRIPs, 472*t*, 473
- Drug detoxification/interactions,
 - cytochromes P450 and, 89–90, 90*f*, 628
- Drug development, pharmacogenetics and, 631–632
- Drug resistance, gene amplification in, 393
- DS-PG I/DS-PG II, in cartilage, 551*t*
- dsDNA. *See* Double-stranded DNA
- DTPA, as preventive antioxidant, 119
- Dubin-Johnson syndrome, 283
- Duchenne muscular dystrophy, 556, 565–566, 566*f*
- DUE. *See* DNA unwinding element
- Dwarfism, 551*t*, 553–554
- Dynamin, in absorptive pinocytosis, 430, 577
- Dyneins, 577
- Dysbetalipoproteinemia, familial, 228*t*
- Dyslipoproteinemias, 228*t*, 229
- Dystrophin, 556, 565–566, 566*t*, 567*f*
 - mutation in gene for, in muscular dystrophy, 565–566, 566*f*
- E_0 . *See* Redox (oxidation-reduction) potential
- E_{act} . *See* Activation energy
- E. coli*, lactose metabolism in, operon hypothesis and, 376–378, 376*f*, 377*f*
- E. coli* bacteriophage P1-based (PAC) vector, 401–402, 402*t*, 413
- E cyclins, 333, 334*f*, 335*t*
- E-selectin, 529*t*
- E (exit) site, in protein synthesis, 38*f*, 368
- ECF. *See* Extracellular fluid
- ECM. *See* Extracellular matrix

- EcoRI*, 398, 399*t*, 401*f*
EcoRII, 399*t*
 Edema
 in kwashiorkor, 479
 plasma protein concentration and, 580
 in thiamin deficiency, 489
 Edman reaction, for peptide/protein sequencing, 25, 26*f*
 Edman reagent (phenylisothiocyanate), in protein sequencing, 25, 26*f*
 EDRF. *See* Endothelium-derived relaxing factor
 EDTA, as preventive antioxidant, 119
 EFA. *See* Essential fatty acids
 EFs. *See* Elongation factors
 EGF. *See* Epidermal growth factor
 Egg white, uncooked, biotin deficiency caused by, 494
 Ehlers-Danlos syndrome, 538, 538*t*
 Eicosanoids, 112, 190, 192, 193*f*, 194*f*, 621*t*
 Eicosapentaenoic acid, 190*f*
 eIF-4E complex, in protein synthesis, 367, 367*f*
 eIFs, in protein synthesis, 365
 80S initiation complex, in protein synthesis, 366*f*, 367
 Elaidic acid, 112, 113, 113*t*, 114*f*
 Elastase, in digestion, 477
 Elastin, 539, 539*t*
 Electrochemical potential difference, in oxidative phosphorylation, 96
 Electron carriers, flavin coenzymes as, 490
 Electron movement, in active transport, 427
 Electron-transferring flavoprotein, 87, 181
 Electron transport chain system, 622. *See also* Respiratory chain
 Electrophiles, 7
 Electrophoresis
 for plasma protein analysis, 580
 polyacrylamide, for protein/peptide purification, 24, 24*f*, 25*f*
 pulsed-field gel, for gene isolation, 635*t*
 two-dimensional, protein expression and, 28
 Electrospray dispersion, in mass spectrometry, 27
 Electrostatic bonds/interactions, 7. *See also* Salt (electrostatic) bonds
 oxygen binding rupturing, Bohr effect
 protons and, 44–45, 45*f*
 ELISAs. *See* Enzyme-linked immunoassays
 Elliptocytosis, hereditary, 617
 Elongase, 177, 177*f*
 in polyunsaturated fatty acid synthesis, 191, 191*f*, 192*f*
 Elongation
 chain
 in fatty acid synthesis, 177, 177*f*
 in transcription cycle, 342, 342*f*
 in DNA synthesis, 328
 in glycosaminoglycan synthesis, 543
 in protein synthesis, 367–370, 368*f*
 in RNA synthesis, 342, 342*f*, 344
 Elongation arrest, 504
 Elongation factor 2, in protein synthesis, 368, 368*f*
 Elongation factor EF1A, in protein synthesis, 368, 368*f*
 Elongation factors, in protein synthesis, 367, 368, 368*f*
 Emelin, 539
 Emphysema, α_1 -antitrypsin deficiency and, 589, 589*f*, 623–624
 Emulsions, amphipathic lipids forming, 120*f*, 121
 Encephalopathies
 hyperbilirubinemia causing (kernicterus), 282, 283
 mitochondrial, with lactic acidosis and stroke (MELAS), 100–101
 spongiform (prion diseases), 37
 Wernicke's, 489
 Endergonic reaction, 80, 81
 coupling and, 81–82, 81*f*, 82*f*
 ATP in, 82, 84
 Endocrine system, 434–455. *See also* Hormones
 diversity of, 437–438
 Endocytosis, 428, 429–430, 429*f*
 receptor-mediated, 429*f*
 Endoglycosidase F, 517
 Endoglycosidase H, 517
 Endoglycosidases, in glycoprotein analysis, 515*t*, 517, 517*t*
 Endonucleases, 312, 413
 apurinic and apyrimidinic, in base excision-repair, 337
 restriction, 312, 397–399, 399*t*, 400*f*, 414
 in recombinant DNA technology, 399–400, 399*t*, 400*f*, 400*t*, 401*f*
 Endopeptidases, 477
 Endoplasmic reticulum, 370
 acylglycerol synthesis and, 126, 127*f*
 core protein synthesis in, 543
 fatty acid chain elongation in, 177, 177*f*
 rough
 glycosylation in, 524–525, 525*f*
 in protein sorting, 498, 499*f*, 500*f*
 protein synthesis and, 370
 routes of protein insertion into, 505–507, 506*f*
 signal hypothesis of polyribosome binding to, 503–505, 504*t*, 505*f*
 smooth, cytochrome P450 isoforms in, 627
 Endoproteinase, for polypeptide cleavage, 26*t*
 Endorphins, 453, 453*f*
 Endothelial cells
 in clotting and thrombosis, 607, 607*t*
 neutrophil interaction and
 integrins in, 529*t*, 620–621, 622*t*
 selectins in, 528–529, 529*t*, 530*f*
 Endothelium-derived relaxing factor, 572, 607*t*. *See also* Nitric oxide
 Energy
 activation, 61, 63
 conservation of, 83
 free. *See* Free energy
 in muscle, creatine phosphate as reserve for, 573–574, 575*f*
 nutritional requirement for, 478
 transduction of
 membranes in, 415
 in muscle, 556–559
 Energy balance, 478–479
 Energy capture, 82–83, 82*f*, 83
 Energy expenditure, 478
 Energy transfer, 82–83, 82*f*
 Enhanceosome, 385, 386*f*
 Enhancers/enhancer elements, 348
 in gene expression, 384–385, 384*f*, 385*t*
 tissue-specific expression and, 385
 recombinant DNA technology and, 397
 reporter genes in definition of, 385–386, 387*f*, 388*f*
 Enolase, in glycolysis, 137, 138*f*
 Δ^2 -Enoyl-CoA hydratase, 181, 182*f*
 Δ^3 -Enoyl-CoA isomerase, 183
 Δ^2 -trans-Enoyl-CoA isomerase, 183
 Entactin, in basal lamina, 540
 Enterohepatic circulation, 227
 lipid absorption and, 475
 Enterohepatic urobilinogen cycle, 281
 Enteroproteidase, 477
 Enthalpy, 80
 Entropy, 80
 Enzyme induction, 630
 cytochrome P450 and, 272–273, 627–628
 in gluconeogenesis regulation, 155–157, 156*t*
 Enzyme-linked immunoassays (ELISAs), 55
 Enzymes, 7–8
 active sites of, 51, 51*f*
 assay of, 55–56, 56*f*
 branching, in glycogen biosynthesis, 145, 147*f*
 catalytic activity of, 49, 50*f*. *See also* Catalysis
 detection facilitated by, 55–56, 56*f*
 kinetics of, 63–70. *See also* Kinetics (enzyme)
 regulation of, 72–79, 128*f*, 129
 RNA and, 356
 specificity of, 49, 50*f*
 classification of, 49–50
 constitutive, 75
 debranching
 absence of, 152*t*
 in glycogenolysis, 146–147, 148*f*

Enzymes (*cont.*)

- degradation of, control of, 74
 - in disease diagnosis/prognosis, **56–57**, 57*t*, 58*f*, 58*t*
 - in DNA repair, 335, 336*t*, 338–339
 - hydrolysis rate affected by, 7–8
 - irreversible inhibition ("poisoning") of, 69
 - isozymes and, **54–55**
 - kinetics of, **60–71**. *See also* Kinetics (enzyme)
 - mechanisms of action of, **49–59**
 - membranes in localization of, 415
 - metal-activated, 50
 - as mitochondrial compartment markers, **92**
 - plasma, diagnostic significance of, 57, 57*t*
 - quantity of, catalytic capacity affected by, **73–74**
 - rate of degradation of (k_{deg}), control of, 74
 - rate of synthesis of (k_s), control of, 74
 - recombinant DNA technology in study of, **58**, 59*f*
 - regulatory, 126–129, 128*f*
 - restriction. *See* Restriction endonucleases
 - specificity of, 49, 50*f*
 - substrates affecting conformation of, **52**, 53*f*
- Enzymopathies, 619
- Epidermal growth factor (EGF), receptor for, 436
- Epidermolysis bullosa, 538, 538*t*
- Epimerases
- in galactose metabolism, 167, 170*f*
 - in glycosaminoglycan synthesis, 543
 - in pentose phosphate pathway, 163, 165*f*
- Epimers, 104, 104*f*
- Epinephrine, 439*f*, 447, 447*f*. *See also* Catecholamines
- blood glucose affected by, 161
 - in gluconeogenesis regulation, 157
 - in lipogenesis regulation, 178
 - synthesis of, 267, 267*f*, 445–447, 447*f*
- Epitope (antigenic determinant), 33, 591
- Epoxide hydrolase, 631
- Epoxides, 631
- Equilibrium constant (K_{eq}), 62–63
- in enzymatic catalysis, **63**
 - free energy changes and, 60–61
- ER. *See* Estrogens, receptors for
- Ercalcitriol, 484
- ERE. *See* Estrogen response element
- eRF. *See* Releasing factors
- Ergocalciferol (vitamin D₂), 484
- Ergosterol, 118, 119*f*
- Erythrocyte aminotransferases, in vitamin B₆ status assessment, 491
- Erythrocyte transketolase activation, in thiamin nutritional status assessment, 489

Erythrocytes, **609–610**, **610–619**

- 2,3-bisphosphoglycerate pathway in, 140, 140*f*
 - disorders affecting, 609, 610*t*
 - erythropoietin in regulation of, 609–610, 611*f*
 - glucose-6-phosphate dehydrogenase deficiency affecting, 613, 614*f*, 619
 - glucose as metabolic necessity for, 232
 - glycolysis in, 140, 140*f*
 - hemoglobin S "sticky patch" affecting, 46
 - hemolysis of, pentose phosphate pathway/glutathione peroxidase and, **166**, 167*f*, 169–170
 - life span of, 609
 - membranes of, **614–617**, 615*f*, 615*t*, 616*f*, 616*t*
 - glucose transporter of, 611, 612*t*
 - hemolytic anemias and, **619**, 620*t*
 - metabolism of, 235*t*, **610–614**, 612*t*
 - oxidants produced during, 611–613, 613*t*
 - recombinant DNA technology in study of, 624
 - structure and function of, **609–610**
- Erythroid ALA synthase (ALAS2), 272, 273
- in porphyria, 274, 277*t*
- Erythropoiesis, 609–610, 611*f*
- Erythropoietin/recombinant erythropoietin (epoetin alfa/EPO), 526, 583*t*, 609–610, 611*f*
- D-Erythrose, 104*f*
- Escherichia coli*, lactose metabolism in, operon hypothesis and, 376–378, 376*f*, 377*f*
- Escherichia coli* bacteriophage P1-based (PAC) vector, 401–402, 402*t*, 413
- Essential amino acids. *See* Nutritionally essential amino acids
- Essential fatty acids, **190**, 190*f*, 193
- abnormal metabolism of, 195–196
 - deficiency of, **191–192**, 194–195
 - prostaglandin production and, 190
- Essential fructosuria, 163, 171–172
- Essential pentosuria, 163, 170
- Estradiol/17 β -Estradiol, 439*f*, 440*f*
- binding of, 455, 455*t*
 - synthesis of, 442–445, 444*f*
- Estriol, synthesis of, 442, 444*f*
- Estrogen response element, 459*t*
- Estrogens
- binding of, 455, 455*t*
 - receptors for, 471
 - synthesis of, 442–445, 444*f*, 445*f*
- Estrone
- binding of, 455*t*
 - synthesis of, 442, 444*f*
- Ethanol
- CYP2E1 induction and, 628
 - fatty liver and, 212–214

- iron absorption and, 478
 - thiamin deficiency and, 489
- Ethylenediaminetetraacetate (EDTA), as preventive antioxidant, 119
- Euchromatin, 316
- Eukaryotic gene expression, **383–387**, 391–395, 392*t*. *See also* Gene expression
- chromatic remodeling in, 383–384
 - diversity of, 387, 388*f*
 - DNA elements affecting, 384–385, 384*f*, 385*t*, 386*f*
 - DNA-protein interactions in, bacteriophage lambda as paradigm for, 378–383, 379*f*, 380*f*, 381*f*, 382*f*
 - locus control regions and insulators in, 387
 - prokaryotic gene expression compared with, **391–395**, 392*t*
 - reporter genes and, 385–386, 387*f*, 388*f*
 - tissue-specific, 385
- Eukaryotic promoters, in transcription, 346–349, 347*f*, 348*f*, 349*f*
- Eukaryotic transcription complex, **350–352**, 351*t*
- Exchange transporters, **98–100**, 98*f*, 99*f*
- Excitation-response coupling, membranes in, 415
- Exergonic reaction, 80, 81
- coupling and, **81–82**, 81*f*, 82*f*
 - ATP in, 82, 84
- Exonuclease, in DNA repair, 337, 337*f*
- Exit (E) site, in protein synthesis, 368, 368*f*
- Exocytosis, 429, 430–431, 430*f*
- in insulin synthesis, 430–431
- Exocytotic (secretory) pathway, 498
- Exoglycosidases, in glycoprotein analysis, 515*t*, **517**, 517*t*
- Exons, 319, 358, 413
- interruptions in. *See* Introns
 - in recombinant DNA technology, 397, 398*f*
 - splicing, 352–354, 414
 - alternative, in regulation of gene expression, 354, 354*f*
 - 393–394, 636
 - recombinant DNA technology and, 397, 398*f*
- Exonucleases, 312, 413
- in recombinant DNA technology, 400*t*
- Exopeptidases, 477
- Exportins, 503
- Expression vector, 402
- Extra arm, of tRNA, 310, 312*f*
- Extracellular environment, membranes in maintenance of, **415–416**, 416*t*
- Extracellular fluid (ECF), 415–416, 416, 416*t*
- Extracellular matrix, **535–555**. *See also* specific component and under Matrix

- Extrinsic pathway of blood coagulation, 598, 599f, 601
- Eye, fructose and sorbitol in, diabetic cataract and, 172
- F_0 , in ATP synthesis, 96, 97f, 98f
- F_1 , in ATP synthesis, 96, 97f, 98f
- Fab region, 591, 592f
- Fabry's disease, 203t
- Facilitated diffusion/transport system, 423, 423t, 424f, 426–427, 427f, 427f
- for bilirubin, 280
- for glucose. *See also* Glucose transporters
- insulin affecting, 427
- in red cell membrane, 611
- hormones in regulation of, 427
- "Ping-Pong" model of, 427, 427f
- Factor I (fibrinogen), 580, 600, 600t
- conversion of to fibrin, 601–602
- Factor II (prothrombin), 600t, 601
- coumarin drugs affecting, 487, 604
- vitamin K in synthesis of, 487
- Factor III (tissue factor), 599f, 600t, 601
- Factor IV. *See* Calcium
- Factor V (proaccelerin/labile factor/accelerator globulin), 600t, 601, 602f
- Factor V Leiden, 603–604
- Factor VII (proconvertin/serum prothrombin conversion accelerator/cothromboplastin), 599f, 600t, 601
- coumarin drugs affecting, 604
- Factor VIII (antihemophilic factor A/globulin), 599f, 600, 600t
- deficiency of, 604
- Factor VIII concentrates, recombinant
- DNA technology in production of, 604
- Factor IX (antihemophilic factor B/Christmas factor/plasma thromboplastin component), 599f, 600, 600t
- coumarin drugs affecting, 604
- deficiency of, 604
- Factor X (Stuart-Prower factor), 599f, 600, 600t
- activation of, 599f, 600–601
- coumarin drugs affecting, 604
- Factor XI (plasma thromboplastin antecedent), 599f, 600, 600t
- deficiency of, 601
- Factor XII (Hageman factor), 599f, 600, 600t
- Factor XIII (fibrin stabilizing factor/fibrinoligase), 600t
- Facultative heterochromatin, 316
- FAD. *See* Flavin adenine dinucleotide
- FADH₂, fatty acid oxidation yielding, 181
- Familial hypertrophic cardiomyopathy, 569–570, 570f
- Fanconi's anemia, 338
- Farber's disease, 203t
- Farnesoid X receptor, in bile acid synthesis regulation, 227
- Farnesyl diphosphate, in cholesterol/polyisoprenoid synthesis, 219, 220, 221f
- Fast acetylators, 630
- Fast (white) twitch fibers, 574–576, 575t
- Fat tissue. *See* Adipose tissue
- Fatal infantile mitochondrial myopathy and renal dysfunction, oxidoreductase deficiency causing, 100
- Fatigue (muscle), 136
- Fats, 111. *See also* Lipids
- diets high in, fatty liver and, 212
- metabolism of, 122f, 123–124, 123f, 125–126, 126f
- Fatty acid-binding protein, 180, 207
- Fatty acid chains, elongation of, 177, 177f
- Fatty acid elongase system, 177, 177f
- in polyunsaturated fatty acid synthesis, 191, 191f, 192f
- Fatty acid oxidase, 181, 182f
- Fatty acid synthase, 156t, 173
- Fatty acid synthase complex, 173–176, 174f, 175f, 179
- Fatty acid-transport protein, membrane, 207
- Fatty acids, 2, 111–114
- activation of, 180–181, 181f
- calcium absorption affected by, 477
- eicosanoids formed from, 190, 192, 193f, 194f
- essential, 190, 190f, 193
- abnormal metabolism of, 195–196
- deficiency of, 191–192, 194–195
- prostaglandin production and, 190
- free. *See* Free fatty acids
- interconvertibility of, 231
- in membranes, 417, 418f
- metabolism of, 123–124, 123f
- nomenclature of, 111–112, 112f
- oxidation of, 180–189. *See also* Ketogenesis
- acetyl-CoA release and, 123–124, 123f, 181–183, 181f, 182f
- β , 181–183, 181f, 182f
- ketogenesis regulation and, 186–187, 187f, 188f
- modified, 183, 183f
- clinical aspects of, 187–189
- hypoglycemia caused by impairment of, 187–188
- in mitochondria, 180–181, 181f
- physical/physiologic properties of, 114
- saturated, 111, 112, 112t
- synthesis of, 173–179, 174f, 175f. *See also* Lipogenesis
- carbohydrate metabolism and, 123
- citric acid cycle in, 133, 134, 135f
- extramitochondrial, 173
- trans*, 113–114, 192
- transport of, carnitine in, 180–181, 181f
- triacylglycerols (triglycerides) as storage form of, 114, 115f
- unesterified (free). *See* Free fatty acids
- unsaturated. *See* Unsaturated fatty acids
- Fatty liver
- alcoholism and, 212–214
- of pregnancy, 188
- triacylglycerol metabolism imbalance and, 212
- Favism, 170
- Fc fragment, 591, 592f
- receptors for, in neutrophils, 621t
- Fe. *See* Iron
- Fed state, metabolic fuel reserves and, 232, 234t
- Feedback inhibition, in allosteric regulation, 74–76, 75f, 76, 129
- Feedback regulation
- in allosteric regulation, 76, 129
- thrombin levels controlled by, 602
- Fenton reaction, 612
- Ferric iron, 278
- in methemoglobinemia, 46
- Ferredoxin, 585
- Ferritin, 478, 585, 586
- protein synthesis affected by, 370
- Ferritin receptor, 586
- Ferrochelatase (heme synthase), 271, 272f
- in porphyria, 277t
- Ferrous iron
- incorporation of into protoporphyrin, 271–272, 272f
- in oxygen transport, 40–41
- Fertilization, glycoproteins in, 528
- FeS. *See* Iron sulfur protein complex
- Fetal hemoglobin, P₅₀ of, 42
- Fetal warfarin syndrome, 488
- α -Fetoprotein, 583t
- FFA. *See* Free fatty acids
- FGFs. *See* Fibroblast growth factors
- Fibrillin, 535, 539
- Marfan syndrome caused by mutations in gene for, 539–540, 540f
- Fibrils, collagen, 535–539, 536f, 537t
- Fibrin
- dissolution of by plasmin, 604–605, 604f
- formation of, 598–601, 599f
- thrombin in, 601–602, 603f
- in thrombi, 598
- Fibrin deposit, 598
- Fibrin mesh, formation of, 598
- Fibrin split products, in inflammation, 621t
- Fibrin stabilizing factor (factor XIII), 600t
- Fibrinogen (factor I), 580, 600, 600t
- conversion of to fibrin, 601–602
- Fibrinoligase (factor XIII), 600t
- Fibrinolysis, 604–605
- Fibrinopeptides A and B, 602, 603f

- Fibroblast growth factor receptor 3, achondroplasia caused by mutation in gene for, 551*t*, 554, 554*f*
- Fibroblast growth factor receptors, chondrodysplasias caused by mutation in gene for, 551*t*, 554, 554*f*
- Fibroblast growth factors (FGFs), 554
- Fibronectin, 535, 537–538, **540**, 541*f*
- Fibrous proteins, 30
- collagen as, 38
- Figlu. *See* Formiminoglutamate
- Final common pathway of blood coagulation, 599, 601, 602*f*
- Fingerprinting, DNA, 413
- FISH. *See* Fluorescence in situ hybridization
- Fish-eye disease, 228*t*
- 5' cap, mRNA modification and, 355
- Flanking-sequence DNA, 397
- Flavin adenine dinucleotide (FAD), 86–87, 290*t*, 489
- in citric acid cycle, 133
- Flavin mononucleotide (FMN), 50, 86–87, 489
- Flavoproteins
- electron-transferring, 87
- as oxidases, 86–87, 88*f*
- Flip-flop rate, phospholipid, membrane asymmetry and, 420
- Flippases, membrane asymmetry and, 420
- Fluid mosaic model, 421*f*, **422**
- Fluid-phase pinocytosis, 429–430, 429*f*
- Fluidity, membrane, 422
- Fluorescence, of porphyrins, **273–274**, 277*f*
- Fluorescence in situ hybridization, in gene mapping, 406–407, 407*t*, 635*t*
- Fluoride, 496*t*
- Fluoroacetate, 130, 132*f*
- 1-Fluoro-2,4-dinitrobenzene (Sanger's reagent), for polypeptide sequencing, 25
- 5-Fluorouracil, 290, 291*f*, 297
- Flux-generating reaction, 129
- FMN. *See* Flavin mononucleotide
- Folate. *See* Folic acid
- Folate trap, 492*f*, 494
- Folding
- polar and charged group positioning and, 6
- protein, **36–37**, 37*f*
- after denaturation, 36
- Folic acid (folate/pteroylglutamic acid), 482*t*, 492–494, 493*f*
- coenzymes derived from, 51
- deficiency of, 250, 482*t*, 494
- functional, 492, 494
- forms of in diet, 492, 493*f*
- inhibitors of metabolism of, 494
- supplemental, 494
- Folinic acid, 493
- Follicle-stimulating hormone (FSH), 437, 438, 439*f*
- Footprinting, DNA, 413
- Forbes' disease, 152*t*
- Forensic medicine
- polymerase chain reaction (PCR) in, 405
- restriction fragment length polymorphisms (RFLPs) in, 411
- variable numbers of tandemly repeated units (VNTRs) in, 411
- Formic acid, p*K*_a, value of, 12*t*
- Formiminoglutamate, in histidine catabolism, 250, 251*f*
- Formyl-tetrahydrofolate, 493, 493*f*, 494
- 43S initiation complex, in protein synthesis, 365, 366*f*
- 43S preinitiation complex, in protein synthesis, 365, 366*f*
- FPA/FPB. *See* Fibrinopeptides A and B
- Frameshift mutations, 363, 364*f*
- ABO blood group and, 619
- Framework regions, 592
- Free amino acids, absorption of, 477
- Free energy
- changes in, **80–81**
- chemical reaction direction and, **60–61**
- coupling and, **81–82**, 81*f*, 82*f*
- enzymes affecting, 63
- equilibrium state and, 60–61
- redox potential and, **86**, 87*t*
- transition states and, 61
- of hydrolysis of ATP, 82–83, 82*t*
- liberation of as heat, 95
- Free fatty acids, 111, 180, 205, 206*t*
- in fatty liver, 212
- glucose metabolism affecting, 215
- insulin affecting, 215
- ketogenesis regulation and, 186–187, 187*f*, 188*f*
- lipogenesis affected by, 177–178, 177*f*
- metabolism of, **206–207**
- starvation and, 232–234, 234*f*, 234*t*
- Free polyribosomes, protein synthesis on, 498, 506. *See also* Polyribosomes
- Free radicals (reactive oxygen species). *See also* Antioxidants
- hydroperoxidases in protection against, 88
- in kwashiorkor, 479
- lipid peroxidation producing, **118–119**, 120*f*
- in oxygen toxicity, 90–91, 611–613, 613*t*
- xenobiotic cell injury and, 631, 631*f*
- D-Fructofuranose, 103*f*
- Fructokinase, 167, 169*f*
- deficiency of, 171–172
- D-Fructopyranose, 103*f*
- Fructose
- absorption of, 475, 475*f*
- in diabetic cataract, 172
- glycemic index of, 474
- hepatic
- hyperlipidemia/hyperuricemia and, 170–171
- metabolism affected by, **167**, 169*f*
- iron absorption affected by, 478
- metabolism of, **167**, 169*f*
- defects in, 171–172
- pyranose and furanose forms of, 103*f*
- D-Fructose, 105*t*, 106*f*
- Fructose-1,6-bisphosphatase, 156*t*, 166
- deficiency of, 171–172
- Fructose-2,6-bisphosphatase, 157, 158*f*
- in covalent catalysis, 54, 55*f*
- Fructose-1,6-bisphosphate
- in gluconeogenesis, 153, 154*f*
- in glycolysis, 137, 138*f*
- Fructose-2,6-bisphosphate, 157–158, 158*f*
- Fructose intolerance, hereditary, 171
- Fructose 6-phosphate
- free energy of hydrolysis of, 82*t*
- in gluconeogenesis, 153, 154*f*
- in glycolysis, 137, 138*f*
- Fructosuria, essential, 163, 171–172
- FSF. *See* Fibrin stabilizing factor
- FSH. *See* Follicle-stimulating hormone
- Fucose, in glycoproteins, 516*t*
- Fucosidosis, 532–533, 533*t*
- Fucosylated oligosaccharides, selectins binding, 530
- Fucosyltransferase/fucosyl (Fuc) transferase, 618
- Fumarate (fumarate hydratase), 132*f*, 133
- Fumarate, 132*f*, 133
- in tyrosine catabolism, 254, 255*f*
- in urea synthesis, 246*f*, 247
- Fumarylacetoacetate, in tyrosine catabolism, 254*f*, 255
- Fumarylacetoacetate hydrolase, defect at, in tyrosinemia, 255
- Functional groups
- amino acid chemical reactions affected by, **18–20**
- amino acid properties affected by, **18**
- physiologic significance of, 10–11
- p*K* of, medium affecting, 13
- Functional plasma enzymes, 57. *See also* Enzymes
- Furanose ring structures, 103*f*, 104
- Fusion proteins, recombinant, in enzyme study, 58, 59*f*
- FXR. *See* Farnesoid X receptor
- Δ*G*. *See* Free energy
- Δ*G*⁰, 60, 61, 81
- Δ*G*_D, 61

- AGP, 61
 enzymes affecting, 63
 G-CSF. *See* Granulocyte colony-stimulating factor
 G protein-coupled receptors (GPCRs), 458, 459, 460f
 G proteins, 459, 461t
 in calcium-dependent signal transduction, 464f, 465
 in cAMP-dependent signal transduction, 436, 459, 461t
 in Jak/STAT pathway, 467
 in respiratory burst, 623
 GABA. *See* γ -Aminobutyrate
 GAGs. *See* Glycosaminoglycans
 Gal-Gal-Xyl-Ser trisaccharide, 518
 Gal-hydroxyllysine (Hyl) linkage, 518
 Gal transferase, 618–619, 619f
 Galactokinase, 167, 170f
 inherited defects in, 172
 Galactosamine, 169, 171f
 D-Galactosamine (chondrosamine), 106
 Galactose, 102, **167–169**, 170f
 absorption of, 475, 475f
 glycemic index of, 474
 in glycoproteins, 516f
 metabolism of, **167–169**, 170f
 enzyme deficiencies and, 172
 D-Galactose, 104f, 105t
 α -D-Galactose, 104f
 Galactose 1-phosphate uridyl transferase, 167, 170f
 Galactosemia, 102, 163, 172
 Galactosidases, in glycoprotein analysis, 517
 Galactoside, 106
 Galactosylceramide, 116, 117f, 201, 203f
 GalCer. *See* Galactosylceramide
 Gallstones, 474
 cholesterol, 219
 GalNAc, in glycoproteins, 515, 516f
 GalNAc-Ser(Thr) linkage
 in glycoproteins, 518, 519f
 in glycosaminoglycans, 543
 GalNAc transferase, in ABO system, 618–619, 619f
 Gamma- (γ) aminobutyrate. *See* γ -Aminobutyrate
 Gamma- (γ) carotene, 482
 Gamma-globulin, 581f
 Gamma- (γ) glutamyltransferase, 630
 Gamma- (γ) glutamyl transpeptidase (γ -glutamyltransferase),
 diagnostic significance of, 57t
 Gangliosides, 116
 amino sugars in, 106, 169, 171f
 sialic acids in, 110
 synthesis of, 201–202, 203f
 Gap junctions, 431
 GAPs. *See* Guanine activating proteins
 Gastric lipase, 475
 Gastroenteropathy, protein-losing, 582
 Gated ion channels, 424
 Gaucher's disease, 203t
 GDH. *See* Glutamate dehydrogenase/
 L-Glutamate dehydrogenase
 GDP-Fuc, 516t
 GDP-Man, 516t, 517
 GEFs. *See* Guanine nucleotide exchange factors
 Gel electrophoresis
 polyacrylamide, for protein/peptide purification, 24, 24f, 25f
 pulsed-field, for gene isolation, 635t
 Gel filtration, for protein/peptide purification, 21–22, 23f
 Gemfibrozil, 229
 Gender, xenobiotic-metabolizing enzymes affected by, 630
 Gene. *See* Genes; Genome
 Gene array chips, protein expression and, 28
 Gene conversion, 325
 Gene disruption/knockout, targeted, 412
 Gene expression
 constitutive, 376, 378
 in pyrimidine nucleotide synthesis, regulation of, 297–299
 regulation of, **374–395**
 alternative splicing and, 354, 354f, 393–394, 636
 eukaryotic transcription and, **383–387**
 hormones in, 458f
 negative versus positive, 374, 375t, 378, 380
 in prokaryotes versus eukaryotes, **391–395**, 392t
 regulatory protein–DNA binding motifs and, **387–390**, 388t, 389f, 390f, 391f
 regulatory protein DNA binding and trans-activation domains and, **390–391**, 392f
 retinoic acid in, 483
 temporal responses and, **374–375**, 375f
 Gene mapping, 319, 406–407, 407t, 633, 634f, 635t
 Gene products, diseases associated with deficiency of, 407t
 gene therapy for, 411
 Gene therapy, 411
 for α_1 -antitrypsin deficiency emphysema, 589
 for urea biosynthesis defects, 248
 Gene transcription. *See* Transcription
 General acid/base catalysis, 52
 Genes
 alteration of, **323–326**, 324f, 325f
 amplification of, in gene expression regulation, **323–326**, 324f, 325f
 disease causing, recombinant DNA technology in detection of, 407–408, 408f, 409t
 human genome information and, 638
 heterogeneous nuclear RNA processing in regulation of, 354
 housekeeping, 376
 immunoglobulin, DNA rearrangement and, 325–326, 393, 593–594
 double-strand break repair and, 337–338
 inducible, 376
 knockout, 412
 processed, 325
 reporter, 385–386, 387f, 388f
 targeted disruption of, 412
 variations in
 methods for isolation of, 635t
 normal, recombinant DNA techniques for identification of, 407
 size/complexity and, 397, 399t
 Genetic code, 303, **358–363**, 359t
 features of, **358–359**, 360t
 L- α -amino acids encoded by, 14, 15–16t
 Genetic diseases
 diagnosis of
 enzymes in, 57
 recombinant DNA technology in, 407–412, 408f, 409t, 410f, 411f
 gene therapy for, 411
 Genetic linkage. *See* Linkage analysis
 Genetic mapping, 633, 634f. *See also* Human Genome Project
 Genetics. *See also* Human Genome Project
 molecular, 1
 xenobiotic-metabolizing enzymes affected by, 630
 Genevan system, for fatty acid nomenclature, 111
 Genome
 redundancy in, **320–322**
 removal of gene from (targeted gene disruption/knockout), 412
 sequencing. *See also* Human Genome Project
 approaches used in, 634, 635t
 results of, **636–637**, 636t, 637t
 working draft of, 633
 Genomic library, 402, 413
 Genomic technology, 396. *See also* Recombinant DNA/recombinant DNA technology
 Genomics, protein sequencing and, 28
 Geometric isomerism, of unsaturated fatty acids, 112–114, 114f
 Geranyl diphosphate, in cholesterol synthesis, 219, 221f
 GGT. *See* γ -Glutamyltransferase
 Ghosts, red cell membrane analysis and, 614
 Gibbs free energy/Gibbs energy. *See* Free energy

- Gilbert syndrome, 283
- GK (glucokinase) gene, regulation of, 355, 355f
- Gla. *See* γ -Carboxyglutamate
- GlcCer. *See* Glucosylceramide
- GlcNAc. *See* N-Acetylglucosamine
- Glial fibrillary acid protein, 577t
- Glibenclamide. *See* Glyburide
- Globin, 278
- α -Globin gene, localization of, 407t
- β -Globin gene
- localization of, 407t
 - recombinant DNA technology in
 - detection of variations in, 407–408, 408f, 409t
- Globular proteins, 30
- β -turns in, 32, 34f
- β_1 -Globulin, 581f
- transferrin as, 586
- γ -Globulin, 581f
- Globulins, 580
- Glomerular filtration, basal lamina in, 540
- Glomerular membrane, laminin in, 540–542
- Glomerulonephritis, 541
- Glomerulus, renal, laminin in, 540–542
- Glucagon, 148, 160–161
- in gluconeogenesis regulation, 157
 - in lipogenesis regulation, 178, 178f
- Glucagon/insulin ratio, in ketogenesis regulation, 187
- Glucagon-like peptide, 437
- Glucan (glucosan), 107
- Glucan transferase, in glycogenolysis, 146, 146f, 148f
- Glucocorticoid receptor-interacting protein (GRIP1 coactivator), 472, 472t
- Glucocorticoid response element (GRE), 456, 458f, 459t
- Glucocorticoids, 437. *See also specific type*
- in amino acid transport, 427
 - blood glucose affected by, 161
 - in lipolysis, 215, 216f
 - NF- κ B pathway regulated by, 468, 468f
 - receptors for, 471
 - synthesis of, 440, 441f
 - transport of, 454–455, 455t
- D-Glucofuranose, 103f
- Glucogenic amino acids, 231–232
- Glucokinase, 156t
- in blood glucose regulation, 159–160, 160f
 - in glycogen biosynthesis, 145, 146f, 156t
 - in glycolysis, 137, 138f, 156t
- Glucokinase gene, regulation of, 355, 355f
- Gluconeogenesis, 123, 125, 153–162, 154f
- blood glucose regulation and, 158–161, 159f, 160f
 - citric acid cycle in, 133–134, 134f, 153–155, 154f
 - glycolysis and, 136–140, 138f, 139f, 153–155, 154f
 - regulation of, 155–158, 156t, 158f
 - allosteric modification in, 157
 - covalent modification in, 157
 - enzyme induction/repression in, 155–157, 156t
 - fructose 2,6-bisphosphate in, 157–158, 158f
 - substrate (futile) cycles in, 158
 - thermodynamic barriers to glycolysis and, 153–155, 154f
- Gluconolactone hydrolase, 163, 165f
- D-Glucopyranose, 103f
- α -D-Glucopyranose (α -anomer), 103f, 104
- β -D-Glucopyranose (β -anomer), 103f, 104
- Glucosamine, 106f, 169, 171f
- in heparin, 545
- Glucosan (glucan), 107
- Glucose, 102, 102–106
- absorption of, 474, 475, 475f
 - as amino sugar precursor, 169, 171f
 - blood levels of. *See* Blood glucose
 - epimers of, 104, 104f
 - in extracellular and intracellular fluid, 416, 416t
 - furanose forms of, 103f, 104
 - galactose conversion to, 167–169, 170f
 - glycemic index of, 474
 - in glycogen biosynthesis, 145, 146f
 - in glycoproteins, 516t
 - insulin secretion and, 160, 161–162
 - interconvertibility of, 231
 - isomers of, 102–104, 103f
 - as metabolic necessity, 232
 - metabolism of, 122–123, 122f, 123f, 124–125, 125f, 136–140, 138f, 139f, 140f, 159, 159f. *See also* Gluconeogenesis; Glycolysis
 - ATP generated by, 142, 143t
 - in fed state, 232
 - free fatty acids and, 215
 - insulin affecting, 160, 161–162
 - by pentose phosphate pathway, 123, 163–166, 164f, 165f, 167f
 - starvation and, 232–234, 234f, 234t, 236
 - permeability coefficient of, 419f
 - pyranose forms of, 103f, 104
 - renal threshold for, 161
 - structure of, 102, 103f
 - transport of, 159, 160t, 428, 429f, 475, 475f
 - insulin affecting, 427
- D-Glucose, 103f, 104f, 105t
- α -D-Glucose, 104f
- L-Glucose, 103f
- Glucose-alanine cycle, 159
- Glucose-6-phosphatase
- deficiency of, 152t, 300
 - in gluconeogenesis, 156t
 - in glycogenolysis, 147
- Glucose 1-phosphate
- free energy of hydrolysis of, 82t
 - in gluconeogenesis, 154f, 155
- Glucose 6-phosphate
- free energy of hydrolysis of, 82t
 - in gluconeogenesis, 153, 154f
 - in glycogen biosynthesis, 145, 146f
 - in glycolysis, 137, 138f
- Glucose-6-phosphate dehydrogenase
- deficiency of, 163, 169–170, 613, 614f, 619, 630t
 - in pentose phosphate pathway, 156t, 163, 164f, 165f
- Glucose tolerance, 161–162, 161f
- Glucose transporters, 159, 160t
- in blood glucose regulation, 159, 160
 - insulin affecting, 427
 - red cell membrane, 611, 612t
- Glucoside, 106
- Glucosuria, 161
- Glucosylceramide, 116, 201, 203f
- Glucuronate/glucuronic acid, 166–167, 168f
- bilirubin conjugation with, 280, 280f, 281f
- D-Glucuronate, 105, 106f
- β -Glucuronidases, 281
- Glucuronidation
- of bilirubin, 280, 280f, 281f
 - of xenobiotics, 628–629
- Glucuronides, 163
- GLUT 1–4. *See* Glucose transporters
- Glutamate
- carboxylation of, vitamin K as cofactor for, 487–488, 488f
 - catabolism of, 249, 250f
 - in proline synthesis, 238, 239f
 - synthesis of, 237, 238f
 - transamination and, 243–244, 243f, 244f
 - in urea biosynthesis, 243–244, 243f, 244f
- L-Glutamate decarboxylase, 267, 268f
- Glutamate dehydrogenase/L-glutamate dehydrogenase, 237, 238f
- in nitrogen metabolism, 244–245, 244f, 245f
- Glutamate- α -ketoglutarate transaminase (glutamate transaminase), in urea biosynthesis, 243–244, 244f
- Glutamate- γ -semialdehyde dehydrogenase, block at in hyperprolinemia, 250
- Glutamic acid, 15t
- Glutaminase, in amino acid nitrogen catabolism, 245, 245f
- Glutamine, 15t
- in amino acid nitrogen catabolism, 245, 245f
 - catabolism of, 249, 250f
 - synthesis of, 237, 238f

- Glutamine analogs, purine nucleotide synthesis affected by, 293
- Glutamine synthetase/synthase, 237, 238f, 245, 245f
- Glutamyl amidotransferase, PRPP, regulation of, 294, 295f
- γ -Glutamyltransferase, 630
- γ -Glutamyl transpeptidase (γ -glutamyltransferase), diagnostic significance of, 571
- Glutaric acid, pK/pK_a value of, 121
- Glutathione
as antioxidant, 611–613, 613t
in conjugation of xenobiotics, 629–630
as defense mechanism, 629
functions of, 629–630
- Glutathione peroxidase, 88, **166**, 167f, 170, 612, 613t
- Glutathione reductase, erythrocyte pentose phosphate pathway and, 166, 167f
riboflavin status and, 490
- Glutathione *S*-transferases, 629
in enzyme study, 58, 59f
- Glyburide (glibenclamide), 188
- Glycan intermediates, formation of during N-glycosylation, 526
- Glycemic index, 474
- Glyceraldehyde (glycero), D and L isomers of, 103f, 104f
- Glyceraldehyde 3-phosphate
in glycolysis, 137, 138f
oxidation of, 137, 139f
- Glyceraldehyde 3-phosphate dehydrogenase
in glycolysis, 137, 138f
in red cell membranes, 615f, 616t
- Glycerol, 114
in lactic acid cycle, 159
permeability coefficient of, 419f
synthesis of, 155
- Glycerol ether phospholipids, synthesis of, 199, 200f
- Glycerol kinase, 155, 197, 198f, 214
- Glycerol moiety, of triacylglycerols, 123
- Glycerol phosphate pathway, 198f
- Glycerol-3-phosphate
acylglycerol biosynthesis and, 197, 197f, 198f
free energy of hydrolysis of, 82t
triacylglycerol esterification and, 214–215, 214f
- Glycerol-3-phosphate acyltransferase, 198f, 199
- Glycerol-3-phosphate dehydrogenase, 155, 198f, 199
mitochondrial, 87
- Glycerophosphate shuttle, 99, 100f
- Glycerophospholipids, 111
- Glycero (glyceraldehyde), D and L isomers of, 103f, 104f
- Glycine, 151, 264
catabolism of, pyruvate formation and, 250, 252f
in collagen, 535
in heme synthesis, 264, **270–273**, 273f, 274f, 275f, 276f
synthesis of, 238, 239f
- Glycine synthase complex, 250
- Glycinuria, 250
- Glycocalyx, 110
- Glycochenodeoxycholic acid, synthesis of, 226f
- Glycocholic acid, synthesis of, 226f
- Glycoconjugate (complex) carbohydrates, glycoproteins as, 514
- Glycoforms, 514
- Glycogen, 102, 107, 108f
in carbohydrate metabolism, 123, 123f, 155
carbohydrate storage and, 145, 146t
metabolism of, **145–152**. *See also*
Glycogenesis; Glycogenolysis
branching in, 145, 147f
clinical aspects of, **151–152**, 152f
regulation of
cyclic AMP in, **147–150**, 148f, 149f, 150f
glycogen synthase and phosphorylase in, **150–151**, 151f
in starvation, 234
muscle, 145, 146t, 573, 575f
- Glycogen phosphorylase, 145–146, 146f
pyridoxal phosphate as cofactor for, 491
regulation of, 148–150, **150–151**, 150f, 151f
- Glycogen storage diseases, 102, 145, 151–152, 152t
- Glycogen synthase, in glycogen metabolism, 145, 146f, 155, 156t
regulation of, 148–150, **150–151**, 150f, 151f
- Glycogen synthase a, 148–150, 150f
- Glycogen synthase b, 150, 150f
- Glycogenesis, 124–125, **145**, 146f
regulation of
cyclic AMP in, **147–150**, 148f, 149f, 150f
enzymes in, 156t
glycogen synthase and phosphorylase in, 148–150, **150–151**, 150f, 151f
- Glycogenin, 145, 146f
- Glycogenolysis, 125, **145–147**, 146f
blood glucose regulation and, **158–161**, 159f, 160f
cyclic AMP-independent, 148
cyclic AMP in regulation of, **147–150**, 148f, 149f, 150f
debranching enzymes in, 146–147, 148f
- glycogen synthase and phosphorylase in regulation of, 148–150, **150–151**, 150f, 151f
- Glycolipid storage diseases, 197
- Glycolipids (glycosphingolipids), 111, **116**, 117f
ABO blood group and, 618
amino sugars in, 169, 171f
galactose in synthesis of, **167–169**, 170f
- Glycolysis, 83, 122, 123f, **136–144**, 137f
aerobic, 139
anaerobic, **136**, 137f, 139
as muscle ATP source, 574–576, 575f, 575t
- ATP generated by, 142, 143t
clinical aspects of, **142–143**
in erythrocytes, 140, 140f
glucose utilization/gluconeogenesis and, **136–140**, 138f, 139f, **153–155**, 154f. *See also* Gluconeogenesis
pathway of, **136–140**, 138f, 139f, 140f
pyruvate oxidation and, 134, 135f, **140–142**, 141f, 142f, 143t
regulation of, 140
enzymes in, 156t
fructose 2,6-bisphosphate in, 157–158, 158f
gluconeogenesis and, 140, **155–158**, 156t, 158f
at subcellular level, 126, 127f
thermodynamic barriers to reversal of, 153–155
- Glycolytic enzymes, in muscle, 556
- Glycomics, 533
- Glycophorins, 110, 518, 615–616, 615f, 616f, 616t
- Glycoprotein IIb-IIIa, in platelet activation, 607, 622t
- Glycoprotein glycosyltransferases, 520
- Glycoproteins, 30, 109–110, 109t, 439f, **514–534**, 580, 581–582. *See also* specific type and Plasma proteins
amino sugars in, 106, 169, 171f
asialoglycoprotein receptor in clearance of, 517
as blood group substances, 514, 618
carbohydrates in, 109t
classes of, **518**, 519f
complex, 521, 522f
formation of, 521, 524
diseases associated with abnormalities of, 530, 530t, 531f, 531t, 532f, 533t
extracellular, absorptive pinocytosis of, 430
in fertilization, 528
functions of, **514**, 515t, **528–533**, 529t
galactose in synthesis of, **167–169**, 170f
glycosylphosphatidylinositol-anchored, 518, 519f, **527–528**, 528t
high-mannose, 521, 522f
formation of, 521, 524

- Glycoproteins (*cont.*)
 hybrid, 521, 522f
 formation of, 521
 immunoglobulins as, 593
 membrane asymmetry and, 420
 N-linked, 518, 519f, 521–527
 nucleotide sugars, 516–517, 516t
 O-linked, 518, 518–520, 519f, 520f, 520t, 521t
 oligosaccharide chains of, 514
 red cell membrane, 615, 615f
 sugars in, 515–517, 516t
 techniques for study of, 514, 515t
 asialoglycoprotein receptor in, 517
 glycosidases in, 517, 517t
 lectins in, 517–518, 518t
 in zona pellucida, 528
- Glycosaminoglycans, 109, 109f, 542, 542–547. *See also specific type*
 amino sugars in, 106
 deficiencies of enzymes in degradation of, 545–547, 546t, 547f
 disease associations of, 548–549
 distributions of, 543–545, 544f, 544t
 functions of, 547–549, 548t
 structural differences among, 543–545, 544f, 544t, 545f
 synthesis of, 542–543
- Glycosidases, in glycoprotein analysis, 517
- Glycosides, 105–106
- β -N-Glycosidic bond, 286, 287f
- Glycosphingolipids (glycolipids), 111, 116, 117f, 201–202, 203f
 ABO blood group and, 618
 amino sugars in, 169, 171f
 galactose in synthesis of, 167–169, 170f
 in membranes, 417
 membrane asymmetry and, 420
- Glycosuria, 161
- N-Glycosylases, in base excision-repair, 337, 337f
- Glycosylated hemoglobin (HbA_{1c}), 47
- Glycosylation
 of collagen, 537
 congenital disorders of, 531, 531t
 in covalent modification, mass increases and, 27t
 inhibitors of, 527, 527t
 nucleotide sugars in, 516–517, 516t
 N-Glycosylation, 521–527, 523f, 524f, 525f, 526t
 dolichol-P-P-oligosaccharide in, 521–524, 523f
 in endoplasmic reticulum, 524–525, 525f
 glycan intermediates formed during, 526
 in Golgi apparatus, 524–525, 525f
 inhibition of, 527, 527t
 regulation of, 526–527, 527t
 tunicamycin affecting, 527, 527t
 O-Glycosylation, 520, 521f
- Glycosylphosphatidylinositol-anchored (GPI-anchored/GPI-linked) glycoproteins, 518, 519f, 527–528, 528t
 in paroxysmal nocturnal hemoglobinuria, 531, 531f
- Glycosyltransferases, glycoprotein, 520, 526–527
- Glypiation, 528
- GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
- G_{M1} ganglioside, 116, 117f
- G_{M3} ganglioside, 116
- GMP, 288t, 297f
 cyclic, 289f, 290
 as second messenger, 290, 436, 437t, 457, 462–463
 IMP conversion to, 293, 296f
 feedback-regulation of, 294, 296f
 PRPP glutamyl amidotransferase regulated by, 294
- Golgi apparatus
 core protein synthesis in, 543
 glycosylation and, 509, 524–525, 525f
 in membrane synthesis, 509
 in protein sorting, 498, 500f, 509
 in VLDL formation, 213f
 retrograde transport from, 507
- Gout/gouty arthritis, 299
- GPIIb-IIIa, in platelet activation, 607, 622t
- GPCRs. *See* G protein-coupled receptors
- GPI-anchored/linked glycoproteins, 518, 519f, 527–528, 528t
 in paroxysmal nocturnal hemoglobinuria, 531, 531f
- Granulocyte-colony stimulating factor, 610
- Granulocyte-macrophage colony-stimulating factor, 610
- Granulomatous disease, chronic, 623, 623f
- Granulosa cells, hormones produced by, 442
- Gratuitous inducers, 378
- GRE. *See* Glucocorticoid response element
- GRIP1 coactivator, 472, 472t
- Group transfer potential, 83, 83f
 of nucleoside triphosphates, 289–290, 289f, 290f, 290t
- Group transfer reactions, 8
- Growth factors, hematopoietic, 610
- Growth hormone, 437, 438
 amino acid transport affected by, 427
 localization of gene for, 407t
 receptor for, 436
- GSH. *See* Glutathione
- GSLs. *See* Glycosphingolipids
- GST (glutathione S-transferase) tag, in enzyme study, 58, 59f
- GTP, 290
 cyclic GMP formed from, 462
 in phosphorylation, 85
- GTPases, 459
- GTP- γ -S, vesicle coating and, 510
- Guanine, 288t
- Guanine activating proteins, 501, 502f
- Guanine nucleotide exchange factors, 501, 502f
- Guanosine, 287f, 288t
 base pairing of in DNA, 303, 304, 305f
 in uric acid formation, 299, 299f
- Guanosine diphosphate fucose (GDP-Fuc), 516t
- Guanosine diphosphate mannose (GDP-Man), 516t, 517
- Guanosine monophosphate. *See* GMP
- Guanylyl cyclase, 462, 463
- Gyrase, bacterial, 306
- Gyrate atrophy of retina, 250
- H bands, 556, 557f, 558f
- H blood group substance, 618, 619f
- H chains. *See* Heavy chains
- H1 histones, 314, 315f
- H2A histones, 314, 315
- H2B histones, 314, 315
- H3 histones, 314, 314–315
- H4 histones, 314, 314–315
- H₂S. *See* Hydrogen sulfide
- H substance, ABO blood group and, 618
- Haber-Weiss reaction, 612
- Hageman factor (factor XII), 599f, 600, 600t
- Hairpin, 306, 309f, 413
- Half life
 enzyme, 242
 protein, 242
 plasma protein, 582
- Half-transfer signal, 506
- Hapten, in xenobiotic cell injury, 631, 631f
- Haptoglobin, 583t, 584, 584f
- Hartnup disease, 258, 490
- HAT activity. *See* Histone acetyltransferase activity
- HbA (hemoglobin A), P₅₀ of, 42
- HbA_{1c} (glycosylated hemoglobin), 47
- HbF (fetal hemoglobin), P₅₀ of, 42
- HbM (hemoglobin M), 46, 363, 614
- HbS (hemoglobin S), 46, 46f, 363
- hCG. *See* Human chorionic gonadotropin
- HDL. *See* High-density lipoproteins
- Health, normal biochemical processes as basis of, 2–4, 3t
- Heart
 developmental defects of, 570
 metabolism in, 235t
 thiamin deficiency affecting, 489
- Heart disease, coronary (ischemic). *See also* Atherosclerosis
 cholesterol and, 227
- Heart failure, 556
 in thiamin deficiency, 489

- Heat, free energy liberated as, 95
- Heat-shock proteins, as chaperones, 36–37
- Heavy chains
- immunoglobulin, 591, 592f
 - genes producing, 593
 - myosin, 560
 - familial hypertrophic cardiomyopathy caused by mutations in gene for, 569–570, 570f
- Heavy meromyosin, 560f, 561, 561f
- Heinz bodies, 613
- Helicases, DNA, 326–327, 327f, 328, 328t
- Helicobacter pylori*, ulcers associated with, 474
- Helix
- Double, of DNA structure, 7, 303, 304, 305f
 - recombinant DNA technology and, 396, 397
 - triple, of collagen structure, 38, 38f, 535–539, 536f
- α -Helix, 31–32, 32f, 33f
- amphipathic, 31–32
 - in myoglobin, 40, 41f
- Helix-loop-helix motifs, 33
- Helix-turn-helix motif, 387, 388t, 389–390, 389f
- Hemagglutinin, influenza virus, calnexin binding to, 526
- Hematology, recombinant DNA technology affecting, 624
- Hematopoietic growth factors, 610
- Heme, 40, 41f, 270
- catabolism of, bilirubin produced by, 278–280, 279f
 - in proteins, 270. *See also* Heme proteins
 - synthesis of, 270–273, 273f, 274f, 275f, 276f
 - disorders of (porphyrias), 274–278, 277f, 277t
- Heme iron, 278, 585
- absorption of, 478, 585, 585f
 - hindered environment for, 41, 41f
- Heme oxygenase system, 278, 279f
- Heme proteins (hemoproteins), 270, 271t
- See also* Hemoglobin; Myoglobin
 - cytochrome P450 isoforms as, 627
- Heme synthase (ferrochelatase), 271, 272f
- in porphyria, 277t
- Hemin, 278, 279f
- Hemochromatosis, 478, 586–587, 587f
- Hemoglobin, 40–48, 581f
- allosteric properties of, 42–46
 - β subunits of, myoglobin and, 42
 - bilirubin synthesis and, 278–280, 279f
 - in carbon dioxide transport, 44, 45f
 - extracorporeal, haptoglobin binding of, 583f, 584
 - glycosylated (HbA_{1c}), 47
 - mutant, 46, 362–363
 - oxygen affinities (P₅₀) and, 42–43, 43f
 - oxygen dissociation curve for, 41–42, 42f
 - in oxygen transport, 40–41
 - oxygenation of
 - conformational changes and, 43, 43f, 44f
 - apoprotein, 42
 - 2,3-bisphosphoglycerate stabilizing, 45, 45f
 - high altitude adaptation and, 46
 - mutant hemoglobins and, 46 - in proton transport, 44
 - tetrameric structure of, 42
 - changes in during development, 42–43, 43f
- Hemoglobin A (HbA), P₅₀ of, 42
- Hemoglobin A_{1c} (glycosylated hemoglobin), 47
- Hemoglobin A₂
- Hemoglobin Bristol, 362
- Hemoglobin Chesapeake, 46
- Hemoglobin F (fetal hemoglobin), P₅₀ of, 42
- Hemoglobin Hikari, 362–363
- Hemoglobin M, 46, 363, 614
- Hemoglobin Milwaukee, 362
- Hemoglobin S, 46, 46f, 363
- Hemoglobin Sydney, 362
- Hemoglobinopathies, 46, 619
- Hemoglobinuria, paroxysmal nocturnal, 432t, 528, 530t, 531, 531f
- Hemolytic anemias, 136, 143, 609, 619, 620t
- glucose-6-phosphate dehydrogenase deficiency causing, 163, 169–170, 613, 614f, 619
 - haptoglobin levels in, 584
 - hyperbilirubinemia/jaundice in, 282, 284, 284t
 - pentose phosphate pathway/glutathione peroxidase and, 166, 167f, 169–170
 - primaquine-sensitive, 613
 - red cell membrane abnormalities causing, 619
- Hemopexin, 583t
- Hemophilia A, 604
- Hemophilia B, 604
- Hemoproteins. *See* Heme proteins
- Hemosiderin, 586
- Hemostasis, 598–608. *See also* Coagulation
- laboratory tests in evaluation of, 608
 - phases of, 598
- HEMPAS. *See* Hereditary erythroblastic multinuclearity with a positive acidified lysis test
- Henderson-Hasselbalch equation, 11
- Heparan sulfate, 538, 544f, 544t, 545, 547–548
- in basal lamina, 540
 - clotting/thrombosis affected by, 607, 607t
- Heparin, 109, 109f, 544f, 544t, 545, 545f, 603–604
- antithrombin III activity affected by, 547, 603–604
 - in basal lamina, 540
 - binding of, fibronectin in, 540, 541f
 - functions of, 547
 - lipoprotein and hepatic lipases affected by, 207
- Heparin cofactor II, as thrombin inhibitor, 603
- Hepatic ALA synthase (ALAS1), 272
- in porphyria, 277t, 278
- Hepatic lipase, 207
- in chylomicron remnant uptake, 209, 209f
 - deficiency of, 228t
- Hepatic portal system, 158
- in metabolite circulation, 124, 125f
- Hepatitis, 130
- in α_1 -antitrypsin deficiency, 590
 - jaundice in, 284t
- Hepatocytes
- glycoprotein clearance from, asialoglycoprotein receptor in, 517
 - heme synthesis in, 272
 - ALA synthase in regulation of, 272–273, 276f
- Hepatolenticular degeneration (Wilson disease), 432t, 587, 588–589
- ceruloplasmin levels in, 587
 - gene mutations in, 432t, 588–589
- Heptoses, 102, 102t
- Hereditary elliptocytosis, 617
- Hereditary erythroblastic multinuclearity with a positive acidified lysis test (HEMPAS), 530t, 531
- Hereditary hemochromatosis, 586–587, 587f
- Hereditary nonpolyposis colon cancer, mismatch repair genes in, 336
- Hereditary spherocytosis, 432t, 617, 617f
- Hermansky-Pudlak syndrome, 512t
- Hers' disease, 152t
- Heterochromatin, 316
- Heterogeneous nuclear RNA (hnRNA), 310
- processing of, gene regulation and, 354
- Heterotrophic organisms, 82
- Hexapeptide, in albumin synthesis, 583
- Hexokinase, 156t
- in blood glucose regulation, 159, 160f
 - in fructose metabolism, 167, 169f
 - in glycogen biosynthesis, 145, 156t
 - in glycolysis, 136–137, 138f, 156t
 - as flux-generating reaction, 129
 - regulation and, 140
- Hexosamines (amino sugars), 106, 106f
- glucose as precursor of, 169, 171f
 - in glycosaminoglycans, 109, 169, 171f
 - in glycosphingolipids, 169, 171f
 - interrelationships in metabolism of, 171f

- Hexose monophosphate shunt. *See* Pentose phosphate pathway
- Hexoses, 102, 102*t*
in glycoproteins, 109*t*
metabolism of, 163–166, 164*f*, 165*f*, 167*f*. *See also* Pentose phosphate pathway
clinical aspects of, 169–172
physiologic importance of, 105, 105*t*
- HFE mutations, in hemochromatosis, 586–587
- HGP. *See* Human Genome Project
- HhaI, 399*t*
- Hierarchical shotgun sequencing, 634
- High altitude, adaptation to, 46
- High-density lipoproteins, 205, 206*t*
apolipoproteins of, 205–206, 206*t*
atherosclerosis and, 210–211, 227
metabolism of, 209–211, 211*f*
ratio of to low-density lipoproteins, 227
receptor for, 210, 211*f*
- High-density microarray technology, 412
- High-energy phosphates, 83. *See also* ATP
in energy capture and transfer, 82–83, 82*f*, 82*t*, 83*f*
as “energy currency” of cell, 83–85, 84*f*, 85*f*
symbol designating, 83
transport of, creatine phosphate shuttle in, 100, 101*f*
- High-mannose oligosaccharides, 521, 522*f*
formation of, 521, 524
- High-molecular-weight kininogen, 599*f*, 600
- High-performance liquid chromatography, reversed phase, for protein/peptide purification, 23–24
- Hill coefficient, 67
- Hill equation, 66–67, 67*f*
- Hindered environment, for heme iron, 41, 41*f*
- HindIII, 399*t*
- Hinge region
immunoglobulin, 591, 592*f*
nuclear receptor protein, 460
- Hippuric acid/hippurate, synthesis of, 264, 265*f*
- Histamine, 621*t*
formation of, 265
- Histidine, impaired, 250
- Histidine, 16*t*, 265, 265*f*
 β -alanine dipeptides and, 264, 265*f*
catabolism of, 250, 251*f*
conserved residues and, 55*t*
decarboxylation of, 265
in oxygen binding, 40, 41*f*
requirements for, 480
- Histidine 57, in covalent catalysis, 53–54, 54*f*
- Histidine E7, in oxygen binding, 40, 41*f*
- Histidine F8
in oxygen binding, 40, 41*f*
replacement of in hemoglobin M, 46
- Histidinemia, 250
- Histone acetyltransferase activity, of coactivators, 383, 472, 473
- Histone chaperones, 315
- Histone dimer, 315
- Histone octamer, 315, 315*f*
- Histone tetramer, 314–315, 315
- Histones, 314, 314–315, 315*f*, 315*t*
acetylation and deacetylation of, gene expression affected by, 383
- HIV-1, glycoproteins in attachment of, 533
- HIV protease, in acid-base catalysis, 52, 53*f*
- HMG-CoA. *See* 3-Hydroxy-3-methylglutaryl-CoA
- HMM. *See* Heavy meromyosin
- hMSH1/hMSH2*, in colon cancer, 336
- HNCC. *See* Hereditary nonpolyposis colon cancer
- hnRNA. *See* Heterogeneous nuclear RNA
- Holocarboxylase synthetase, biotin as coenzyme of, 494
- Homeostasis
blood in maintenance of, 580
hormone signal transduction in regulation of, 456, 457*f*
- Homocarnosine, 264, 265*f*
- Homocarnosinosis, 264
- Homocysteine
in cysteine and homoserine synthesis, 238–239, 239*f*
functional folate deficiency and, 494
- Homocystinurias, 250
vitamin B₁₂ deficiency/functional folate deficiency and, 492*f*, 494
- Homodimers, 34
- Homogentisate, in tyrosine catabolism, 254*f*, 255
- Homogentisate dioxygenase/oxidase, 89
deficiency of, in alkaptonuria, 255
- Homology
conserved residues and, 54, 55*t*
in protein classification, 30
- Homopolymer tailing, 399
- Homoserine, synthesis of, 239, 239*f*
- Hormone-dependent cancer, vitamin B₆ deficiency and, 491
- Hormone response elements, 349, 386, 388*f*, 456–457, 459*t*, 469, 470*f*
- Hormone-sensitive lipase, 214–215, 214*f*
insulin affecting, 215
- Hormones. *See also specific type*
in blood glucose regulation, 159
classification of, 436–437, 437*t*
facilitated diffusion regulated by, 427
glycoproteins as, 514
lipid metabolism regulated by, 215–217, 216*f*
in metabolic control, 128*f*, 129
- receptors for, 435–436, 436*f*, 471
proteins as, 436
recognition and coupling domains on, 435–436
specificity/selectivity of, 435, 436*f*
signal transduction and, 456–473
intracellular messengers and, 457–468, 461*t*, 463*t*
response to stimulus and, 456, 457*f*
signal generation and, 456–457, 458*f*, 459*f*, 459*t*
transcription modulation and, 468–473, 470*f*, 471*f*, 472*t*
stimulus recognition by, 456, 457*f*
storage/secretion of, 453, 454*t*
synthesis of
chemical diversity of, 438, 439*f*
cholesterol in, 438, 438–445, 439*t*, 440*f*
peptide precursors and, 449–453
specialization of, 437
tyrosine in, 438, 439–449, 439*t*
target cells for, 434–435, 435*t*
transport of, 454–455, 454*t*, 455*t*
vitamin D as, 484–486
- Housekeeping genes, 376
- Hp. *See* Haptoglobin
- HpaI, 399*t*
- HPETE. *See* Hydroperoxides
- HPLC. *See* High-performance liquid chromatography
- HREs. *See* Hormone response elements
- HRPT. *See* Hypoxanthine-guanine phosphoribosyl transferase
- hsp60/hsp70, as chaperones, 36–37
- 5HT (5-hydroxytryptamine). *See* Serotonin
- Human chorionic gonadotropin (hCG), 438
- Human Genome Project, 3–4, 633–641
approaches used in elucidation of, 634, 635*t*
future work and, 637
goals of, 633–635
implications of, 637–638
major findings of, 636–637, 636*t*, 637*t*
protein sequencing and, 28
- Human immunodeficiency virus (HIV-1), glycoproteins in attachment of, 533
- Hunter syndrome, 546*t*
- Hurler syndrome, 546*t*
- Hurler-Scheie syndrome, 546*t*
- Hyaluronic acid, 109, 109*f*, 543, 544*f*, 544*t*
disease associations and, 548
functions of, 547
- Hyaluronidase, 547
- Hybrid glycoproteins, 521, 522*f*
formation of, 521
- Hybrid mapping, radiation, 635*t*
- Hybridization, 397, 403–404, 413
in situ, in gene mapping, 406–407, 407*t*, 635*t*

- Hybridomas, 595–596, 596f
- Hydrocortisone. *See* Cortisol
- Hydrogen bonds, 5, 6f
in DNA, 303, 304, 305f
- Hydrogen ion concentration. *See also* pH
enzyme-catalyzed reaction rate affected
by, 64, 64f
- Hydrogen peroxide
glutathione in decomposition of, 629
as hydroperoxidase substrate, 88–89
production of in respiratory burst, 622
- Hydrogen sulfide, respiratory chain affected
by, 95, 96f
- Hydrolases, 50
cholesteryl ester, 223
fumarylacetoacetate, defect at, in
tyrosinemia, 255
gluconolactone, 163, 165f
lysosomal, deficiencies of, 532–533, 533t
- Hydrolysis (hydrolytic reactions), 7–8. *See also specific reaction*
free energy of, 82–83, 82t
in glycogenolysis, 146, 146f; 148f
of triacylglycerols, 197
- Hydropathy plot, 419
- Hydroperoxidases, 86, 88–89
- Hydroperoxides, formation of, 194, 195f
- Hydrophilic compounds, hydroxylation
producing, 627
- Hydrophilic portion of lipid molecule, 119, 120f
- Hydrophobic effect, in lipid bilayer self-assembly, 418
- Hydrophobic interaction chromatography,
for protein/peptide purification,
23
- Hydrophobic interactions, 6–7
- Hydrophobic portion of lipid molecule,
119, 120f
- Hydrostatic pressure, 580
- L(+)-3-Hydroxyacyl-CoA dehydrogenase,
181, 182f
- 3-Hydroxyanthranilate dioxygenase/
oxygenase, 89
- Hydroxyapatite, 549
- D(-)-3-Hydroxybutyrate (β -hydroxy-
butyrate), 183–184, 184f
- D(-)-3-Hydroxybutyrate dehydrogenase,
184, 184f
- 24-Hydroxycalcidiol (24,25-dihydroxyvita-
min D₃), in vitamin D
metabolism, 484, 485f
- 25-Hydroxycholecalciferol (calcidiol), in
vitamin D metabolism, 484, 485f
- 4-Hydroxydicoumarin (dicoumarol), 486
- Hydroxylamine, for polypeptide cleavage,
26t
- 7 α -Hydroxylase, bile acid synthesis
regulated by, 226, 226f; 227
- 11 β -Hydroxylase, in steroid synthesis, 440, 441f
- 17 α -Hydroxylase, in steroid synthesis, 440, 441f; 442, 443f
- 18-Hydroxylase, in steroid synthesis, 440, 441f
- 21-Hydroxylase, in steroid synthesis, 440, 441f
- 27-Hydroxylase, sterol, 226
- Hydroxylase cycle, 89, 90f
- Hydroxylases, 89–90
in steroid synthesis, 438, 440, 441f
- Hydroxylation
in collagen processing, 537
in covalent modification, mass increases
and, 27t
of xenobiotics, 626, 626–628, 629t
- Hydroxylysine, synthesis of, 240
- 5-Hydroxymethylcytosine, 287, 289f
- 3-Hydroxy-3-methylglutaryl-CoA
(HMG-CoA)
in ketogenesis, 184–185, 185f
in mevalonate synthesis, 219, 220f
- 3-Hydroxy-3-methylglutaryl-CoA
(HMG-CoA) lyase
deficiency of, 188
in ketogenesis, 185, 185f
- 3-Hydroxy-3-methylglutaryl-CoA
(HMG-CoA) reductase
cholesterol synthesis controlled by, 220, 223f
in mevalonate synthesis, 219, 220f
- 3-Hydroxy-3-methylglutaryl-CoA
(HMG-CoA) synthase
in ketogenesis, 185, 185f
in mevalonate synthesis, 219, 220f
- p-Hydroxyphenylpyruvate, in tyrosine
catabolism, 254f; 255
- 17-Hydroxyprogesterone, 440, 441f
- 17-Hydroxyprogesterone, 440, 441f
- Hydroxyproline
synthesis of, 240, 240f; 535–537
tropoelastin hydroxylation and, 539
- 4-Hydroxyproline, catabolism of, 253f; 255
- 4-Hydroxyproline dehydrogenase, defect in,
in hyperhydroxyprolinemia,
255
- 15-Hydroxyprostaglandin dehydrogenase,
194
- 3 β -Hydroxysteroid dehydrogenase, 438, 441f; 442, 443f
- 17 β -Hydroxysteroid dehydrogenase, 442, 443f
- 5-Hydroxytryptamine. *See* Serotonin
- Hyperalphalipoproteinemia, familial, 228t
- Hyperammonemia, types 1 and 2, 247
- Hyperargininemia, 248
- Hyperbilirubinemia, 281–284, 284t
- Hypercholesterolemia, 205
familial, 1, 228t, 432t
LDL receptor deficiency in, 209, 432t
- Hyperchromicity of denaturation, 304–305
- Hyperglycemia. *See also* Diabetes mellitus
glucagon causing, 161
insulin release in response to, 466f
- Hyperhomocysteinemia, folic acid supple-
ments in prevention of, 494
- Hyperhydroxyprolinemia, 255
- Hyperkalemic periodic paralysis, 569t
- Hyperlactacidemia, 212
- Hyperlipidemia, 170–171, 490
- Hyperlipoproteinemias, 205, 228t, 229
familial, 228t
- Hyperlysinemia, periodic, 258
- Hypermetabolism, 136, 479
- Hyperornithinemia-hyperammonemia
syndrome, 250
- Hyperoxaluria, primary, 250
- Hyperparathyroidism, bone and cartilage
affected in, 551t
- Hyperphenylalaninemias, 255
- Hyperprolinemias, types I and II, 249–250
- Hypersensitive sites, chromatin, 316
- Hypersplenism, in hemolytic anemia, 619
- Hypertension, hyperhomocysteinemia and,
folic acid supplements in
prevention of, 494
- Hyperthermia, malignant, 556, 564–565, 565f; 569t
- Hypertriacylglycerolemia
in diabetes mellitus, 205
familial, 228t
- Hypertrophic cardiomyopathy, familial,
569–570, 570f
- Hyperuricemia, 170–171, 300
- Hypervariable regions, 591–592, 594f
- Hypoglycemia, 153
fatty acid oxidation and, 180, 187–188
fructose-induced, 171–172
insulin excess causing, 162
during pregnancy and in neonate, 161
- Hypoglycin, 180, 188
- Hypokalemic periodic paralysis, 569t
- Hypolipidemic drugs, 229
- Hypolipoproteinemia, 205, 228t, 229
- Hypouricemia, 300
- Hypoxanthine, 289
- Hypoxanthine-guanine phosphoribosyl
transferase (HGPRT)
defect of in Lesch-Nyhan syndrome, 300
localization of gene for, 407t
- Hypoxia, lactate production and, 136, 137f; 139–140
- I. *See* Iodine/iodide
- I bands, 556, 557f; 558f
- I-cell disease, 431, 432t, 512t, 524, 530t, 531–532, 532t, 546–547, 546t
- Ibuprofen, cyclooxygenases affected by, 193
- ICAM-1, 529, 529t
- ICAM-2, 529, 529t
- ICF. *See* Intracellular fluid

- Icterus (jaundice), 270, **281–284**, 284*t*
 IDDM. *See* Insulin-dependent diabetes mellitus
 Idiotypes, 594
 IDL. *See* Intermediate-density lipoproteins
 L-Iduronate, 105, 106*f*
 IEF. *See* Isoelectric focusing
 IgA, 591, 594*t*, 595*f*
 IgD, 591, 594*t*
 IgE, 591, 594*t*
 IGF-I. *See* Insulin-like growth factor-I
 IgG, 591, 592*f*, 594*t*
 deficiency of, 595
 hypervariable regions of, 591–592, 594*f*
 IgM, 591, 594*t*, 595*f*
 Immune response, class/isotype switching and, 594
 Immunoglobulin genes, 593
 DNA rearrangement and, 325–326, 393, 593–594
 double-strand break repair and, 337–338
 Immunoglobulin heavy chain binding protein, 508
 Immunoglobulin heavy chains, 591, 592*f*
 genes producing, 593
 Immunoglobulin light chains, 591, 592*f*
 in amyloidosis, 590
 genes producing, 593
 DNA rearrangement and, 325–326, 393, 593–594
 Immunoglobulins, 583*t*, **591–597**, 593*t*.
 See also specific type under Ig
 class switching and, 594
 classes of, 591, 593*t*, 594*t*
 diseases caused by over- and underproduction of, 594–595
 functions of, 593, 594*t*
 genes for. *See* Immunoglobulin genes
 hybridomas as sources of, 595–596, 596*f*
 structure of, 591, 592, 592*f*, 594*f*, 595*f*
 IMP (inosine monophosphate)
 conversion of to AMP and GMP, 293, 296*f*
 feedback regulation of, 294, 296*f*
 synthesis of, **293–294**, 295*f*, 296*f*, 297*f*
 Importins, 501, 502*f*
 In situ hybridization/fluorescence in situ
 hybridization, in gene mapping, 406–407, 407*t*, 635*t*
 Inactive chromatin, **316–318**, 383
 Inborn errors of metabolism, 1, 249, 545
 Inclusion cell (I-cell) disease, 431, 432*t*, 512*t*, 524, 530*t*, 531–532, 532*t*
 Indole, permeability coefficient of, 419*f*
 Indomethacin, cyclooxygenases affected by, 193
 Induced fit model, 52, 53*f*
 Inducers
 enzyme synthesis affected by, 74
 in gluconeogenesis regulation, 155–157
 gratuitous, 378
 in regulation of gene expression, 376
 Inducible gene, 376
 Infantile Refsum disease, 188, 503, 503*t*
 Infection
 glycoprotein hydrolase deficiencies and, 533
 neutrophils in, 620, 621*t*
 protein loss and, 480
 respiratory burst in, 622–623
 Inflammation, 190
 acute phase proteins in, 583, 583*t*
 complement in, 596
 neutrophils in, 620, 621*t*
 integrins and, 529*t*, 620–621, 622*t*
 selectins and, 528–529, 529*t*, 530*f*
 NF- κ B in, 468
 prostaglandins in, 190
 selectins in, 528–530, 529*f*, 529*t*, 530*f*
 Influenza virus
 hemagglutinin in, calnexin binding to, 526
 neuraminidase in, 533
 Information pathway, 457, 459*f*
 Inhibition
 competitive versus noncompetitive, **67–69**, 67*f*, 68*f*, 69*f*
 feedback, in allosteric regulation, **74–76**, 75*f*
 irreversible, 69
 Inhibitor-1, 148, 149*f*, 151, 151*f*
 Initial velocity, **64**
 inhibitors affecting, 68, 68*f*, 69*f*
 Initiation
 in DNA synthesis, 328–330, 329*f*, 330*f*, 331*f*
 in protein synthesis, **365–367**, 366*f*
 in RNA synthesis, 342, 342*f*, **343–344**
 Initiation complexes, in protein synthesis, 365, 366*f*, 367
 Initiator sequence, 346–348, 347*f*
 Inner mitochondrial membrane, 92, 93*f*
 impermeability of, exchange transporters and, **98–100**, 98*f*, 99*f*
 protein insertion in, 501
 Inorganic pyrophosphatase, in fatty acid activation, 85
 Inosine monophosphate (IMP)
 conversion of to AMP and GMP, 293, 296*f*
 feedback-regulation of, 294, 296*f*
 synthesis of, **293–294**, 295*f*, 296*f*, 297*f*
 Inositol hexaphosphate (phytic acid), calcium absorption affected by, 477
 Inositol trisphosphate, 464–465, 464*f*, 465*f*
 in platelet activation, 606, 606*f*, 607
 in respiratory burst, 623
 Inotropic effects, 566
 Inr. *See* Initiator sequence
 Insert/insertions, DNA, 413
 recombinant DNA technology in detection of, 409
 Inside-outside asymmetry, membrane, 419–420
 Insulators, 387
 nonpolar lipids as, 111
 Insulin, 107–109, 438, 449, 450*f*
 adipose tissue metabolism affected by, 216–217
 in blood glucose regulation, 160–162
 deficiency of, 161. *See also* Diabetes mellitus
 free fatty acids affected by, 215
 gene for, localization of, 407*t*
 glucagon opposing actions of, 160–161
 in glucose transport, 427
 in glycolysis, 137, 155–157
 initiation of protein synthesis affected by, 367, 367*f*
 in lipogenesis regulation, 178–179
 in lipolysis regulation, 178–179, 215, 216*f*
 phosphorylase b affected by, 148
 receptor for, 436, 465, 466*f*
 signal transmission by, 465–467, 466*f*
 storage/secretion of, 453, 454*t*
 synthesis of, 449, 450*f*
 Insulin-dependent diabetes mellitus (IDDM/type 1), 161–162. *See also* Diabetes mellitus
 Insulin/glucagon ratio, in ketogenesis regulation, 187
 Insulin-like growth factor I, receptor for, 436
 Insulin resistance, 611
 Integral proteins, 30, 420, 421*f*
 as receptors, 431
 red cell membrane, 615–616, 615*f*, 616*f*, 616*t*
 Integration, chromosomal, 324, 324*f*
 Integrins, neutrophil interactions and, 529*t*, 620–621, 622*t*
 Intercellular junctions, 431
 Intermediate-density lipoproteins, 206*t*
 Intermediate filaments, 577–578, 577*t*
 Intermembrane space, proteins in, 501
 Intermittent branched-chain ketonuria, 259
 Internal presequences, 501
 Internal ribosomal entry site, 371, 371*f*
 Interphase chromosomes, chromatin fibers in, 316
 Intervening sequences. *See* Introns
 Intestinal bacteria, in bilirubin conjugation, 281
 Intracellular environment, membranes in maintenance of, **415–416**, 416*t*
 Intracellular fluid (ICF), 415, 416, 416*t*
 Intracellular membranes, 415
 Intracellular messengers, **457–468**, 461*t*, 463*t*. *See also specific type and* Second messengers

- Intracellular signals, 457–458
- Intracellular traffic, **498–513**. *See also* Protein sorting
- disorders due to mutations in genes encoding, 512*t*, 513
- Intrinsic factor, 477, 491–492
- in pernicious anemia, 492
- Intrinsic pathway of blood coagulation, 598, 599*f*, 600–601
- Introns (intervening sequences), 319, 352–354, 353*f*, 358, 413
- in recombinant DNA technology, 397, 398*f*
- removal of from primary transcript, 352–354, 353*f*
- Inulin, glomerular membrane permeability to, 540
- "Invert sugar," 107
- Iodine/iodide, 496*t*
- deficiency of, 447–449
- in thyroid hormone synthesis, 447, 448*f*, 449
- 5-Iodo-2'-deoxyuridine, 291*f*
- Iodopsin, 483
- o*-Iodobenzene, for polypeptide cleavage, 26*t*
- Iodothyronyl residues, 447. *See also* Thyroxine; Triiodothyronine
- 5-Iodouracil, 290
- Ion channels, 415, 423–424, 425*f*, 426*t*, 568*t*
- in cardiac muscle, 566–567, 568, 568*t*
- diseases associated with disorders of, 568, 569*t*
- Ion exchange chromatography, for protein/peptide purification, 22–23
- Ion product, 8–9
- Ion transport, in mitochondria, 99
- Ionizing radiation, nucleotide excision-repair of DNA damage caused by, 337
- Ionophores, 99, 424
- IP₃. *See* Inositol trisphosphate
- IPTG. *See* Isopropylthiogalactoside
- IREG1. *See* Iron regulatory protein
- IRES. *See* Internal ribosomal entry site
- Iron, 496*t*
- absorption of, 478, 584–586, 585*f*, 585*t*
- in hemochromatosis, 478
- vitamin C and ethanol affecting, 478, 496
- deficiency of, 497
- distribution of, 585*t*
- ferrous, in oxygen transport, **40–41**
- heme, 278, 585
- absorption of, 478, 585, 585*f*
- hindered environment for, 41, 41*f*
- in methemoglobinemia, 46
- incorporation of into protoporphyrin, 271–272, 272*f*
- metabolism of, 585, 585*f*
- disorders of, 586, 587*t*
- nonheme, 92, 95*f*, 585
- transferrin in transport of, 584–586, 585*f*, 585*t*
- Iron-binding capacity, total, 586
- Iron deficiency/iron deficiency anemia, 478, 497, 586
- Iron porphyrins, 270
- Iron regulatory protein, 585
- Iron response elements, 586
- Iron-sulfur protein complex, 92, 95*f*
- Irreversible covalent modifications, **76–77**, 77*f*
- Irreversible inhibition, enzyme, 69
- IRS 1–4, in insulin signal transmission, 465, 466*f*
- Ischemia, 136, 431
- Islets of Langerhans, insulin produced by, 160
- Isocitrate dehydrogenase, 130–131, 132*f*
- in NADPH production, 176, 176*f*
- Isoelectric focusing, for protein/peptide purification, 24, 25*f*
- Isoelectric pH (pI), amino acid net charge and, 17
- Isoenzymes. *See* Isozymes
- Isoleucine, 15*t*
- catabolism of, 259, 260*f*, 261*f*
- interconversion of, 240
- requirements for, 480
- Δ^3 -Isomerase, 438, 441*f*, 442, 443*f*
- Isomerases, 50
- in steroid synthesis, 438, 441*f*, 442, 443*f*
- Isomerism
- geometric, of unsaturated fatty acids, 112–114, 114*f*
- of steroids, 117, 118*f*
- of sugars, 102–104, 103*f*
- Isotiazid, acetylation of, 630
- Isopentenyl diphosphate, in cholesterol synthesis, 219, 221*f*
- Isoprene units, polyprenoids synthesized from, 118, 119*f*
- Isoprenoids, synthesis of, in cholesterol synthesis, 219, 221*f*, 222*f*
- Isopropylthiogalactoside, 378
- Isoprostanes (prostanoids), 112, 119
- cyclooxygenase pathway in synthesis of, 192, 192–194, 193*f*, 194*f*
- Isothermic systems, biologic systems as, 80
- Isotopes. *See also specific type*
- in plasma protein analysis, 581
- Isotype (class) switching, 594
- Isozymes, 594
- Isovaleric acidemia, 259, 259–262
- Isovaleryl-CoA dehydrogenase, in isovaleric acidemia, 259–262
- Isozymes, **54–55**
- J chain, 595*f*
- Jackson-Weiss syndrome, 551*t*
- JAK kinases, 436, 467, 467*f*
- Jak-STAT pathway, 436, 467, 467*f*
- Jamaican vomiting sickness, 188
- Jaundice (icterus), 270, **281–284**, 284*t*
- Joining region, gene for, 593
- DNA rearrangement and, 393, 593–594
- "Jumping DNA," 325
- Junctional diversity, 593–594
- Juxtaglomerular cells, in renin-angiotensin system, 451
- K*. *See* Dissociation constant
- K*. *See* Potassium
- k*. *See* Rate constant
- K_d*. *See* Dissociation constant
- k_{deg}*. *See* Rate of degradation
- K_{eq}*. *See* Equilibrium constant
- K_m*. *See* Michaelis constant
- k_i*. *See* Rate of synthesis
- K_p*. *See* Ion product
- Kappa (κ) chains, 591
- Kartagener syndrome, 577
- Karyotype, 320*f*
- Kayser-Fleischer ring, 588
- KDEL-containing proteins, 506–507, 508*t*
- Keratan sulfates, 544*f*, 544*t*, 545
- functions of, 547
- Keratins, 577*t*, 578
- Kernicterus, 282, 283
- α -Keto acid decarboxylase, defect/absence of, in maple syrup urine disease (branched-chain ketonuria), 259
- α -Keto acid dehydrogenase, branched-chain, 259
- thiamin diphosphate as coenzyme for, 488–489
- α -Keto acids
- amino acids in diet replaced by, 240
- oxidative carboxylation of, 259, 260*f*, 261*f*, 262*f*
- Ketoacidosis, 180, 188–189
- 3-Ketoacyl-CoA thiolase deficiency, 188
- 3-Ketoacyl synthase, 173, 175*f*
- Ketogenesis, 125–126, 126*f*, **183–187**
- high rates of fatty acid oxidation and, **183–186**, 184*f*
- HMG-CoA in, 184–185, 185*f*
- regulation of, **186–187**, 187*f*, 188*f*
- Ketogenic amino acids, 232
- α -Ketoglutarate, 131
- in amino acid carbon skeleton catabolism, 249, 250, 250*f*, 251*f*
- in glutamate synthesis, 237, 238*f*, 243, 243*f*, 244*f*
- transporter systems for, 99
- in urea synthesis, 244, 244*f*

- α -Ketoglutarate dehydrogenase complex, 131, 132f
regulation of, 135
thiamin diphosphate as coenzyme for, 488–489
- Ketone bodies, 124, 125–126, 126f, 180, 183–184, 184f
free fatty acids as precursors of, 186
as fuel for extrahepatic tissues, 185–186, 186f
in starvation, 232–234, 234f, 234t
- Ketonemia, 186, 188
- Ketoneuria, 188
branched chain (maple syrup urine disease), 259
- Ketoses (sugars), 102, 102t
- Ketosis, 180, 186, 188
in cattle
fatty liver and, 212
lactation and, 188
in diabetes mellitus, 188
ketoacidosis caused by, 188–189
nonpathologic, 188–189
in starvation, 188
- Kidney
glycogenolysis in, 147
metabolism in, 235t
in renin-angiotensin system, 451
vitamin D₃ synthesis in, 445, 446f, 484
- Kinases, protein. *See* Protein kinases
- Kinesin, 577
- Kinetic (collision) theory, 61
- Kinetics (enzyme), **60–71**. *See also* Catalysis
activation energy affecting, **61**, 63
balanced equations and, **60**
competitive versus noncompetitive inhibition and, **67–69**, 67f, 68f, 69f
factors affecting reaction rate and, **61–63**, 62f, **63–64**, 64f
free energy changes affecting, **60–61**
initial velocity and, **64**
multisubstrate enzymes and, **69–70**, 69f, 70f
saturation, 64f, 66
sigmoid (Hill equation), 66–67, 67f
substrate concentration and, **64**, 64f, 65f
models of effects of, **65–67**, 66f, 67f
transition states and, 61
- Kinetochores, 318
- Kininogen, high-molecular-weight, 599f, 600
- Kinky hair disease (Menkes disease), 588
- Knockout genes, 412
- Korsakoff's psychosis, 489
- Kozak consensus sequences, 365
- Krabbe's disease, 203t
- Krebs cycle. *See* Citric acid cycle
- Ku, in double-strand break repair, 338, 338f
- Kwashiorkor, 237, 478, 478–479
- Kynureninase, 257f, 258
- Kynurenine-anthranilate pathway, for tryptophan catabolism, 257f, 258
- Kynurenine formylase, 257f, 258
- L- α -amino acids, 14. *See also* Amino acids
genetic code specifying, 14, 15–16t
in proteins, 14
- L chains. *See* Light chains
- L-Dopa, 446, 447f
- L isomerism, 102–104, 103f
- L-selectin, 529f, 529t
- L-type calcium channel, 567
- Labile factor (factor V), 600t, 601, 602f
lacA gene, 376, 376f, 377f, 378
lacI gene, 377, 377f, 378
lac operon, 375, 376–378, 376f, 377f
lac repressor, 377, 377f
lacY gene, 376, 376f, 377f, 378
lacZ gene, 376, 376f, 377f, 378
- Lactase, 475
deficiency of (lactose/milk intolerance), 102, 474, 475
- Lactate
anaerobic glycolysis and, 136, 137f, 139–140
hypoxia and, 137f, 139–140
- Lactate dehydrogenase, in anaerobic glycolysis, 139
- Lactate dehydrogenase isozymes, 57, 139
diagnostic significance of, 57, 57t, 58f
- Lactic acid, pK_a/pK_s value of, 12t
- Lactic acid cycle, 159, 159f
- Lactic acidosis, 92, 136
with mitochondrial encephalopathy and stroke-like episodes (MELAS), 100–101
pyruvate metabolism and, 142–143
thiamin deficiency and, 489
- Lactoferrin, 621t
- Lactogenic hormone. *See* Prolactin
- Lactose, 106–107, 107f, 107t
galactose in synthesis of, **167–169**, 170f
metabolism of, operon hypothesis and, 376–378, 376f, 377f
- Lactose (milk) intolerance, 102, 474, 475
- Lactose synthase, 167, 170f
- Lagging (retrograde) strand, in DNA replication, 327f, 328, 330–331
- Lambda (λ) chains, 591
- Lambda (λ) phage, 378–383, 379f, 380f, 381f, 382f
- Lambda repressor (cI) protein/gene, 379–383, 380f, 381f, 382f
- Laminin, 535, **540–542**, 541f
- Lamins, 577t, 578
- Langerhans, islets of, insulin produced by, 160
- Lanosterol, in cholesterol synthesis, 219, 220, 222f
- Latch state, 571
- Lauric acid, 112t
- Laws of thermodynamics, 80–81
hydrophobic interactions and, 7
- LBD. *See* Ligand-binding domain
- LCAT. *See* Lecithin:cholesterol acyltransferase
- LCRs. *See* Locus control regions
- LDH. *See* Lactate dehydrogenase isozymes
- LDL. *See* Low-density lipoproteins
- LDL:HDL cholesterol ratio, 227
- Lead poisoning, ALA dehydratase inhibition and, 270, 278
- Leader sequence. *See* Signal peptide
- Leading (forward) strand, in DNA replication, 327f, 328, 330
- Lecithin:cholesterol acyltransferase (LCAT), 200–201, 209–210, 211f, 223, 224
familial deficiency of, 228t
- Lecithins (phosphatidylcholines), 114–115, 115f
in cytochrome P450 system, 617
membrane asymmetry and, 420
synthesis of, 197, 197f, 198f
- Lectins, 110, **517–518**, 518t
in glycoprotein analysis, 515t, **517–518**, 518t
- Leiden factor V, 603
- Lens of eye, fructose and sorbitol in, diabetic cataract and, 172
- Leptin, 215–216
- Lesch-Nyhan syndrome, 300
- Leucine, 15t
catabolism of, 259, 260f, 261f
interconversion of, 240
requirements for, 480
- Leucine aminomutase, 492
- Leucine zipper motif, 387–388, 388t, 390, 391f
- Leucovorin, 493
- Leukocyte adhesion deficiency
type I, 621
type II, 530t, 531
- Leukocytes, **620–624**
growth factors regulating production of, **610**
recombinant DNA technology in study of, 624
- Leukodystrophy, metachromatic, 203t
- Leukotriene A₄, 114f
- Leukotrienes, 112, 114f, 190, 192
clinical significance of, 196
lipoxygenase pathway in formation of, 192, 193f, **194**, 195f
- LFA-1, 529, 529t, 620, 622t
- LH. *See* Luteinizing hormone
- Library, 402, 413
- Lifestyle changes, cholesterol levels affected by, 227–228
- Ligand-binding domain, 470
- Ligand-gated channels, 424, 568t

- Ligand-receptor complex, in signal generation, 456–457
- Ligases, 50
- DNA, 328*t*, 330, 332, 332*f*
- Ligation, 413
- in RNA processing, 352
- Light, in active transport, 427
- Light chains
- immunoglobulin, 591, 592*f*
- in amyloidosis, 590
- genes producing, 593
- DNA rearrangement and, 325–326, 393, 593–594
- myosin, 560
- in smooth muscle contraction, 570
- Light meromyosin, 560–561, 560*f*
- Limit dextrinosis, 152*t*
- Lines, definition of, 413
- LINEs. *See* Long interspersed repeat sequences
- Lineweaver-Burk plot
- inhibitor evaluation and, 68, 68*f*, 69*f*
- K_m and V_{max} estimated from, 66, 66*f*
- Lingual lipase, 475
- Link trisaccharide, in glycosaminoglycan synthesis, 543
- Linkage analysis, 635*t*
- in glycoprotein study, 515*t*
- Linoleic acid/linoleate, 113*t*, 190, 190*f*, 192
- in essential fatty acid deficiency, 191
- synthesis of, 191*f*
- α -Linolenic acid/ α -linolenate, 113*t*, 190, 190*f*, 192
- in essential fatty acid deficiency, 191
- synthesis of, 191, 191*f*
- γ -Linolenic acid/ γ -linolenate, 113*t*
- in essential fatty acid deficiency, 191
- in polyunsaturated fatty acid synthesis, 191, 192*f*
- Lipases
- diagnostic significance of, 57*t*
- in digestion, 475, 476*f*
- in triacylglycerol metabolism, 197, 214–215, 214*f*, 475, 476*f*
- Lipid bilayer, 418–419, 418*f*, 419*f*
- membrane proteins and, 419
- Lipid core, of lipoprotein, 205
- Lipid rafts, 422
- Lipid storage disorders (lipidoses), 202–203, 203*t*
- Lipids, 111–121. *See also specific type*
- amphipathic, 119–121, 120*f*
- asymmetry of, membrane assembly and, 511, 512*f*
- classification of, 111
- complex, 111
- in cytochrome P450 system, 627
- derived, 111
- digestion and absorption of, 475–477, 476*f*
- disorders associated with abnormalities of, 431
- fatty acids, 111–114
- glycolipids, 111, 116, 117*f*
- interconvertibility of, 231
- in membranes, 416–418
- ratio of to protein, 416, 416*f*
- metabolism of, 122*f*, 123–124, 123*f*, 125–126, 126*f*. *See also* Lipolysis
- in fed state, 232
- in liver, 211–212, 213*f*
- neutral, 111
- peroxidation of, 118–119, 120*f*
- phospholipids, 111, 114–116, 115*f*
- precursor, 111
- simple, 111
- steroids, 117–118, 117*f*, 118*f*, 119*f*
- transport and storage of, 205–218
- adipose tissue and, 214–215, 214*f*
- brown adipose tissue and, 217, 217*f*
- clinical aspects of, 212–214
- fatty acid deficiency and, 194–195
- as lipoproteins, 205–206, 206*t*, 207*f*
- liver in, 211–212, 213*f*
- triacylglycerols (triglycerides), 114, 115*f*
- turnover of, membranes and, 511–512
- Lipogenesis, 125, 173–177, 174*f*, 175*f*
- acetyl-CoA for, 176–177
- fatty acid synthase complex in, 173–176, 174*f*, 175*f*
- malonyl-CoA production in, 173, 174*f*
- NADPH for, 175*f*, 176, 176*f*
- regulation of, 178–179, 178*f*
- enzymes in, 156*t*, 173, 174*f*, 178, 178*f*
- nutritional state in, 177–178
- Lipolysis, 125, 126*f*, 216–217, 216*f*. *See also* Lipids, metabolism of
- hormone-sensitive lipase in, 214–215, 214*f*
- hormones affecting, 215–216, 216*f*
- insulin affecting, 178–179
- triacylglycerol, 197
- Lipophilic compounds, cytochrome P450 isoforms in hydroxylation of, 627
- Lipoprotein lipase, 125, 126*f*, 207–208, 209*f*, 210*f*
- familial deficiency of, 228*t*
- involvement in remnant uptake, 208, 209*f*
- α_1 -Lipoprotein, 581*f*
- β_1 -Lipoprotein, 581*f*
- Lipoprotein(a) excess, familial, 228*t*
- Lipoproteins, 30, 111, 125, 205–206, 206*t*, 207*f*, 580, 583*t*. *See also specific type*
- carbohydrates in, 110
- in cholesterol transport, 223–224, 225*f*
- classification of, 205, 206*t*
- deficiency of, fatty liver and, 212
- disorders of, 228*t*, 229
- remnant, 206*t*, 208, 209*f*
- liver uptake of, 208–209
- Liposomes, 421
- amphipathic lipids forming, 119–121, 120*f*
- artificial membranes and, 421
- Lipotropic factor, 212
- β -Lipotropin, 453, 453*f*
- Lipoxins, 112, 114*f*, 190, 192
- clinical significance of, 196
- lipoxigenase pathway in formation of, 192, 193*f*, 194, 195*f*
- Lipoxigenase, 119, 194, 195*f*
- reactive species produced by, 119
- 5-Lipoxygenase, 194, 195*f*
- Lipoxigenase pathway, 192, 193*f*, 194, 195*f*
- Liquid chromatography, high-performance reversed-phase, for peptide separation, 23–24
- Lithium, 496*t*
- Lithocholic acid, synthesis of, 226*f*
- Liver
- angiotensinogen made in, 451
- bilirubin uptake by, 280–281, 280*f*, 281*f*, 282*f*
- cirrhosis of, 130, 212
- in α_1 -antitrypsin deficiency, 590
- cytochrome P450 isoforms in, 627
- disorders of, in α_1 -antitrypsin deficiency, 589–590, 590*f*
- fatty
- alcoholism and, 212–214
- of pregnancy, 188
- triacylglycerol metabolism imbalance and, 212
- fructose overload and, 170–171
- glycogen in, 145, 146*t*
- heme synthesis in, 272
- ALA synthase in regulation of, 272–273, 276*f*
- ketone bodies produced by, 183–184, 184*f*, 186
- metabolism in, 124–125, 125*f*, 126*f*, 130, 235*t*
- fatty acid oxidation, ketogenesis and, 183–186, 184*f*
- fructose, 167, 169*f*
- glucose, 154*f*, 159, 159–160, 159*f*
- fructose 2,6-bisphosphate in regulation of, 157–158, 158*f*
- glycogen, 145–147, 145, 146*f*, 148
- lipid, 211–212, 213*f*
- plasma protein synthesis in, 125, 581
- vitamin D₃ synthesis in, 445, 446*f*, 484, 485*f*
- Liver phosphorylase, 147
- deficiency of, 152*t*
- LMM. *See* Light meromyosin
- Lock and key model, 52

- Locus control regions, 387
- Long interspersed repeat sequences (LINEs), 321–322
- Looped domains, chromatin, 316, 318, 319f
- Loops (protein conformation), 32–33
- Loose connective tissue, keratan sulfate I in, 545
- Low-density lipoprotein receptor-related protein, 206
- in chylomicron remnant uptake, 208–209, 209f
- Low-density lipoproteins, 205, 206t
- apolipoproteins of, 206, 206t
- metabolism of, 209, 210f
- ratio of to high-density lipoproteins, atherosclerosis and, 227
- receptors for, 209
- in chylomicron remnant uptake, 208–209, 209f
- in cotranslational insertion, 505–506, 506f
- regulation of, 223
- Low-energy phosphates, 83
- β -LPH. *See* β -Lipotropin
- LRP. *See* Low-density lipoprotein receptor-related protein
- L-tryptophan dioxygenase (tryptophan pyrrolase), 89
- LTs. *See* Leukotrienes
- Lung surfactant, 115, 197
- deficiency of, 115, 202
- Luteinizing hormone (LH), 437, 438, 439f
- LXs. *See* Lipoxins
- LXXLL motifs, nuclear receptor coregulators, 473
- Lyases, 50
- in steroid synthesis, 440–442, 441f, 443f
- Lymphocyte homing, selectins in, 528–530, 529f, 529t, 530f
- Lymphocytes. *See also* B lymphocytes; T lymphocytes
- recombinant DNA technology in study of, 624
- Lysine, 16t
- catabolism of, 256f, 258
- pI of, 17
- requirements for, 480
- Lysine hydroxylase, vitamin C as coenzyme for, 496
- Lysis, cell, complement in, 596
- Lysogenic pathway, 379, 379f
- Lysolecithin (lysophosphatidylcholine), 116, 116f
- metabolism of, 200–201, 201f
- Lysophosphatidylcholine. *See* Lysolecithin
- Lysophospholipase, 200, 201f
- Lysophospholipids, 116, 116f
- Lysosomal degradation pathway, defect in in lipidoses, 203
- Lysosomal enzymes, 623
- in I-cell disease, 431, 432t, 531–532, 532f
- Lysosomal hydrolases, deficiencies of, 532–533, 533t
- Lysosomes
- in oligosaccharide processing, 524
- protein entry into, 507, 507f, 508t
- disorders associated with defects in, 512t, 513
- Lysozyme, 621t
- Lysyl hydroxylase
- diseases caused by deficiency of, 538t
- in hydroxylysine synthesis, 240, 537
- Lysyl oxidase, 537, 539
- Lytic pathway, 379, 379f
- D-Lyxose, 104f, 105t
- Mac-1, 529, 529t
- α_2 -Macroglobulin, 583t, 590, 624
- antithrombin activity of, 603
- Macromolecules, cellular transport of, 428–431, 429f, 430f
- Mad cow disease (bovine spongiform encephalopathy), 37
- Magnesium, 496t
- in chlorophyll, 270
- in extracellular and intracellular fluid, 416, 416t
- Major groove, in DNA, 305f, 306
- operon model and, 378
- Malate, 132f, 133
- Malate dehydrogenase, 132f, 133
- Malate shuttle, 99, 100f
- MALDI. *See* Matrix-assisted laser-desorption
- Maleylacetoacetate, in tyrosine catabolism, 254f, 255
- Malic enzyme, 156t, 157
- in NADPH production, 176, 176f
- Malignancy/malignant cells. *See* Cancer/cancer cells
- Malignant hyperthermia, 556, 564–565, 565f, 569t
- Malonate
- respiratory chain affected by, 95, 96f
- succinate dehydrogenase inhibition by, 67–68, 67f
- Malonyl-CoA, in fatty acid synthesis, 173, 174f
- Malonyl transacylase, 173, 174f, 175f
- Maltase, 475
- Maltose, 106–107, 107f, 107t
- Mammalian target of rapamycin (mTOR), in insulin signal transmission, 466f, 467
- Mammotropin. *See* Prolactin
- Manganese, 496t
- Mannosamine, 169, 171f
- D-Mannosamine, 106
- Mannose, in glycoproteins, 516t
- D-Mannose, 104f, 105t
- α -D-Mannose, 104f
- Mannose-binding protein, deficiency of, 533
- Mannose 6-phosphate/mannose 6-P signal, 526
- in I-cell disease, 531, 532, 532f
- in protein flow, 507, 508t
- Mannosidosis, 532–533, 533t
- MAP (mitogen-activated protein) kinase
- in insulin signal transmission, 466f, 467
- in Jak/STAT pathway, 467
- Maple syrup urine disease (branched-chain ketonuria), 259
- Marasmus, 80, 237, 478, 478–479
- Marble bone disease (osteopetrosis), 552
- Marfan syndrome, fibrillin mutations causing, 539–540, 540f
- Maroteaux-Lamy syndrome, 546t
- Mass spectrometry, 27, 27f
- covalent modifications detected by, 27f, 27t
- for glycoprotein analysis, 514, 515t
- tandem, 27
- transcript-protein profiling and, 412
- Mast cells, heparin in, 545
- Matrix
- extracellular, 535–555. *See also specific component*
- mitochondrial, 92, 93f, 130
- Matrix-assisted laser-desorption (MALDI), in mass spectrometry, 27
- Matrix-processing peptidase, 499
- Matrix proteins, 499
- diseases caused by defects in import of, 503
- Maxam and Gilbert's method, for DNA sequencing, 404–405
- Maximal velocity (V_{max})
- allosteric effects on, 75–76
- inhibitors affecting, 68, 68f, 69f
- Michaelis-Menten equation in
- determination of, 65–66, 66f
- substrate concentration and, 64, 64f
- McArdle's disease/syndrome, 152t, 573
- Mechanically gated ion channels, 568t
- Mediator-related proteins, 472t, 473
- Medicine
- preventive, biochemical research affecting, 2
- relationship of to biochemistry, 1–4, 3f
- Medium-chain acyl-CoA dehydrogenase, deficiency of, 188
- Megaloblastic anemia
- folate deficiency causing, 482t, 492, 610t
- vitamin B₁₂ deficiency causing, 482t, 492, 494, 610t
- Melanocyte-stimulating hormone (MSH), 453, 453f
- MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes), 100–101

- Melting point, of amino acids, 18
- Melting temperature/transition temperature, 305, 422
- Membrane attack complex, 596
- Membrane fatty acid-transport protein, 207
- Membrane proteins, 419, 420*t*, 514. *See also* Glycoproteins
- association of with lipid bilayer, 419
 - flow of, 507, 507*f*, 508*t*
 - integral, 30, 420, 421*f*
 - mutations affecting, diseases caused by, 431–432, 432*f*, 432*t*
 - peripheral, 420–421, 421*f*
 - red cell, 614–617, 615*f*, 616*f*, 616*t*
 - structure of, dynamic, 419
- Membrane transport, 423, 423*t*, 424*f*, 426–431, 426*f*. *See also* specific mechanism
- Membranes, 415–433
- artificial, 421–422
 - assembly of, 511–513, 512*f*, 512*t*
 - asymmetry of, 416, 419–420
 - bilayers of, 418–419, 418*f*, 419*f*
 - membrane protein association and, 419
 - biogenesis of, 511–513, 512*f*, 512*t*
 - cholesterol in, 417
 - fluid mosaic model and, 422
 - depolarization of, in nerve impulse transmission, 428
 - function of, 415–416, 421–422
 - fluidity affecting, 422
 - glycosphingolipids in, 417
 - Golgi apparatus in synthesis of, 509
 - intracellular, 415
 - lipids in, 416–418
 - amphipathic, 119, 120*f*, 417–418, 417*f*
 - mutations affecting, diseases caused by, 431–432, 432*f*, 432*t*
 - phospholipids in, 114–116, 115*f*, 416–417, 417*f*
 - plasma. *See* Plasma membrane
 - protein:lipid ratio in, 416, 416*f*
 - proteins in, 419, 420*t*. *See also* Membrane proteins
 - red cell, 614–617, 615*f*, 615*t*, 616*f*, 616*t*
 - hemolytic anemia and, 619, 620*t*
 - selectivity of, 415, 423–426, 423*t*, 424*f*, 425*f*, 426*t*
 - sterols in, 417
 - structure of, 416–421, 416*f*
 - asymmetry and, 416, 419–420
 - fluid mosaic model of, 421*f*, 422
- Menadiol, 486, 487*f*
- Menadiol diacetate, 486, 488*f*
- Menadione, 486. *See also* Vitamin K
- Menaquinone, 482*t*, 486, 488*f*. *See also* Vitamin K
- Menkes disease, 588
- MEOS. *See* Cytochrome P450-dependent microsomal ethanol oxidizing system
- 6-Mercaptopurine, 290, 291*f*
- Mercapturic acid, 629
- Mercuric ions, pyruvate metabolism affected by, 142
- Meromyosin
- heavy, 560*f*, 561, 561*f*
 - light, 560–561, 560*f*
- Messenger RNA (mRNA), 307, 309–310, 310*f*, 311*f*, 341, 342*t*, 359. *See also* RNA
- alternative splicing and, 354, 354*f*, 393–394, 636
 - codon assignments in, 358, 359*t*
 - editing of, 356
 - expression of, detection of in gene isolation, 635*t*
 - modification of, 355–356
 - nucleotide sequence of, 358
 - mutations caused by changes in, 361–363, 361*f*, 362*f*, 364*f*
 - polycistronic, 376
 - recombinant DNA technology and, 397
 - relationship of to chromosomal DNA, 321*f*
 - stability of, regulation of gene expression and, 394–395, 394*f*
 - transcription starting point and, 342
 - variations in size/complexity of, 397, 399*t*
- Metabolic acidosis, ammonia in, 245
- Metabolic alkalosis, ammonia in, 245
- Metabolic fuels, 231–236. *See also* Digestion
- clinical aspects of, 236
 - diet providing, 474, 478
 - in fed and starving states, 232–234, 233*f*, 234*f*, 234*t*
 - interconvertibility of, 231–232
- Metabolic pathway/metabolite flow, 122, 122–124. *See also* specific type and Metabolism
- flux-generating reactions in, 129
 - nonequilibrium reactions in, 128–129
 - regulation of, 72, 73*f*, 126–129, 128*f*
 - covalent modification in, 79
 - unidirectional nature of, 72, 73*f*
- Metabolism, 81, 122–129, 235*t*. *See also* specific type and Catalysis; Metabolic pathway
- blood circulation and, 124–126, 125*f*, 126*f*
 - group transfer reactions in, 8
 - inborn errors of, 1, 249
 - integration of, metabolic fuels and, 231–236
 - regulation of, 72, 73*f*, 126–129, 128*f*
 - allosteric and hormonal mechanisms in, 74, 74–76, 75*f*, 128*f*, 129
 - enzymes in, 126–129, 128*f*
 - allosteric regulation and, 74, 74–76, 75*f*, 128*f*, 129
 - compartmentation and, 72–73
 - control of quantity and, 73–74
 - covalent modification and, 74, 76, 77–78, 78*f*
 - rate-limiting reactions and, 73
 - at subcellular level, 126, 127*f*
 - at tissue and organ levels, 124–126, 125*f*, 126*f*, 235*t*
 - of xenobiotics, 626–632
- Metachromatic leukodystrophy, 203*t*
- Metal-activated enzymes, 50
- Metal ions, in enzymatic reactions, 50
- Metalloenzymes, 50
- Metalloflavoproteins, 86–87
- Metalloproteins, 30
- Metallothioneins, 588
- Metaphase chromosomes, 317*f*, 318, 319*t*
- Metastasis
- glycoproteins and, 514, 526, 530*t*, 531
 - membrane abnormalities and, 432*t*
- Methacrylyl-CoA, catabolism of, 262*f*
- Methemoglobin, 46, 363, 613–614
- Methemoglobinemia, 46, 614
- Methionine, 15*t*, 264, 266*f*
- active (*S*-adenosylmethionine), 258*f*, 259, 264, 266*f*, 289, 290*f*, 290*t*
 - catabolism of, 258*f*, 259, 259*f*
 - requirements for, 480
- Methionine synthase, 492, 494
- Methotrexate, 296–297, 494
- dihydrofolate/dihydrofolate reductase affected by, 296–297, 494
- Methylation
- in covalent modification, mass increases and, 27*t*
 - of deoxycytidine residues, gene expression affected by, 383
 - in glycoprotein analysis, 515*t*
 - of xenobiotics, 626, 630
- β -Methylcrotonyl-CoA, catabolism of, 261*f*
- 5-Methylcytosine, 287, 289*f*
- α -Methylidopa, 446
- Methylene tetrahydrofolate, 493, 493*f*
- in folate trap, 493*f*, 494
- 7-Methylguanine, 289*f*
- Methylhistidine, 576
- in Wilson's disease, 265
- Methylmalonic aciduria, 155
- Methylmalonyl-CoA, accumulation of in vitamin B₁₂ deficiency, 492
- Methylmalonyl-CoA isomerase (mutase), in propionate metabolism, 155, 155*f*, 492
- Methylmalonyl-CoA mutase (isomerase), 155, 155*f*, 492
- Methylmalonyl-CoA racemase, in propionate metabolism, 155, 155*f*
- Methyl pentose, in glycoproteins, 109*t*
- Methyl-tetrahydrofolate, in folate trap, 493*f*, 494
- Mevalonate, synthesis of, in cholesterol synthesis, 219, 220*f*, 221*f*, 222*f*

- Mg. *See* Magnesium
- Micelles, 418, 418f
amphipathic lipids forming, 119, 120f, 418, 418f
in lipid absorption, 475
- Michaelis constant (K_m), 65
allosteric effects on, 75–76
binding constant approximated by, 66
enzymatic catalysis rate and, 65–66, 66f, 72, 73f
inhibitors affecting, 68, 69f
Michaelis-Menten equation in
determination of, 65–66, 66f
- Michaelis-Menten equation, 65
Bi-Bi reactions and, 70, 70f
regulation of metabolite flow and, 72, 73f
- Microfilaments, 576–577
 α_2 -Microglobulin, 583t
- Microsatellite instability, 322
- Microsatellite polymorphism, 322, 411, 413
- Microsatellite repeat sequences, 322, 413
- Microsomal elongase system, 177, 177f
- Microsomal fraction, cytochrome P450
isoforms in, 627
- Microtubules, 577
- Migration, cell, fibronectin in, 540
- Milk (lactose) intolerance, 102, 474, 475
- Mineralocorticoid response element, 459t
- Mineralocorticoids, 437
receptor for, 471
synthesis of, 438–440, 441f
- Minerals, 2, 496–497, 496t
digestion and absorption of, 477–478
- Minor groove, in DNA, 305f, 306
- Mismatch repair of DNA, 336, 336f, 336t
colon cancer and, 336
- Missense mutations, 361, 362–363, 362f
familial hypertrophic cardiomyopathy
caused by, 569–570, 570f
- MIT. *See* Monoiodotyrosine
- Mitchell's chemiosmotic theory. *See*
Chemiosmotic theory
- Mitochondria
ALA synthesis in, 270, 273f
citric acid cycle in, 122, 122f, 123f, 124f, 126, 127f, 130, 133–135, 134f
fatty acid oxidation in, 180–181, 181f
ion transport in, 99
protein synthesis and import by, 499–501, 501t
respiration rate of, ADP in control of, 94–95, 97t, 98f
respiratory chain in, 92. *See also*
Respiratory chain
- Mitochondrial cytochrome P450, 89–90, 627. *See also* Cytochrome P450
system
- Mitochondrial DNA, 322–323, 322f, 323t
- Mitochondrial encephalomyopathies, with
lactic acidosis and stroke-like
episodes (MELAS), 100
- Mitochondrial genome, 499
- Mitochondrial glycerol-3-phosphate
dehydrogenase, 87
- Mitochondrial membrane proteins, muta-
tions of, 431
- Mitochondrial membranes, 92, 93f
enzymes as markers and, 92
exchange transporters and, 98–100, 98f, 99f
protein insertion in, 501
- Mitochondrial myopathies, fatal infantile,
and renal dysfunction, oxidore-
ductase deficiency causing, 100
- Mitogen-activated protein (MAP) kinase
in insulin signal transmission, 466f, 467
in Jak/STAT pathway, 467
- Mitotic spindle, microtubules in formation
of, 577
- Mixed-function oxidases, 89–90, 627. *See*
also Cytochrome P450 system
- ML. *See* Mucopolidoses
- MOAT. *See* Multispecific organic anion
transporter
- Modeling, molecular, in protein structure
analysis, 36
- Molecular biology, 1. *See also* Recombinant
DNA/recombinant DNA
technology
in primary structure determination,
25–26
- Molecular chaperones. *See* Chaperones
- Molecular genetics, 1, 396. *See also*
Recombinant DNA/recombinant
DNA technology
- Molecular modeling, in protein structure
analysis, 36
- Molecular motors, 577
- Molybdenum, 496t
- Monoacylglycerol acyltransferase, 198f, 199
- Monoacylglycerol pathway, 198f, 199, 475–477, 476f
- 2-Monoacylglycerols, 198f, 199
- Monoclonal antibodies, hybridomas in
production of, 595–596, 596f
- Monoglycosylated core structure, calnexin
binding and, 526
- Monoiodotyrosine (MIT), 447, 448f, 449
- Monomeric proteins, 34
- Mononucleotides, 287
"salvage" reactions and, 294, 295f, 297f
- Monoxygenases, 89–90. *See also*
Cytochrome P450 system
in metabolism of xenobiotics, 626
- Monosaccharides, 102. *See also specific type*
and Glucose
absorption of, 475, 475f
physiologic importance of, 104–105, 105t
- Monounsaturated fatty acids, 112, 113t. *See*
also Fatty acids; Unsaturated fatty
acids
dietary, cholesterol levels affected by, 227
synthesis of, 191, 191f
- Morquio syndrome, 546t
- MPP. *See* Matrix-processing peptidase
- MPS. *See* Mucopolysaccharidoses
- MRE. *See* Mineralocorticoid response
element
- mRNA. *See* Messenger RNA
- MRP2. *See* Multidrug resistance-like
protein 2
- MSH. *See* Melanocyte-stimulating hormone
- MtH, 399t
in sickle cell disease, 409, 410f
- mtDNA. *See* Mitochondrial DNA
- mTOR, in insulin signal transmission,
466f, 467
- Mucins, 519–520, 520t
genes for, 520
O-glycosidic linkages in, 518, 519–520, 519f
repeating amino acid sequences in, 519, 520f
- Mucopolidoses, 546–547, 546t
- Mucopolysaccharides, 109, 109f
- Mucopolysaccharidoses, 545–547, 546t, 547f
- Mucoproteins. *See* Glycoproteins
- Mucus, 519–520
- Multidrug resistance-like protein 2, in
bilirubin secretion, 280
- Multipass membrane protein, anion
exchange protein as, 615, 615f, 616t
- Multiple myeloma, 595
- Multiple sclerosis, 202
- Multiple sulfatase deficiency, 203
- Multisite phosphorylation, in glycogen
metabolism, 151
- Multispecific organic anion transporter, in
bilirubin secretion, 280
- Muscle, 556–576, 557f. *See also* Cardiac
muscle; Skeletal muscle
ATP in, 556, 561–562, 573–574, 575f
contraction of. *See* Muscle contraction
in energy transduction, 556–559, 557f, 558f, 559f
fibers in, 556
glycogen in, 145, 146t
metabolism in, 125, 125f, 235t, 576t
glycogen, 145
lactate production and, 139
as protein reserve, 576
proteins of, 566t. *See also* Actin; Myosin;
Titin
- Muscle contraction, 556, 558f, 561–565, 564t
ATP hydrolysis in, 561–562, 561f
in cardiac muscle, 566–568

- regulation of
 actin-based, 562–563
 calcium in, 562
 in cardiac muscle, 566–568
 sarcoplasmic reticulum and, 563–564, 563*f*, 564*f*
 in smooth muscle, 570–571, 571*f*
 myosin-based, 570
 myosin light chain kinase in, 570–571, 571*f*
 relaxation phase of, 561, 564, 564*t*
 in smooth muscle
 calcium in, 571
 nitric oxide in, 571–573, 573*f*
 sliding filament cross-bridge model of, 557–559, 558*f*
 in smooth muscle, 570–573
 tropomyosin and troponin in, 562
- Muscle fatigue, 136
- Muscle phosphorylase, 147
 absence of, 152*t*
 activation of
 calcium/muscle contraction and, 148
 cAMP and, 147–148, 149*f*
- Muscular dystrophy, Duchenne, 556, 565–566, 566*f*
- Mutagenesis, site-directed, in enzyme study, 58
- Mutations, 314, 323–326, 323*f*, 324*f*, 325*f*
 base substitution, 361, 361*f*, 362
 constitutive, 376
 frameshift, 363, 364*f*
 ABO blood group and, 619
 gene conversion and, 325
 integration and, 324, 324*f*
 of membrane proteins, diseases caused by, 431–432, 432*f*, 432*t*
 missense, 361, 362–363, 362*f*
 familial hypertrophic cardiomyopathy caused by, 569–570, 570*f*
 mRNA nucleotide sequence changes causing, 361–363, 361*f*, 362*f*, 364*f*
 nonsense, 362
 point, 361
 recombinant DNA technology in
 detection of, 408–409, 408*f*
 recombination and, 323–324, 323*f*, 324*f*
 silent, 361
 sister chromatid exchanges and, 325, 325*f*
 suppressor, 363
 transition, 361, 361*f*
 transposition and, 324–325
 transversion, 361, 361*f*
- Myasthenia gravis, 431
- Myelin sheets, 428
- Myeloma, 595
- Myeloma cells, hybridomas grown from, 596, 596*f*
- Myeloperoxidase, 612, 621*t*, 623
- Myocardial infarction, lactate dehydrogenase isoenzymes in diagnosis of, 57, 57*t*, 58*f*
- Myofibrils, 556, 557*f*, 558*f*
- Myoglobin, 40–48
 α -helical regions of, 40, 41*f*
 β subunits of hemoglobin and, 42
 oxygen dissociation curve for, 41–42, 42*f*
 oxygen stored by, 40, 41–42, 42*f*, 573
- Myoglobinuria, 47
- Myokinase (adenylyl kinase), 84
 deficiencies of, 151–152
 in gluconeogenesis regulation, 157
 as source of ATP in muscle, 573, 575*f*
- Myopathies, 92
 mitochondrial, 100–101
 fatal infantile, and renal dysfunction, oxidoreductase deficiency causing, 100
- Myophosphorylase deficiency, 152*t*
- Myosin, 557, 559, 560*f*
 in muscle contraction, 557–559, 558*f*, 561–562, 561*f*, 562*f*
 regulation of smooth muscle contraction and, 570
 in striated versus smooth muscle, 572*t*
 structure and function of, 560–561, 560*f*
- Myosin-binding protein C, 566*t*
- Myosin (thick) filaments, 557, 558*f*
- Myosin head, 560, 560*f*
 conformational changes in, in muscle contraction, 561
- Myosin heavy chains, 560
 familial hypertrophic cardiomyopathy caused by mutations in gene for, 569–570, 570*f*
- Myosin light chain kinase, 570–571, 571*f*
- Myosin light chains, 560
 in smooth muscle contraction, 570
- Myotonia congenita, 569*t*
- Myristic acid, 112*t*, 510
- Myristylation, 510
 in covalent modification, mass increases and, 27*t*
- N*-acetyl neuraminic acid, 169, 171*f*
 in gangliosides, 201, 203*f*
 in glycoproteins, 169, 171*f*, 515, 516*t*
 in mucins, 519*f*, 520
- N*-linked glycoproteins, 518, 519*f*, 521–527
 classes of, 521, 522*f*
 synthesis of, 521–527, 523*f*, 524*f*, 525*f*, 526*t*
 dolichol-P-P-oligosaccharide in, 521–524, 523*f*
 in endoplasmic reticulum and Golgi apparatus, 524–525, 526*t*
 glycan intermediates formed during, 526
- regulation of, 526–527, 527*t*
 tunicamycin affecting, 527, 527*t*
- Na. See Sodium
- Na⁺-Ca²⁺ exchanger, 463
- Na⁺-K⁺ ATPase, 427–428, 428*f*
 in glucose transport, 428, 429*f*
- NAD⁺ (nicotinamide adenine dinucleotide), 87, 490, 490*f*
 absorption spectrum of, 56, 56*f*
 in citric acid cycle, 133
 as coenzyme, 87, 89*f*, 290*t*
- NADH
 absorption spectrum of, 56, 56*f*
 extramitochondrial, oxidation of, 99, 100*f*
 fatty acid oxidation yielding, 181
 in pyruvate dehydrogenase regulation, 141–142, 142*f*
- NADH dehydrogenase, 87, 93
- NADP⁺ (nicotinamide adenine dinucleotide phosphate), 87, 490
 as coenzyme, 87, 89*f*, 290*t*
 in pentose phosphate pathway, 163, 164*f*, 165*f*
- NAD(P)⁺-dependent dehydrogenases, in enzyme detection, 56
- NADPH
 in cytochrome P450 reactions, 90*f*, 627
 intramitochondrial, proton-translocating transhydrogenase and, 99
 for lipogenesis, 175*f*, 176, 176*f*
 pentose phosphate pathway and, 163, 164*f*, 165*f*, 169
- NADPH-cytochrome P450 reductase, 627
- NADPH oxidase, 621*t*, 622–623
 chronic granulomatous disease associated with mutations in, 623, 623*f*
- NCoA-1/NCoA-2 coactivators, 472, 472*t*
- NCoR, 472*t*, 473
- NDPs. See Ribonucleoside diphosphates
- Nebulin, 566*t*
- NEFA (nonesterified fatty acids). See Free fatty acids
- Negative nitrogen balance, 479
- Negative regulators, of gene expression, 374, 375*t*, 378, 380
- Negative supercoils, DNA, 306
- NEM-sensitive factor (NSF), 509, 510*f*
- Neonatal adrenoleukodystrophy, 503, 503*t*
- Neonatal (physiologic) jaundice, 282–283
- Neonatal tyrosinemia, 255
- Neonate, hypoglycemia in, 151
- Nerve cells. See Neurons
- Nerve impulses, 428
- Nervous system
 glucose as metabolic necessity for, 232
 thiamin deficiency affecting, 489
- NESs. See Nuclear export signals
- Net charge, of amino acid, 16–17, 17*f*
- Net diffusion, 423

- NeuAc. *See* *N*-Acetylneuraminic acid
- Neural tube defects, folic acid supplements
in prevention of, 494
- Neuraminic acid, 110, 116
- Neuraminidases
deficiency of, 532–533, 533*t*
in glycoprotein analysis, 517
influenza virus, 533
- Neurofilaments, 577*t*
- Neurologic diseases, protein conformation
alterations and, 37
- Neurons, membranes of
impulses transmitted along, 428
ion channels in, 424, 425*f*
synaptic vesicle fusion with, 511
- Neuropathy, sensory, in vitamin B₆ excess,
491
- Neutral lipids, 111
- Neutropenia, 610
- Neutrophils, 620–624
activation of, 621–622
biochemical features of, 620*t*
enzymes and proteins of, 621*t*
in infection, 620
in inflammation, 620, 621*t*
integrins and, 620–621, 622*t*
selectins and, 528–529, 529*t*, 530*f*
proteinases of, 623–624, 624*t*
respiratory burst and, 622–623
- NF- κ B pathway, 468, 468*f*, 469*f*
- Niacin, 482*t*, 490, 490*f*. *See also*
Nicotinamide; Nicotinic acid
in citric acid cycle, 133
deficiency of, 482*t*, 490
excess/toxicity of, 490
- Nick translation, 413
- Nickel, 496*t*
- Nicks/nick-sealing, in DNA replication,
332, 332*f*
- Nicotinamide, 482*t*, 490, 490*f*. *See also*
Niacin
coenzymes derived from, 50–51
dehydrogenases and, 87, 89*f*
excess/toxicity of, 490
- Nicotinamide adenine dinucleotide
(NAD⁺), 87, 490, 490*f*
absorption spectrum of, 56, 56*f*
in citric acid cycle, 133
as coenzyme, 87, 89*f*, 290*t*
- Nicotinamide adenine dinucleotide
phosphate (NADP⁺), 87, 490
as coenzyme, 87, 89*f*, 290*t*
in pentose phosphate pathway, 163,
164*f*, 165*f*
- Nicotinic acid, 482*t*, 490, 490*f*. *See also*
Niacin
as hypolipidemic drug, 229
- NIDDM. *See* Non-insulin dependent
diabetes mellitus
- Nidogen (entactin), in basal lamina, 540
- Niemann-Pick disease, 203*t*
- Night blindness, vitamin A deficiency
causing, 482*t*, 483
- Nitric oxide, 556, 571–573, 573*f*, 574*t*,
607*t*
clotting/thrombosis affected by, 607,
607*t*
- Nitric oxide synthases, 572–573, 573*f*, 574*t*
- Nitrite, nitric oxide formation from, 572
- Nitrogen, amino acid (α -amino)
catabolism of, 242–248
end products of, 242–243
urea as, 242–243, 245–247, 246*f*
L-glutamate dehydrogenase in,
244–245, 244*f*, 245*f*
- Nitrogen balance, 479
- Nitroglycerin, 572
- NLS. *See* Nuclear localization signal
- NMR. *See* Nuclear magnetic resonance
(NMR) spectroscopy
- NO. *See* Nitric oxide
- NO synthase. *See* Nitric oxide synthase
- Noncoding regions, in recombinant DNA
technology, 397, 398*f*
- Noncoding strand, 304
- Noncompetitive inhibition, competitive
inhibition differentiated from,
67–69, 67*f*, 68*f*, 69*f*
- Noncovalent assemblies, in membranes, 416
- Noncovalent forces
in biomolecule stabilization, 6
peptide conformation and, 20
- Nonequilibrium reactions, 128–129
citric acid cycle regulation and, 135
glycolysis regulation and, 140, 153–155
- Nonesterified fatty acids. *See* Free fatty acids
- Nonfunctional plasma enzymes, 57. *See also*
Enzymes
in diagnosis and prognosis, 57, 57*t*
- Nonheme iron, 92, 95*f*, 585
- Nonhistone proteins, 314
- Non-insulin dependent diabetes mellitus
(NIDDM/type 2), 161
- Nonoxidative phase, of pentose phosphate
pathway, 163–166
- Nonrepetitive (unique-sequence) DNA,
320, 320–321
- Nonsense codons, 359, 361, 363
- Nonsense mutations, 361
- Nonsteroidal anti-inflammatory drugs
cyclooxygenase affected by, 193
prostaglandins affected by, 190
- Norepinephrine, 439*f*, 447, 447*f*. *See also*
Catecholamines
synthesis of, 267, 267*f*, 445–447, 447*f*
in thermogenesis, 217, 217*f*
- Northern blot transfer procedure, 305–306,
403, 404*f*, 413
in gene isolation, 635*t*
- NPCs. *See* Nuclear pore complexes
- NSF. *See* NEM-sensitive factor
- Nuclear export signals, 503
- Nuclear genes, proteins encoded by, 499
- Nuclear localization signal (NLS), 501,
502*f*, 508*t*
- Nuclear magnetic resonance (NMR)
spectroscopy
for glycoprotein analysis, 514, 515*t*
protein structure demonstrated by,
35–36
- Nuclear pore complexes, 501
- Nuclear proteins, O-glycosidic linkages in,
518
- Nuclear receptor coactivators
(NCoA-1/NCoA-2), 472, 472*t*
- Nuclear receptor corepressor (NCoR), 472*t*,
473
- Nuclear receptor superfamily, 436, 469,
469–471, 471*f*, 472*t*
- Nucleases, 8, 312
active chromatin and, 316
- Nucleic acids. *See also* DNA; RNA
bases of, 287–289, 288*t*
dietarily nonessential, 293
digestion of, 312
structure and function of, 303–313
- Nucleolytic processing, of RNA, 352
- Nucleophile, water as, 7–8
- Nucleophilic attack, in DNA synthesis,
328, 329*f*
- Nucleoplasmin, 315
- Nucleoproteins, packing of, 318, 319*t*, 320*f*
- Nucleosidases (nucleoside phosphorylases),
purine, deficiency of, 300
- Nucleoside diphosphate kinase, 85
- Nucleoside triphosphates
group transfer potential of, 289–290,
289*f*, 290*f*, 290*t*
nonhydrolyzable analogs of, 291, 292*f*
in phosphorylation, 85
- Nucleosides, 286–287, 288*t*
- Nucleosomes, 314, 315–316, 315*f*
- Nucleotide excision-repair of DNA, 336,
337, 338*f*
- Nucleotide sugars, in glycoprotein biosyn-
thesis, 516–517, 516*t*, 520, 521*t*
- Nucleotides, 286–292, 288*t*. *See also*
Purine; Pyrimidines
adenylyl kinase (myokinase) in
interconversion of, 84
as coenzymes, 290, 290*t*
DNA, deletion/insertion of, frameshift
mutations and, 363, 364*f*
metabolism of, 293–302
in mRNA, 358
mutations caused by changes in,
361–363, 361*f*, 362*f*, 364*f*
physiologic functions of, 289
as polyfunctional acids, 290
polynucleotides, 291–292
synthetic analogs of, in chemotherapy,
290–291, 291*f*
ultraviolet light absorbed by, 290

- Nucleus (cell), importins and exportins in transport and, **501–503**, 502f
- Nutrition, **474–480**. *See also* Diet
 biochemical research affecting, 2
 lipogenesis regulated by, **177–178**
- Nutritional deficiencies, 474
 in AIDS and cancer, 479
- Nutritionally essential amino acids, 124, 237t, 480. *See also* Amino acids
- Nutritionally essential fatty acids, **190**. *See also* Fatty acids
 abnormal metabolism of, 195–196
 deficiency of, 191–192, 194–195
- Nutritionally nonessential amino acids, 124, 237, 237t, 480
 synthesis of, **237–241**
- O_R . *See* Right operator
- O blood group substance, 618–619, 619f
- O gene, 618–619
- O-glycosidic linkage
 of collagen, 537
 of proteoglycans, 542–543
- O-linked glycoproteins, 518, **518–520**, 519f, 520f, 520t
 synthesis of, 520, 521t
- O-linked oligosaccharides, in mucins, 519–520, 519f, 520f
- Obesity, 80, 205, 231, 474, 478
 lipogenesis and, 173
- Octamers, histone, 315, 315f
- Oculocerebrorenal syndrome, 512t
- 1,25(OH)₂D₃. *See* Calcitriol
- 3 β -OHSD. *See* 3 β -Hydroxysteroid dehydrogenase
- Okazaki fragments, 327, 330, 331f
- Oleic acid, 112, 112f, 113, 113t, 114f, 190f
 synthesis of, 191, 191f
- Oligomers, import of by peroxisomes, 503
- Oligomycin, respiratory chain affected by, 95, 96f, 97f
- Oligonucleotide
 definition of, 413
 in primary structure determination, 26
- Oligosaccharide:protein transferase, 523
- Oligosaccharide branches (antennae), 521
- Oligosaccharide chains
 glycoprotein, **514**, 515t, 581–582
 in N-glycosylation, 524, 525f
 regulation of, 526
 sugars in, **515**, 516t
 glycosaminoglycans, 543
- Oligosaccharide processing, 521, 524, 525f
 Golgi apparatus in, 509
 regulation of, 526, 527f
- Oligosaccharides, 102
 O-linked, in mucins, 519–520, 519f, 520f
- OMP (orotidine monophosphate), 296, 298f
- Oncogenes, 1
 cyclins and, 334
- Oncoproteins, Rb protein and, 334
- Oncotic (osmotic) pressure, 580, 584
- Oncoviruses, cyclins and, 334
- Open complex, 345
- Operator locus, 377–378, 377f, 378
- Operon/operator hypothesis, 375, 376–378, 376f, 377f
- Optical activity/isomer, 104
- ORC. *See* Origin replication complex
- ORE. *See* Origin replication element
- Ori (origin of replication), 326, 327f, 413
- Origin replication complex, 326
- Origin replication element, 326
- Origin of replication (ori), 326, 327f, 413
- Ornithine, 265, 266f
 catabolism of, 250, 251f
 in urea synthesis, 245, 246–247, 246f, 247
- Ornithine δ -aminotransferase, mutations in, 250
- Ornithine-citrulline antiporter, defective, 250
- Ornithine transcarbamoylase/1-Ornithine transcarbamoylase
 deficiency of, 247, 300
 in urea synthesis, 246–247, 246f
- Orosomucoid (α_1 -acid glycoprotein), 583t
- Orotate phosphoribosyltransferase, 296, 297, 298f
- Orotic aciduria, 300, 301
- Orotidine monophosphate (OMP), 296, 298f
- Orotidinuria, 301
- Orphan receptors, 436, 471
- Osmotic fragility test, 617
- Osmotic lysis, complement in, 596
- Osmotic (oncotic) pressure, 580, 584
- Osteoarthritis, 535, 551t
 proteoglycans in, 548
- Osteoblasts, 549, 549f, 550
- Osteocalcin, 488, 496, 548t
- Osteoclasts, 549–550, 549f, 550f
- Osteocytes, 549, 549f
- Osteogenesis imperfecta (brittle bones), 551–552, 551t
- Osteoid, 549f, 550
- Osteomalacia, 482t, 484, 485, 551t
- Osteonectin, 548t
- Osteopetrosis (marble bone disease), 552
- Osteoporosis, 485, 551t, 552
- Osteopontin, 548t
- Ouabain, 106
 Na⁺-K⁺ ATPase affected by, 428
- Outer mitochondrial membrane, 92, 93f
 protein insertion in, 501
- Ovary, hormones produced by, 437, 442–445, 444f, 445f
- Overnutrition, **478–479**
- Oxaloacetate
 in amino acid carbon skeleton catabolism, 249, 250f
 in aspartate synthesis, 237–238, 238f
 in citric acid cycle, 126, 127f, 130, 131f, 133, 134f, 135
- Oxalosis, 170
- Oxidases, 86, **86–87**, 87f. *See also specific type*
 ceruloplasmin as, 587
 copper in, 86
 flavoproteins as, 86–87, 88f
 mixed-function, 89–90, 627. *See also* Cytochrome P450 system
- Oxidation, **86–91**
 definition of, 86
 dehydrogenases in, **87–88**, 88f, 89f
 fatty acid, **180–189**. *See also* Ketogenesis
 acetyl-CoA release and, 123–124, 123f, **181–183**, 181f, 182f
 β , **181–183**, 181f, 182f
 ketogenesis regulation and, 186–187, 187f, 188f
 modified, **183**, 183f
 clinical aspects of, **187–189**
 hypoglycemia caused by impairment of, 187–188
 in mitochondria, **180–181**, 181f
 hydroperoxidases in, **88–89**
 oxidases in, **86–87**, 87f, 88f
 oxygen toxicity and, **90–91**, 611–613, 613t
 oxygenases in, **89–90**, 90f
 redox potential and, **86**, 87t
- Oxidation-reduction (redox) potential, **86**, 87t
- Oxidative decarboxylation, of
 α -ketoglutarate, 131, 132f
- Oxidative phase, of pentose phosphate pathway, 163, 164f, 165f
- Oxidative phosphorylation, 83, **92–101**, 122. *See also* Phosphorylation; Respiratory chain
 chemiosmotic theory of, 92, **95–97**, 97f
 clinical aspects of, **100–101**
 muscle generation of ATP by, 573, 574–576, 575f, 575t
 poisons affecting, 92, **95**, 96f
- Oxidative stress, 612
- Oxidoreductases, 49, 86. *See also specific type*
 deficiency of, 100
- Oxidosqualene:lanosterol cyclase, 220, 222f
- Oxygen
 binding, 42, 42f. *See also* Oxygenation
 Bohr effect and, 44, 45f
 histidines F8 and E7 in, 40, 41f
 hemoglobin affinities (P_{50}) for, 42–43, 43f
 myoglobin in storage of, 40, 41–42, 42f, 573

- Oxygen (*cont.*)
 reductive activation of, 627
 transport of, ferrous iron in, **40–41**
- Oxygen dissociation curve, for myoglobin and hemoglobin, **41–42**, 42*f*
- Oxygen radicals. *See* Free radicals
- Oxygen toxicity, superoxide free radical and, 90–91, 611–613, 613*t*. *See also* Free radicals
- Oxygenases, 86, **89–90**
- Oxygenation of hemoglobin
 conformational changes and, 42, 43*f*, 44*f*
 apoprotein, 42
 2,3-bisphosphoglycerate stabilizing, 45, 45*f*
 high altitude adaptation and, 46
 mutant hemoglobins and, 46
- Oxysterols, 119
- P_{10} in muscle contraction, 561, 561*f*
- P_{50} , hemoglobin affinity for oxygen and, 42–43, 43*f*
- p53 protein/p53 gene, 339
- p160 coactivators, 472, 472*t*
- p300 coactivator/CPB/p300, 461, 468, 469, 469*f*, 472, 472*t*
- P450 cytochrome. *See* Cytochrome P450 system
- P450_{sc} (cytochrome P450 side chain cleavage enzyme), 438, 440*f*, 442
- p/CIP coactivator, 472, 472*t*
- P component, in amyloidosis, 590
- P-selectin, 529*t*
- PAC (P1-based) vector, 401–402, 402*t*, 413
- PAF. *See* Platelet-activating factor
- PAGE. *See* Polyacrylamide gel electrophoresis
- Pain, prostaglandins in, 190
- Palindrome, 413
- Palmitate, 173, 173–174
- Palmitic acid, 112*t*
- Palmitoleic acid, 113*t*, 190*f*
- Palmitoylation, in covalent modification, mass increases and, 27*t*
- Pancreatic insufficiency, in vitamin B₁₂ deficiency, 492
- Pancreatic islets, insulin produced by, 160
- Pancreatic lipase, 475, 476*f*
- Panprotease inhibitor, α_1 -macroglobulin as, 590
- Pantothenic acid, 173, 482*t*, **495**, 495*i*
 in citric acid cycle, 133
 coenzymes derived from, 51
 deficiency of, 482*t*
- Papain, immunoglobulin digestion by, 591
- PAPS. *See* Adenosine 3'-phosphate-5'-phosphosulfate
- Parallel β sheet, 32, 33*f*
- Parathyroid hormone (PTH), 438, 450, 451*f*
 storage/secretion of, 453, 454*t*
 synthesis of, 450, 451*f*
- Paroxysmal nocturnal hemoglobinuria, 432*t*, 528, 530*t*, 531, 531*f*
- Partition chromatography, for protein/peptide purification, 21
- Passive diffusion/transport, 423, 423*t*, 424*f*
- Pasteur effect, 157
- pBR322, 402, 402*t*, 403*f*
- PCR. *See* Polymerase chain reaction
- PDH. *See* Pyruvate dehydrogenase
- PDI. *See* Protein disulfide isomerase
- PECAM-1, 529, 529*t*
- Pedigree analysis, 409, 410*f*
- Pellagra, 482*t*, 490
- Penicillamine, for Wilson disease, 589
- Pentasaccharide, in N-linked glycoproteins, 521, 522*f*
- Pentose phosphate pathway, 123, **163–166**, 164*f*, 165*f*, 167*f*
 cytosol as location for reactions of, **163**
 enzymes of, 156*t*
 erythrocyte hemolysis and, 169–170, 613
 impairment of, 169–170
 NADPH produced by, **163**, 164*f*, 165*f*
 for lipogenesis, 175*f*, 176, 176*f*
 nonoxidative phase of, 163–166
 oxidative phase of, 163, 164*f*, 165*f*
 ribose produced by, **163**, 164*f*
- Pentoses, 102, 102*t*
 in glycoproteins, 109*t*
 physiologic importance of, 104–105, 105*t*
- Pentosturia, essential, 163, 170
- PEPCK. *See* Phosphoenolpyruvate carboxykinase
- Pepsin, 477
 in acid-base catalysis, 52
- Pepsinogen, 477
- Peptidases, in protein degradation, **242**, 243*f*
- Peptide bonds. *See also* Peptides
 formation of, 7, 368
 partial double-bond character of, 19–20, 20*f*
- Peptides, **14–20**, 439*f*. *See also* Amino acids; Proteins
 absorption of, 477
 amino acids in, 14, 19, 19*f*
 formation of, L- α -amino acids in, 14
 as hormone precursors, **449–453**
 intracellular messengers used by, **457–468**, 461*t*, 463*t*
 as polyelectrolytes, 19
 purification of, **21–24**
- Peptidyl prolyl isomerase, 508
- Peptidylglycine hydroxylase, vitamin C as coenzyme for, 496
- Peptidyltransferase, 368, 370*t*
- Periodic acid-Schiff reagent, in glycoprotein analysis, 515*t*
- Periodic hyperlysinemia, 258
- Periodic paralysis
 hyperkalemic, 569*t*
 hypokalemic, 569*t*
- Peripheral proteins, 420–421, 421*f*
- Peripherin, 577*t*
- Permeability coefficients, of substances in lipid bilayer, 418, 419*f*
- Pernicious anemia, 482*t*, 492
- Peroxidases, 88, 192
- Peroxidation, lipid, free radicals produced by, **118–119**, 120*f*
- Peroxisins, 503
- Peroxisomal-matrix targeting sequences (PTS), 503, 508*t*
- Peroxisomes, 89, **503**
 absence/abnormalities of, 503, 503*t*
 in Zellweger's syndrome, 188, 503
 biogenesis of, 503
 in fatty acid oxidation, 182–183
- Pfeiffer syndrome, 551*t*
- PFK-1. *See* Phosphofructokinase
- PGHS. *See* Prostaglandin H synthase
- PGIs. *See* Prostaglandins
- PGs. *See* Prostaglandins
- pH, **9–13**. *See also* Acid-base balance
 amino acid net charge and, 16, 17*f*
 buffering and, 11–12, 12*f*. *See also* Buffers
 calculation of, 9–10
 definition of, 9
 enzyme-catalyzed reaction rate affected by, 64, 64*f*
 isoelectric, amino acid net charge and, 17
- Phage lambda, 378–383, 379*f*, 380*f*, 381*f*, 382*f*
- Phages
 for cloning in gene isolation, 635*t*
 in recombinant DNA technology, 401
- Phagocytic cells, respiratory burst of, 622–623
- Phagocytosis, 429
- Pharmacogenetics, 630, **631–632**
- Pharmacogenomics, 632, 638
- Phasing, nucleosome, 315–316
- Phenobarbital, warfarin interaction and, cytochrome P450 induction affecting, 628
- Phenylalanine, 16*t*
 catabolism of, 255–258, 255*f*
 in phenylketonuria, 255, 255*f*
 requirements for, 480
 in tyrosine synthesis, 239, 240*f*
- Phenylalanine hydroxylase
 defect in, 255
 localization of gene for, 407*t*
 in tyrosine synthesis, 239, 240*f*
- Phenylethanolamine-N-methyltransferase (PNMT), 447, 447*f*

- Phenylisothiocyanate (Edman reagent), in protein sequencing, 25, 26f
- Phenylketonuria, 255–258
- Phi (ϕ) angle, 31, 31f
- Phosphagens, 83, 84f
- Phosphatases
- acid, diagnostic significance of, 57t
 - alkaline
 - in bone mineralization, 550
 - isozymes of, diagnostic significance of, 57t
 - in recombinant DNA technology, 400t
- Phosphate transporter, 99, 99f
- Phosphates/phosphorus, 496t
- exchange transporters and, 99, 99f, 100, 101f
 - in extracellular and intracellular fluid, 416t
 - free energy of hydrolysis of, 82–83, 82t
 - high-energy, 83. *See also* ATP
 - in energy capture and transfer, 82–83, 82f, 82t, 83f
 - as “energy currency” of cell, 83–85, 84f, 85f
 - symbol designating, 83
 - transport of, creatine phosphate shuttle in, 100, 101f
 - low-energy, 83
- Phosphatide, 198f, 199
- in triacylglycerol synthesis, 197, 197f, 198, 198f, 199
- Phosphatide phosphohydrolase, 198f, 199
- Phosphatidic acid, 114, 115f, 416–417, 417f
- Phosphatidic acid pathway, 476f, 477
- Phosphatidylcholines (lecithins), 114–115, 115f
- in cytochrome P450 system, 617
 - membrane asymmetry and, 420
 - synthesis of, 197, 197f, 198f
- Phosphatidylethanolamine (cephalin), 115, 115f
- membrane asymmetry and, 420
 - synthesis of, 197, 197f
- Phosphatidylglycerol, 115, 115f
- Phosphatidylinositol/phosphatidylinositide, 115, 115f
- in blood coagulation, 601
 - GPI-linked glycoproteins and, 527. *See also* Glycosylphosphatidylinositol-anchored (GPI-anchored/ GPI-linked) glycoproteins
 - metabolism of, 464–465, 464f, 465f
 - as second messenger/second messenger precursor, 115, 115f, 437, 437t, 457, 463–465, 463t, 464f, 465f
 - synthesis of, 197, 197f, 198f
- Phosphatidylinositol 4,5-bisphosphate, 115, 464–465, 465f
- in neutrophil activation, 621–622
 - in platelet activation, 606–607, 606f
- Phosphatidylinositol 3-kinase (PI-3 kinase) in insulin signal transmission, 465, 466f
- in Jak/STAT pathway, 467
- Phosphatidylserine, 115, 115f
- in blood coagulation, 601
 - membrane asymmetry and, 420
- Phosphocreatine, in muscle, 556
- Phosphodiester, 291
- Phosphodiesterases, 291
- in calcium-dependent signal transduction, 463
 - in cAMP-dependent signal transduction, 461, 462f
 - cAMP hydrolyzed by, 147
- Phosphoenolpyruvate, 156t
- free energy of hydrolysis of, 82t
 - in gluconeogenesis, 133, 134f, 156t
- Phosphoenolpyruvate carboxykinase (PEPCK), 133, 134f
- in gluconeogenesis regulation, 133, 134f, 153, 154f
- Phosphofructokinase/ phosphofructokinase-1, 156t
- in gluconeogenesis regulation, 157
 - in glycolysis, 137, 138f, 156t
 - regulation and, 140
 - muscle, deficiency of, 143, 152t
- Phosphofructokinase-2, 157, 158f
- Phosphoglucosylase, in glycogen biosynthesis, 145, 146f
- 6-Phosphogluconate dehydrogenase, 156t, 163, 164f, 165f
- 3-Phosphoglycerate
- in glycolysis, 137, 138f
 - in serine synthesis, 238, 238f
- Phosphoglycerate kinase, in glycolysis, 137, 138f
- in erythrocytes, 140, 140f
- Phosphoglycerate mutase, in glycolysis, 137, 138f
- Phosphoglycerides, in membranes, 416–417, 417f
- Phosphoglycerols
- lysophospholipids in metabolism of, 116, 116f
 - synthesis of, 197f, 198f, 199
- Phosphohexose isomerase, in glycolysis, 137, 138f
- Phosphoinositide-dependent kinase-1 (PDK1), in insulin signal transmission, 465
- Phospholipase A₁, 200, 201f
- Phospholipase A₂, 200, 201f
- in platelet activation, 606f, 607
- Phospholipase C, 200, 201f
- in calcium-dependent signal transduction, 464–465, 464f, 465f
 - in Jak/STAT pathway, 467
 - in respiratory burst, 623
- Phospholipase CB, in platelet activation, 606, 606f
- Phospholipase D, 200, 201f
- Phospholipases
- in glycoprotein analysis, 515t
 - in phosphoglycerol degradation and remodeling, 200–201, 201f
- Phospholipids, 111, 205
- digestion and absorption of, 475–477, 476f
 - glycerol ether, synthesis of, 199, 200f
 - in lipoprotein lipase activity, 207–208
 - in membranes, 114–116, 115f, 416–417, 417f, 419, 511
 - membrane asymmetry and, 420, 511
 - in multiple sclerosis, 202
 - as second messenger precursors, 197
 - synthesis of, 198f
- Phosphoprotein phosphatases, in cAMP-dependent signal transduction, 462, 462f
- Phosphoproteins, in cAMP-dependent signal transduction, 461, 462f
- Phosphoric acid, pK_a/pK_b value of, 12t
- Phosphorus. *See* Phosphates
- Phosphorylase
- in glycogen metabolism, 145–146, 146f
 - regulation of, 148–150, 150–151, 150f, 151f
- liver, 147
- deficiency of, 152t
- muscle, 147
- absence of, 152t
 - activation of
 - calcium/muscle contraction and, 148
 - cAMP and, 147–148, 149f
- Phosphorylase a, 147, 149f
- Phosphorylase b, 147, 149f
- Phosphorylase kinase
- calcium/calmodulin-sensitive, in glycogenolysis, 148
 - deficiency of, 152t
 - protein phosphatase-1 affecting, 147
- Phosphorylase kinase a, 148, 149f
- Phosphorylase kinase b, 148, 149f
- Phosphorylation
- in covalent modification, 76, 77–79, 78f, 78t
 - mass increases and, 27t
 - multisite, in glycogen metabolism, 151
 - oxidative. *See* Oxidative phosphorylation in respiratory burst, 623
- Photolysis reaction, in vitamin D synthesis, 445
- Photosensitivity, in porphyria, 274
- Phototherapy, cancer, porphyrins in, 273
- Phylloquinone, 482t, 486, 488f. *See also* Vitamin K
- Physical map, 633, 634f

- Physiologic (neonatal) jaundice, 282–283
 Phytanic acid, Refsum's disease caused by accumulation of, 188
 Phytase, 477
 Phytic acid (inositol hexaphosphate), calcium absorption affected by, 477
 Pi, 589. *See also* α_1 -Antitrypsinase
 pI (isoelectric pH), amino acid net charge and, 17
 PI-3 kinase
 in insulin signal transmission, 465, 466f
 in Jak/STAT pathway, 467
 PIC. *See* Preinitiation complex
 PIG-A gene, mutations of in paroxysmal nocturnal hemoglobinuria, 531, 531f
 "Ping-Pong" mechanism, in facilitated diffusion, 427, 427f
 Ping-pong reactions, 69–70, 69f
 Pinocytosis, 429–430
 PIP₂, in absorptive pinocytosis, 430
 Pituitary hormones, 437. *See also specific type*
 blood glucose affected by, 161
 pK/pK_a
 of amino acids, 15–16t, 17, 17f, 18
 environment affecting, 18, 18t
 medium affecting, 13
 of weak acids, 10–11, 11–12, 12t, 13, 17
 PKA. *See* Protein kinase A
 PKB. *See* Protein kinase B
 PKC. *See* Protein kinase C
 PKU. *See* Phenylketonuria
 Placenta, estriol synthesis by, 442
 Plaque hybridization, 403. *See also* Hybridization
 Plasma, 580
 Plasma cells, immunoglobulins synthesized in, 591
 Plasma enzymes. *See also* Enzymes
 diagnostic significance of, 57, 57t
 Plasma lipoproteins. *See* Lipoproteins
 Plasma membrane, 415, 426–431, 426f
 See also Membranes
 carbohydrates in, 110
 mutations in, diseases caused by, 431, 432t
 Plasma proteins, 514, 580–591, 581f, 583t
 See also specific type and
 Glycoproteins
 in bone, 548t
 concentration of, 580
 electrophoresis for analysis of, 580, 582f
 functions of, 583, 583t
 half life of, 582
 in inflammation, 621t
 polymorphism of, 582
 synthesis of
 in liver, 125, 581
 on polyribosomes, 581
 transport, 454–455, 454t, 455t, 583t
 Plasma thromboplastin antecedent (PTA/factor XI), 599f, 600, 600t
 deficiency of, 601
 Plasma thromboplastin component (PTC/factor IX), 599f, 600, 600t
 coumarin drugs affecting, 604
 deficiency of, 604
 Plasmalogen, 116, 117f, 199, 200f
 Plasmids, 400–401, 401f, 402, 402t, 403f, 413
 for cloning in gene isolation, 635t
 Plasmin, 604–605, 604f
 Plasminogen, 604
 activators of, 604–605, 604f, 605, 605f, 607t
 Platelet-activating factor, 197, 621t
 synthesis of, 198f, 199, 200f
 Platelets, activation/aggregation of, 598, 605–607, 606f
 aspirin affecting, 607–608
 Pleckstrin, in platelet activation, 607
 PLP. *See* Pyridoxal phosphate
 PNMT. *See* Phenylethanolamine-N-methyltransferase
 pOH, in pH calculation, 9
 Point mutations, 361
 recombinant DNA technology in
 detection of, 408–409, 408f, 409t
 Poisons, oxidative phosphorylation/respiratory chain affected by, 92, 95, 96f
 Pol II
 phosphorylation of, 350–351
 in preinitiation complex formation, 351–352
 in transcription, 350–351
 Polarity
 of DNA replication/synthesis, 330–331
 of protein synthesis, 364
 of xenobiotics, metabolism and, 626
 Poly(A) tail, of mRNA, 309, 355–356
 in initiation of protein synthesis, 365
 Polyacrylamide gel electrophoresis, for protein/peptide purification, 24, 24f, 25f
 Polyadenylation sites, alternative, 394
 Polyamines, synthesis of, 265–266, 266f
 Polycistronic mRNA, 376
 Polycythemia, 46
 Polydystrophy, pseudo-Hurler, 532, 546t
 Polyelectrolytes, peptides as, 19
 Polyfunctional acids, nucleotides as, 290
 Polyisoprenoids, in cholesterol synthesis, 220, 221f
 Polyisoprenol, in N-glycosylation, 521–522
 Polymerase chain reaction (PCR), 57, 405–406, 406f, 413, 414
 in gene isolation, 635t
 in microsatellite repeat sequence detection, 322
 in primary structure determination, 26
 Polymerases
 DNA, 326, 327–328, 327f, 328, 328t
 in recombinant DNA technology, 400t
 RNA, DNA-dependent, in RNA synthesis, 342–343, 342f, 343t
 Polymorphisms, 407
 acetyltransferase, 630
 cytochrome P450, 628, 630t
 microsatellite, 322, 411, 413
 plasma protein, 582
 restriction fragment length. *See* Restriction fragment length polymorphisms
 single nucleotide, 414
 Polynucleotide kinase, in recombinant DNA technology, 400t
 Polynucleotides, 291–292
 posttranslational modification of, 289
 Polyol (sorbitol) pathway, 172
 Polypeptides
 receptors for, 436
 sequencing of
 cleavage in, 25, 26t
 Sanger's determination of, 24–25
 Polyphosphoinositide pathway, platelet activation and, 605–607
 Polyprenoids, 118, 119f
 Polyribosomes (polysomes), 310, 370
 protein synthesis on, 498, 499f, 500f, 506
 plasma proteins, 581
 signal hypothesis of binding of, 503–505, 504t, 505f
 Polysaccharides, 102, 107–110, 108f, 109f
 See also specific type
 Polysomes. *See* Polyribosomes
 Polyene chromosomes, 318, 318f
 Polyunsaturated fatty acids, 112, 113t. *See also* Fatty acids; Unsaturated fatty acids
 dietary, cholesterol levels affected by, 227
 eicosanoids formed from, 190, 192, 193f, 194f
 essential, 190, 190f
 synthesis of, 191, 191f, 192f
 POMC. *See* Pro-opiomelanocortin (POMC) peptide family
 Pompe's disease, 152t
 Porcine stress syndrome, 565
 Porphobilinogen, 270, 273f, 275f
 Porphyrins, 274–278, 277f, 277t
 Porphyrinogens, 272
 accumulation of in porphyria, 274–278
 Porphyrins, 270–278, 271f, 272f
 absorption spectra of, 273–274, 277f
 heme synthesis and, 270–273, 273f, 274f, 275f, 276f
 reduced, 272
 spectrophotometry in detection of, 273–274
 Positive nitrogen balance, 479

- Positive regulators, of gene expression, 374, 375*t*, 378, 380
- Posttranslational processing, 30, 37–39, 38*f*, 371
- of collagen, 537–538, 537*t*
- in membrane assembly, 511–512
- Posttranslational translocation, 499
- Potassium, 496*t*
- in extracellular and intracellular fluid, 416, 416*t*
- permeability coefficient of, 419*f*
- Power stroke, 561
- PPL. *See* Peptidyl prolyl isomerase
- PP_i. *See* Pyrophosphate, inorganic
- PR. *See* Progesterone, receptors for
- Pravastatin, 229
- PRE. *See* Progesterin response element
- Pre- β -lipoproteins, 205, 206*t*, 210
- Precursor proteins, amyloid, 590
- Pregnancy
- estriol synthesis in, 442
- fatty liver of, 188
- hypoglycemia during, 161
- iron needs during, 586
- Pregnancy toxemia of ewes (twin lamb disease)
- fatty liver and, 212
- ketosis in, 188
- Pregnenolone, 440*f*
- in adrenal steroidogenesis, 438–440, 440*f*, 441*f*
- in testicular steroidogenesis, 442, 443*f*
- Preinitiation complex, 343, 351–352
- assembly of, 351–352
- in protein synthesis, 365, 366*f*
- Prekallikrein, 599*f*, 600
- Premenstrual syndrome, vitamin B₆ in
- management of, sensory neuropathy and, 491
- Prenatal diagnosis, recombinant DNA technology in, 409
- Preprocollagen, 537
- Preprohormone, insulin synthesized as, 449, 450*f*
- Preproparathyroid hormone (preproPTH), 450, 451*f*
- Preproprotein, albumin synthesized as, 583
- Preproteins, 498, 581
- Presequence. *See* Signal peptide
- Preventive medicine, biochemical research affecting, 2
- Primaquine-sensitive hemolytic anemia, 613
- Primary structure, 21–29, 31. *See also* Protein sequencing
- amino acid sequence determining, 18–19
- Edman reaction in determination of, 25, 26*f*
- genomics in analysis of, 28
- molecular biology in determination of, 25–26
- of polynucleotides, 291–292
- protomics and, 28–29
- Sanger's technique in determination of, 24–25
- Primary transcript, 342
- Primases, DNA, 327, 327*f*, 328*t*
- Primosome, 328, 414
- Prion diseases (transmissible spongiform encephalopathies), 37
- Prion-related protein (PrP), 37
- Prions, 37
- Proaccelerin (factor V), 600*t*, 601, 602*f*
- Proaminopeptidase, 477
- Probes, 402, 414. *See also* DNA probes for gene isolation, 635*t*
- Probucol, 229
- Procarcinogens, 626
- Processivity, DNA polymerase, 328
- Prochymotrypsin, activation of, 77, 77*f*
- Procollagen, 371, 496, 537
- Procollagen aminoproteinase, 537
- Procollagen carboxypeptidase, 537
- Procollagen N-proteinase, disease caused by deficiency of, 538*t*
- Proconvertin (factor VII), 599*f*, 600*t*, 601
- coumarin drugs affecting, 604
- Prodrugs, 626
- Proelastase, 477
- Proenzymes, 76
- rapid response to physiologic demand and, 76
- Profiling, protein-transcript, 412
- Progesterone, 439*f*, 440*f*
- binding of, 455, 455*t*
- receptors for, 471
- synthesis of, 438, 442, 445*f*
- Progesterone (Δ^4) pathway, 442, 443*f*
- Progesterin response element, 459*t*
- Progestins, binding of, 455
- Prohormones, 371
- Proinsulin, 449, 450*f*
- Prokaryotic gene expression. *See also* Gene expression
- eukaryotic gene expression compared with, 391–395, 392*t*
- as model for study, 375
- unique features of, 375–376
- Prolactin, 437
- localization of gene for, 407*t*
- receptor for, 436
- Proline, 16*t*
- accumulation of (hyperprolinemia), 249–250
- catabolism of, 249–250, 251*f*
- synthesis of, 238, 239*f*
- Proline dehydrogenase, block of proline catabolism at, 249–250
- Proline hydroxylase, vitamin C as coenzyme for, 496
- Proline-*cis,trans*-isomerase, protein folding and, 37, 37*f*
- Prolyl hydroxylase reaction, 240, 240*f*, 535
- Promoter recognition specificity, 343
- Promoters, in transcription, 342, 342*f*
- alternative use of in regulation, 354–355, 355*f*, 393–394
- bacterial, 345–346, 345*f*
- eukaryotic, 346–349, 347*f*, 348*f*, 349*f*, 384
- Promotor site, in operon model, 377*f*, 378
- Proofreading, DNA polymerase, 328
- Pro-opiomelanocortin (POMC) peptide family, 452–453, 453*f*. *See also* specific type
- Pro-oxidants, 612. *See also* Free radicals
- Parathyroid hormone (proPTH), 450, 450*f*
- Propionate
- blood glucose and, 159
- in gluconeogenesis, 154*f*, 155
- metabolism of, 155, 155*f*
- Propionic acid, 112*t*
- Propionyl-CoA
- fatty acid oxidation yielding, 182
- methionine in formation of, 259, 259*f*
- Propionyl-CoA carboxylase, 155, 155*f*
- Proteins, 37–38, 76, 371
- Propyl gallate, as antioxidant/food preservative, 119
- Prostacyclins, 112
- clinical significance of, 196
- clotting/thrombosis affected by, 607, 607*t*
- Prostaglandin E₂, 112, 113*f*
- Prostaglandin H synthase, 192
- Prostaglandins, 112, 113*f*, 190, 192
- cyclooxygenase pathway in synthesis of, 192, 192–194, 193*f*, 194*f*
- Prostanoids, 112, 119
- clinical significance of, 196
- cyclooxygenase pathway in synthesis of, 192, 192–194, 193*f*, 194*f*
- Prosthetic groups, 50
- in catalysis, 50–51, 51*f*
- Protamine, 603
- Proteases/proteinases, 8, 477, 624*t*. *See also* specific type
- α_2 -macroglobulin binding of, 590
- in cartilage, 553
- as catalytically inactive proenzymes, 76–77
- mucin resistance to, 520
- of neutrophils, 623–624, 624*t*
- in protein degradation, 242, 243*f*, 477
- Staphylococcus aureus* V8, for polypeptide cleavage, 25, 26*t*
- Protein 4.1, in red cell membranes, 615*f*, 616*f*, 617
- Protein C, in blood coagulation, 600*t*, 603
- Protein disulfide isomerase, protein folding and, 37, 508
- Protein-DNA interactions, bacteriophage lambda as paradigm for, 378–383, 379*f*, 380*f*, 381*f*, 382*f*

- Protein folding, **36–37**, 37f
 chaperones and, **499**, **507–508**, 508t
 after denaturation, 36
- Protein kinase A (PKA), 460, 462f
- Protein kinase B (PKB), in insulin signal transmission, 465, 466f
- Protein kinase C (PKC)
 in calcium-dependent signal transduction, 464, 464f
 in platelet activation, 606f, 607
- Protein kinase D1, in insulin signal transmission, 466f, 467
- Protein kinase-phosphatase cascade, as second messenger, 437, 437t
- Protein kinases, 77
 in cAMP-dependent signal transduction, 460–461, 462f
 in cGMP-dependent signal transduction, 463
 deficiency of, 151–152
 DNA-dependent, in double-strand break repair, 338
 in glycogen metabolism, 147–148, 149f, 151, 151f
 in hormonal regulation, 436, 465–468
 of lipolysis, 215, 216f
 in initiation of protein synthesis, 365
 in insulin signal transmission, 465–467, 466f
 in Jak/STAT pathway, 467, 467f
 in NF- κ B pathway, 468, 468f
 in protein phosphorylation, 77, 78f
- Protein-lipid respiratory chain complexes, 93
- Protein-losing gastroenteropathy, 582
- Protein phosphatase-1, 147, 148, 149f, 151, 151f
- Protein phosphatases, 77. *See also* Phosphatases
- Protein profiling, 412
- Protein-RNA complexes, in initiation, 365–367, 366f
- Protein S, in blood coagulation, 600t, 603
- Protein sequencing
 Edman reaction in, **25**, 26f
 genomics and, **28**
 mass spectrometry in, **27**, 27f, 27t
 molecular biology in, **25–26**
 peptide purification for, **21–24**
 polypeptide cleavage and, **25**, 26t
 proteomics and, **28–29**
 purification for, **21–24**, 22f, 23f, 24f, 25f
 Sanger's method of, **24–25**
- Protein sorting, **498–513**
 chaperones and, **507–508**, 508t
 cotranslational insertion and, 505–506, 506f
 disorders due to mutations in genes encoding, 512t, 513
 Golgi apparatus in, 498, 500f, 507, 509
 importins and exportins in, **501–503**, 502f
 KDEL amino acid sequence and, 506–507, 508t
 membrane assembly and, **511–513**, 512f, 512t
 mitochondria in, **499–501**, 501f
 peroxisomes/peroxisome disorders and, **503**, 503t
 protein destination and, **507**, 507f, 508t
 retrograde transport and, 507
 signal hypothesis of polyribosome binding and, **503–505**, 504t, 505f
 signal sequences and, 492f, **498–499**, 499f
 transport vesicles and, **508–511**, 509t, 510f
- Protein turnover, 74, **242**
 membranes affecting, 511
 rate of enzyme degradation and, 74
- Proteinases. *See* Proteases/proteinases
- Proteins. *See also specific type and* Peptides
 β -turns in, 32, 34f
 acute phase, 583, 583t
 negative, vitamin A as, 483–484
 L- α -amino acids in, 14
 asymmetry of, membrane assembly and, 511, 512f
 binding, 454–455, 454t, 455t
 catabolism of, **242–248**
 classification of, **30**
 configuration of, **30**
 conformation of, **30**
 peptide bonds affecting, 20
 core, 542, 543f
 in glycosaminoglycan synthesis, 542–543
 degradation of, to amino acids, **242**, 243f
 denaturation of
 protein refolding and, 36
 temperature and, 63
 dietary
 digestion and absorption of, 477
 metabolism of, in fed state, 232
 requirements for, **479–480**
 dimeric, 34
 domains of, 33–34
 encoding of by human genome, 636, 637t
 in extracellular and intracellular fluid, 416, 416t
 fibrous, 30
 collagen as, 38
 function of, bioinformatics in
 identification of, 28–29
 fusion, in enzyme study, 58, 59f
 globular, 30
 Golgi apparatus in glycosylation and sorting of, 509
 import of, by mitochondria, **499–501**, 501t
 loss of in trauma/infection, 480
 in membranes, 419, 420t, 514. *See also* Glycoproteins; Membrane proteins
 ratio of to lipids, 416, 416f
 modular principles in construction of, **30**
 monomeric, 34
 phosphorylation of, 76, **77–79**, 78f, 78t.
See also Phosphorylation
 posttranslational modification of, 30, **37–39**, 38f, 371
 purification of, **21–24**
 receptors as, 431, 436
 soluble, 30
 structure of, **31–36**
 diseases associated with disorders of, **37**
 folding and, **36–37**, 37f
 higher orders of, **30–39**
 molecular modeling and, 36
 nuclear magnetic resonance spectroscopy in analysis of, 35–36
 primary, **21–29**, 31. *See also* Primary structure
 prion diseases associated with
 alteration of, 37
 quaternary, 33–35, 35f
 secondary, 31, **31–33**, 31f, 32f, 33f, 34f
 supersecondary motifs and, 33
 tertiary, 33–35, 35f
 x-ray crystallography in analysis of, **35**
 synthesis of, **358–373**. *See also* Protein sorting
 amino acids in, 124, 124f
 elongation in, **367–370**, 368f
 environmental threats affecting, 370
 in fed state, 232
 genetic code/RNA and, 307–308, 309t, **358–363**. *See also* Genetic code
 inhibition of by antibiotics, **371–372**, 372f
 initiation of, **365–367**, 366f, 367f
 by mitochondria, **499–501**, 501t
 modular principles in, **30**
 polysomes in, 370, 498, 499f
 posttranslational processing and, **371**
 in ribosomes, 126, 127f
 recognition and attachment (charging) in, 360, 360f
 recombinant DNA techniques for, 407
 reticulocytes in, 611
 termination of, 369f, **370**
 translocation and, 368
 viruses affecting, 370–371, 371f
 transmembrane
 ion channels as, 423–424, 425f, 426t
 in red cells, 615–616, 615f, 616f, 616t

- transport, 454–455, 454*t*, 455*t*
 xenobiotic cell injury and, 631
 Proteoglycans, 109, 535, 538, **542–549**,
 542*f*. See also
 Glycosaminoglycans
 in bone, 548*t*
 carbohydrates in, 542, 542*f*, 543*f*
 in cartilage, 551, 553
 disease associations and, 548–549
 functions of, 547–549, 548*t*
 galactose in synthesis of, **167–169**, 170*f*
 link trisaccharide in, 518
 Protocollin
 in covalent modification, 76, **76–77**, 77*f*
 in prothymotrypsin activation, 77, 77*f*
 Proton/protocollin, **28–29**, 414,
 636–637, 637–638
 Prothrombin (factor II), 600*t*, 601, 602*f*
 activation of, 601
 coumarin drugs affecting, 487, 604
 in vitamin K deficiency, 487
 Prothrombinase complex, 601
 Proton acceptors, bases as, 9
 Proton donors, acids as, 9
 Proton pump, respiratory chain complexes
 as, 96, 96*f*, 97*f*
 Proton-translocating transhydrogenase, as
 source of intramitochondrial
 NADPH, 99
 Protons, transport of, by hemoglobin, 44,
 45*f*
 Protoporphyrin, 270, 272*f*
 incorporation of iron into, 271–272, 272*f*
 Protoporphyrin III, 271, 276*f*
 Protoporphyrinogen III, 271, 276*f*
 Protoporphyrinogen oxidase, 271, 275*f*, 276*f*
 Provitamin A carotenoids, 482–483
 Proximal histidine (histidine F8)
 in oxygen binding, 40, 41*f*
 replacement of in hemoglobin M, 46
 Proximity, catalysis by, 51
 PrP (prion-related protein), 37
 PRPP
 in purine synthesis, 294, 295*f*
 in pyrimidine synthesis, 296, 298*f*, 299
 PRPP glutamyl amidotransferase, 294, 295*f*
 PRPP synthetase, defect in, gout caused by,
 299
 Pseudo-Hurler polydystrophy, 532, 546*t*,
 547
 Pseudogenes, 325, 414
 Psi (ψ) angle, 31, 31*f*
 PstI, 399*t*
 PstI site, insertion of DNA at, 402, 403*f*
 PTA. See Plasma thromboplastin antecedent
 PTC. See Plasma thromboplastin
 component
 Pteroylglutamic acid. See Folic acid
 PTH. See Parathyroid hormone
 PTSs. See Peroxisomal-matrix targeting
 sequences
 "Puffs," polytene chromosome, 318, 318*f*
 Pulsed-field gel electrophoresis, for gene
 isolation, 635*t*
 Pumps, 415
 in active transport, 427–428, 428*f*
 Purification, protein/peptide, **21–24**
 Purine nucleoside phosphorylase deficiency,
 300
 Purines/purine nucleotides, **286–290**, 286*f*,
 289*f*
 dietarily nonessential, **293**
 metabolism of, **293–302**
 disorders of, **300**
 gout as, **299**
 uric acid formation and, **299**, 299*f*
 synthesis of, **293–294**, 294*f*, 295*f*, 296*f*,
 297*f*
 catalysts in, 293, 294*f*
 pyrimidine synthesis coordinated with,
 299
 "salvage" reactions in, **294**, 295*f*, 297*f*
 ultraviolet light absorbed by, 290
 Puromycin, 372, 372*f*
 Putrescine, in polyamine synthesis, 266*f*
 Pyranose ring structures, 103*f*, 104
 Pyridoxal phosphate, 50, 491, 491*f*
 in heme synthesis, 270
 in urea biosynthesis, 243
 Pyridoxine/pyridoxal/pyridoxamine
 (vitamin B₆), 482*t*, **491**, 491*f*
 deficiency of, 482*t*, 491
 xanthurenate excretion in, 258, 258*f*
 excess/toxicity of, 491
 Pyrimethamine, 494
 Pyrimidine analogs, in pyrimidine
 nucleotide biosynthesis, 297
 Pyrimidines/pyrimidine nucleotides,
 286–290, 286*f*, 289*f*
 dietarily nonessential, **293**
 metabolism of, 293–302, 301*f*
 diseases caused by catabolite
 overproduction and, **300–301**
 water-soluble metabolites and, **300**,
 301*f*
 precursors of, deficiency of, 300–301
 synthesis of, **296–299**, 298*f*
 catalysts in, 296
 purine synthesis coordinated with, 299
 regulation of, **297–299**, 298*f*
 ultraviolet light absorbed by, 290
 Pyrophosphatase, inorganic
 in fatty acid activation, 85, 180
 in glycogen biosynthesis, 145, 146*f*
 Pyrophosphate
 free energy of hydrolysis of, 82*t*
 inorganic, 85, 85*f*
 Pyrrole, 40, 41*f*
 Pyruvate, 123
 formation of, in amino acid carbon
 skeleton catabolism, **250–255**,
 252*f*, 253*f*
 oxidation of, 134, 135*f*, **140–142**, 141*f*,
 142*f*, 143*t*. See also Acetyl-CoA;
 Glycolysis
 clinical aspects of, 142–143
 enzymes in, 156*t*
 gluconeogenesis and, 153, 154*f*
 Pyruvate carboxylase, 133, 134*f*, 156*t*
 in gluconeogenesis regulation, 133, 134*f*,
 153, 156*t*
 Pyruvate dehydrogenase, 134, 135*f*, 140,
 141*f*, 156*t*
 deficiency of, 143
 regulation of, 141–142, 142*f*
 acyl-CoA in, 141–142, 142*f*, 178
 thiamin diphosphate as coenzyme for,
 488
 Pyruvate dehydrogenase complex, 140
 Pyruvate kinase, 156*t*
 deficiency of, 143, 619
 gluconeogenesis regulation and, 157
 in glycolysis, 137–139, 138*f*, 156*t*
 regulation and, 140
 Q (coenzyme Q/ubiquinone), 92, 95*f*
 Q₁₀ (temperature coefficient), enzyme-
 catalyzed reactions and, 63
 QT interval, congenitally long, 432*t*
 Quaternary structure, 33–35, 35*f*
 of hemoglobins, allosteric properties and,
 42–46
 stabilizing factors and, 35
 R groups, amino acid properties affected by,
 18, 18*t*
 pK_a/pK_b, 18
 R (relaxed) state, of hemoglobin,
 oxygenation and, 43, 43*f*, 44*f*
 Rab protein family, 511
 RAC3 coactivator, 472, 472*t*
 Radiation, nucleotide excision-repair of
 DNA damage caused by, 337
 Radiation hybrid mapping, 635*t*
 Ran protein, 501, 502*f*, 503
 Rancidity, peroxidation causing, 118
 Rapamycin, mammalian target of (mTOR),
 in insulin signal transmission,
 466*f*, 467
 RAR. See Retinoic acid receptor
 RARE. See Retinoic acid response element
 Rate constant, 62
 K_{eq} as ratio of, 62–63
 Rate of degradation (k_{deg}), control of, 74
 Rate-limiting reaction, metabolism regulated
 by, 73
 Rate of synthesis (k_s), control of, 74
 Rb protein. See Retinoblastoma protein
 Reactant concentration, chemical reaction
 rate affected by, 62
 Reactive oxygen species. See Free radicals

- Rearrangements, DNA
in antibody diversity, 325–326, 393, 593–594
recombinant DNA technology in
detection of, 409, 409*t*
- recA, 381, 382*f*
- Receptor-associated coactivator 3 (RAC3
coactivator), 472, 472*t*
- Receptor-effector coupling, 435–436
- Receptor-mediated endocytosis, 429*f*,
430
- Receptors, 431, 436. *See also specific type*
activation of in signal generation,
456–457, 458*f*
nuclear, 436, 469, 469–471, 471*f*, 472*t*
- Recognition domains, on hormone
receptors, 435
- Recombinant DNA/recombinant DNA
technology, 396–414, 635*t*
base pairing and, 396–397
blotting techniques in, 403, 404*f*
chimeric molecules in, 397–406
cloning in, 400–402, 401*f*, 402*t*, 403*f*
definition of, 414
DNA ligase in, 399–400
DNA sequencing in, 404, 405*f*
double helix structure and, 396, 397
in enzyme study, 58, 59*f*
gene mapping and, 406–407, 407*t*
in genetic disease diagnosis, 407–412,
408*f*, 409*t*, 410*f*, 411*f*
hybridization techniques in, 403–404
libraries and, 402
oligonucleotide synthesis in, 404–405
organization of DNA into genes and,
397, 398*f*, 399*t*
polymerase chain reaction in, 405–406,
406*f*
practical applications of, 406–412
restriction enzymes and, 397–400, 399*t*,
400*f*, 400*t*, 401*f*
terminology used in, 413–414
transcription and, 397, 398*f*
- Recombinant erythropoietin (epoetin
alfa/EPO), 526, 610
- Recombinant fusion proteins, in enzyme
study, 58, 59*f*
- Recombination, chromosomal, 323–324,
323*f*, 324*f*
- Recruitment hypothesis, of preinitiation
complex formation, 352
- Red blood cells, 609–610, 610–619. *See also* Erythrocytes
recombinant DNA technology in study
of, 624
- Red thrombus, 598
- Red (slow) twitch fibers, 574–576, 575*t*
- Redox (oxidation-reduction) potential, 86,
87*t*
of respiratory chain components, 92–93,
94*f*, 95*f*
- Redox state, 184
- Reduced porphyrins, 272
- Reducing equivalents
in citric acid cycle, 130–133, 132*f*
in pentose phosphate pathway, 166
respiratory chain in collection and oxida-
tion of, 92–93, 93*f*, 94*f*, 95*f*
- 5 α -Reductase, 442, 444*f*
- Reduction, definition of, 86
- Reductive activation, of molecular oxygen,
627
- Refsum's disease, 188, 503, 503*t*
- Regional asymmetries, membrane, 420
- Regulated secretion, 498
- Regulatory proteins, binding of to DNA,
motifs for, 387–390, 388*t*, 389*f*,
390*f*, 391*f*
- Regurgitation hyperbilirubinemia, 282
- Relaxation phase
of skeletal muscle contraction, 561, 564
of smooth muscle contraction
calcium in, 571
nitric oxide in, 571–573, 573*f*
- Relaxed (R) state, of hemoglobin,
oxygenation and, 43, 43*f*, 44*f*
- Releasing factors (RF1/RF3), in protein
synthesis termination, 369*f*, 370
- Remnant removal disease, 228*t*
- Renal glomerulus, laminin in basal lamina
of, 540–542
- Renal threshold for glucose, 161
- Renaturation, DNA, base pair matching
and, 305–306
- Renin, 451, 452*f*
- Renin-angiotensin system, 451–452, 452*f*
- Repeat sequences, 637
amino acid, 519, 520*f*
short interspersed (SINEs), 321–322,
414
- Repetitive-sequence DNA, 320, 321–322
- Replication/synthesis. *See* DNA,
replication/synthesis of;
RNA, synthesis of
- Replication bubbles, 331–333, 331*f*, 332*f*,
333*f*
- Replication fork, 327–328, 327*f*
- Reporter genes, 385–386, 387*f*, 388*f*
- Repression, enzyme
enzyme synthesis control and, 74
in gluconeogenesis regulation, 155–157
Repressor protein/gene, lambda (cl),
379–383, 380*f*, 381*f*, 382*f*
- Repressors, 348
in gene expression, 374, 377, 378, 385
tissue-specific expression and, 385
- Reproduction, prostaglandins in, 190
- Respiration, 86
- Respiratory burst, 479, 622–623
- Respiratory chain, 92–101. *See also*
Oxidative phosphorylation
clinical aspects of, 100–101
- collection and oxidation of reducing
equivalents and, 92–93, 93*f*, 94*f*,
95*f*
dehydrogenases in, 87
energy for metabolism provided by,
93–95, 98*f*
oxidative phosphorylation at level of, 94
poisons affecting, 92, 95, 96*f*
as proton pump, 96, 96*f*, 97*f*
redox potential of components of,
92–93, 94*f*, 95*f*
substrates for, citric acid cycle providing,
131, 131*f*
- Respiratory control, 81, 94–95, 97, 97*t*,
98*f*, 134–135
- Respiratory distress syndrome, surfactant
deficiency causing, 115, 202
- Restriction endonucleases/enzymes, 312,
397–399, 399*t*, 400*f*, 414
in recombinant DNA technology,
399–400, 399*t*, 400*f*, 400*t*, 401*f*
- Restriction enzymes. *See* Restriction
endonucleases
- Restriction fragment length polymorphisms
(RFLPs), 57, 409–411, 411*f*
in forensic medicine, 411
- Restriction map, 399
- Retention hyperbilirubinemia, 282
- Reticulocytes, in protein synthesis, 611
- Retina
gyrate atrophy of, 250
retinaldehyde in, 483, 484*f*
- Retinal. *See also* Retinol
- Retinaldehyde, 482, 483*f*
- Retinitis pigmentosa, essential fatty acid
deficiency and, 192
- Retinoblastoma protein, 333
- Retinoic acid, 482, 483*f*. *See also* Retinol
functions of, 483
receptors for, 471, 483
- Retinoic acid receptor (RAR), 471, 483
- Retinoic acid response element, 459*t*
- Retinoid X receptor (RXR), 470, 470*f*, 471,
483
- Retinoids, 482–484, 483*f*, 484*f*. *See also*
Retinol
- Retinol, 482, 482*t*, 483*f*, 484*f*. *See also*
Vitamin A
deficiency of, 482*t*
functions of, 482*t*, 483, 484*f*
Retinol-binding protein, 583*t*
- Retrograde transport, 505, 510
from Golgi apparatus, 507
- Retroposons/retrotransposons, 321, 637
- Retroviruses, reverse transcriptases in, 308,
332–333
- Reverse cholesterol transport, 210, 211*f*,
219, 224
- Reverse transcriptase/reverse transcription,
308, 333, 414
in recombinant DNA technology, 400*t*

- Reversed-phase high-pressure chromatography, for protein/peptide purification, 23–24
- Reversible covalent modifications, 77–79, 78f, 78t. *See also* Phosphorylation
- Reye's syndrome, orotic aciduria in, 300
- RFLPs. *See* Restriction fragment length polymorphisms
- RFs. *See* Releasing factors
- Rheumatoid arthritis, glycosylation alterations in, 533
- Rho-dependent termination signals, 344, 346, 346f
- Rhodopsin, 483, 484f
- Riboflavin (vitamin B₂), 86, 482t, 489–490 in citric acid cycle, 133 coenzymes derived from, 50–51, 489, 490 deficiency of, 482t, 490 dehydrogenases dependent on, 87
- Ribonucleases, 312
- Ribonucleic acid. *See* RNA
- Ribonucleoside diphosphates (NDPs), reduction of, 294, 297f
- Ribonucleosides, 286, 287f
- Ribonucleotide reductase complex, 294, 297f
- Ribose, 102 in nucleosides, 286, 287f pentose phosphate pathway in production of, 123, 163, 166
- D-Ribose, 104f, 105t, 286
- Ribose phosphate, pentose phosphate pathway in production of, 163, 164f
- Ribose 5-phosphate, in purine synthesis, 293–294, 295f
- Ribose 5-phosphate ketoisomerase, 163, 165f
- Ribosomal dissociation, in protein synthesis, 365, 366f
- Ribosomal RNA (rRNA), 307–308, 310–311, 341, 342t. *See also* RNA as peptidyltransferase, 368, 370t processing of, 355
- Ribosomes, 310, 312t bacterial, 371–372 protein synthesis in, 126, 127f dissociation and, 370
- Ribozymes, 308, 311, 356
- D-Ribulose, 105t, 106f
- Ribulose 5-phosphate 3-epimerase, 163, 165f
- Richner-Hanart syndrome, 255
- Ricin, 372, 518t
- Rickets, 482t, 484, 551t
- Right operator, 379–383, 380f, 382f
- Rigor mortis, 562, 564
- RNA, 303, 306–312, 341–357 as catalyst, 356 in chromatin, 314 classes/species of, 307–308, 309t, 341, 342t complementarity of, 306, 309f heterogeneous nuclear (hnRNA), 310 gene regulation and, 354 messenger (mRNA), 307, 309–310, 310f, 311f, 341, 342t, 359 alternative splicing and, 354, 354f, 393–394, 636 codon assignments in, 358, 359t editing of, 356 expression of, detection of in gene isolation, 635t modification of, 355–356 nucleotide sequence of, 358 mutations caused by changes in, 361–363, 361f, 362f, 364f polycistronic, 376 recombinant DNA technology and, 397 relationship of to chromosomal DNA, 321f stability of, regulation of gene expression and, 394–395, 394f transcription starting point and, 342 variations in size/complexity of, 397, 399t modification of, 355–356 processing of, 352–355 alternative, in regulation of gene expression, 354, 355f, 393–394 in protein synthesis, 307–308, 309t ribosomal (rRNA), 307–308, 310–311, 341, 342t as peptidyltransferase, 368, 370t processing of, 355 small nuclear (snRNA), 308, 309t, 311, 341, 342t, 414 small stable, 311 splicing, 352–354, 414 alternative, in regulation of gene expression, 354, 354f, 393–394, 636 recombinant DNA technology and, 397, 398f structure of, 306–312, 308f, 309f, 311f, 312f synthesis of, 341–352 initiation/elongation/termination in, 342, 342f, 343–344, 344f transfer (tRNA), 308, 310, 312f, 341, 342t, 360–361, 361f aminoacyl, in protein synthesis, 368 anticodon region of, 359 processing and modification of, 355, 356 suppressor, 363 xenobiotic cell injury and, 631 RNA editing, 356 RNA polymerase III, 343t
- RNA polymerases, DNA-dependent, in RNA synthesis, 342–343, 342f, 343t
- RNA primer, in DNA synthesis, 328, 329f, 330f
- RNA probes, 402, 414
- RNAP. *See* RNA polymerases
- RNase. *See* Ribonucleases
- ROS (reactive oxygen species). *See* Free radicals
- Rotor syndrome, 283
- Rough endoplasmic reticulum glycosylation in, 524–525, 525f in protein sorting, 498, 499f, 500f protein synthesis and, 370 routes of protein insertion into, 505–507, 506f signal hypothesis of polyribosome binding to, 503–505, 504t, 505f
- rRNA. *See* Ribosomal RNA
- RT-PCR, 414
- RXR. *See* Retinoid X receptor
- Ryanodine, 563
- Ryanodine receptor, 563, 564f mutations in gene for, diseases caused by, 564–565, 565f, 630t
- RYS. *See* Ryanodine receptor
- S₁₀₀, 67
- S phase of cell cycle, DNA synthesis during, 333–335, 334f, 335t
- Saccharopine, in lysine catabolism, 256f, 258
- Salt (electrostatic) bonds (salt bridges/linkages), 7 oxygen binding rupturing, Bohr effect protons and, 44–45, 45f
- “Salvage” reactions in purine synthesis, 294, 295f, 297f in pyrimidine synthesis, 296
- Sanfilippo syndrome, 546t
- Sanger's method for DNA sequencing, 404, 405f for polypeptide sequencing, 24–25
- Sanger's reagent (1-fluoro-2,4-dinitrobenzene), for polypeptide sequencing, 25
- Sarcolemma, 556
- Sarcomere, 556–557, 557f
- Sarcoplasm, 556 of cardiac muscle, 566
- Sarcoplasmic reticulum, calcium level in skeletal muscle and, 563–564, 563f, 564f
- Saturated fatty acids, 111, 112, 112t in membranes, 417, 418f
- Saturation kinetics, 64f, 66 sigmoid substrate, Hill equation in evaluation of, 66–67, 67f
- Scavenger receptor B1, 210, 211f

- Scheie syndrome, 546r
 Schindler disease, 532–533, 533r
 Scrapie, 37
 Scruvy, 482t, 496
 collagen affected in, 38–39, 496, 538–539
 SDS-PAGE. *See* Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
 Se gene, 618
 Sec1 proteins, 511
 Sec61p complex, 504
 Second messengers, 76, 436–437, 437t, 457–468, 461t, 463t. *See also specific type*
 calcium as, 436–437, 437t, 457
 cAMP as, 147, 436, 437t, 457, 458–462, 460t, 462f
 cGMP as, 290, 436, 437t, 457, 462–463
 diacylglycerol as, 464, 465f
 inositol triphosphate as, 464–465, 464f, 465f
 precursors of
 phosphatidylinositol as, 115, 115f
 phospholipids as, 197
 Secondary structure, 31, 31–33, 32f, 33f, 34f
 peptide bonds affecting, 31, 31f
 supersecondary motifs and, 33
 Secretor (Se) gene, 618
 Secretory component, of IgA, 595f
 Secretory granules, protein entry into, 507, 507f
 Secretory (exocytotic) pathway, 498
 Secretory vesicles, 498, 500f
 D-Sedoheptulose, 106f
 Selectins, 528–530, 529f, 529t, 530f
 Selectivity/selective permeability, membrane, 415, 423–426, 423t, 424f, 425f, 426t
 Selenium, 496t
 in glutathione peroxidase, 88, 166
 Selenocysteine, synthesis of, 240, 240f
 Selenophosphate synthetase/synthase, 240, 240f
 Self-assembly
 in collagen synthesis, 537
 of lipid bilayer, 418
 Self-association, hydrophobic interactions and, 6–7
 Sensory neuropathy, in vitamin B₆ excess, 491
 Sepharose-lectin column chromatography, in glycoprotein analysis, 515r
 Sequential displacement reactions, 69, 69f
 Serine, 15r
 catabolism of, pyruvate formation and, 250, 252f
 conserved residues and, 54, 55t
 in cysteine and homoserine synthesis, 239, 239f
 in glycine synthesis, 238, 239f
 phosphorylated, 264
 synthesis of, 238, 238f
 tetrahydrofolate and, 492–494, 493f
 Serine 195, in covalent catalysis, 53–54, 54f
 Serine hydroxymethyltransferase, 250, 252f, 493–494
 Serine protease inhibitor, 589. *See also* α_1 -Antiprotease
 Serine proteases. *See also specific type*
 conserved residues and, 54, 55t
 in covalent catalysis, 53–54, 54f
 zymogens of, in blood coagulation, 600, 600t, 601
 Serotonin, 266–267, 621t
 Serpin, 589. *See also* α_1 -Antiprotease
 Serum prothrombin conversion accelerator (SPCA/factor VII), 599f, 600t, 601
 coumarin drugs affecting, 604
 Sex (gender), xenobiotic-metabolizing enzymes affected by, 630
 Sex hormone-binding globulin (testosterone-estrogen-binding globulin), 455, 455t, 583t
 SGLT 1 transporter protein, 475, 475f
 SGOT. *See* Aspartate aminotransferase
 SGPT. *See* Alanine aminotransferase
 SH2 domains. *See* Src homology 2 (SH2) domains
 SHBG. *See* Sex hormone-binding globulin
 Short interspersed repeat sequences (SINEs), 321–322, 414
 Shoshin beriberi, 489
 Shotgun sequencing, 634
 SI nuclease, in recombinant DNA technology, 400t
 Sialic acids, 110, 110f, 116, 169, 171f
 in gangliosides, 171f, 201, 203f
 in glycoproteins, 109t, 516t
 Sialidosis, 532–533, 533t, 546, 546t
 Sialoprotein, bone, 548t, 550
 Sialyl-Lewis^x, selectins binding, 530, 530f
 Sialylated oligosaccharides, selectins binding, 530
 Sickle cell disease, 363, 619
 pedigree analysis of, 409, 410f
 recombinant DNA technology in detection of, 408–409
 Side chain cleavage enzyme P450 (P450_{sc}), 438, 440f, 442
 Side chains, in porphyrins, 270, 271f
 Sigmoid substrate saturation kinetics, Hill equation in evaluation of, 66–67, 67f
 Signal. *See also* Signal peptide
 generation of, 456–457, 458f, 459f, 459t
 in recombinant DNA technology, 414
 transmission of. *See also* Signal transduction
 across membrane, 415, 431
 Signal hypothesis, of polyribosome binding, 503–505, 504t, 505f
 Signal peptidase, 504, 505f
 Signal peptide, 498, 503–504, 508t
 albumin, 583
 in protein sorting, 498–499, 499f, 500f, 503–504, 505, 505f
 Signal recognition particle, 504
 Signal sequence. *See* Signal peptide
 Signal transducers and activators of transcription (STATs), 467, 467f
 Signal transduction, 456–473
 GPI-anchors in, 528
 hormone response to stimulus and, 456, 457f
 intracellular messengers in, 457–468, 461t, 463t. *See also specific type*
 in platelet activation, 606, 606f
 signal generation and, 456–457, 458f, 459f, 459t
 transcription modulation and, 468–473, 470f, 471f, 472t
 Silencers, 348
 recombinant DNA technology and, 397
 Silencing mediator for RXR and TR (SMRT), 472t, 473
 Silent mutations, 361
 Silicon, 496t
 Simple diffusion, 423, 423t, 424f
 Simvastatin, 229
 SINES. *See* Short interspersed repeat sequences
 Single displacement reactions, 69, 69f
 Single nucleotide polymorphism (SNP), 414
 Single-pass membrane proteins, glycoporphins as, 615–616, 615f, 616f, 616t
 Single-stranded DNA, replication from, 326. *See also* DNA, replication/synthesis of
 Single-stranded DNA-binding proteins (SSBs), 326, 327, 327f, 328t
 Sister chromatid exchanges, 325, 325f
 Sister chromatids, 318, 319f
 Site-directed mutagenesis, in enzyme study, 58
 Site-specific DNA methylases, 398
 Site specific integration, 324
 Sitosterol, for hypercholesterolemia, 229
 Size exclusion chromatography, for protein/peptide purification, 21–22, 23f
 SK. *See* Streptokinase
 Skeletal muscle, 556, 568t. *See also* Muscle; Muscle contraction
 glycogen stores in, 573
 metabolism in, 125, 125f
 lactate production and, 139
 as protein reserve, 576
 slow (red) and fast (white) twitch fibers in, 574–576, 575t

- Skin
essential fatty acid deficiency affecting, 194–195
mutant keratins and, 578
vitamin D₃ synthesis in, 445, 446f, 484, 485f
- Sleep, prostaglandins in, 190
- Sliding filament cross-bridge model, of muscle contraction, 557–559, 558f
- Slow acetylators, 630
- Slow-reacting substance of anaphylaxis, 196
- Slow (red) twitch fibers, 574–576, 575t
- Sly syndrome, 546t
- Small intestine
cytochrome P450 isoforms in, 627
monosaccharide digestion in, 475, 475f
- Small nuclear RNA (snRNA), 308, 309t, 311, 341, 342t, 414
- Small nucleoprotein complex (snurp), 353
- Small stable RNA, 311
- Smoking
CYP2A6 metabolism of nicotine and, 628
cytochrome P450 induction and, 628
nucleotide excision-repair of DNA damage caused by, 337
- Smooth endoplasmic reticulum, cytochrome P450 isoforms in, 627
- Smooth muscle, 556, 568t
actin-myosin interactions in, 572t
contraction of
calcium in, 570–571, 571f
myosin-based regulation of, 570
myosin light chain phosphorylation in, 570
relaxation of
calcium in, 571
nitric oxide in, 571–573, 573f
- SMRT, 472t, 473
- SNAP (soluble NSF attachment factor) proteins, 509, 510f
- SNAP 25, 511
- SNARE proteins, 509, 510f, 511
- SNAREpins, 511
- SNP. *See* Single nucleotide polymorphism
- snRNA. *See* Small nuclear RNA
- Snurp (small nucleoprotein [snRNP] complex), 353
- Sodium, 496t
in extracellular and intracellular fluid, 416, 416t
permeability coefficient of, 419f
- Sodium-calcium exchanger, 463
- Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
for protein/peptide purification, 24, 24f, 25f
- red cell membrane proteins determined by, 614–615, 615f
- Sodium-potassium pump (Na⁺-K⁺ ATPase), 427–428, 428f
in glucose transport, 428, 429f
- Solubility point, of amino acids, 18
- Soluble NSF attachment factor (SNAP) proteins, 509, 510f, 511
- Solutions, aqueous, *K_a* of, 9
- Solvent, water as, 5, 6f
- Sorbitol, in diabetic cataract, 172
- Sorbitol dehydrogenase, 167, 169f
- Sorbitol intolerance, 172
- Sorbitol (polyol) pathway, 172
- Soret band, 273
- Southern blot transfer procedure, 305–306, 403, 404f, 414
- Southwestern blot transfer procedure, 403, 414
- SPARC (bone) protein, 548t
- Sparteine, CYP2D6 in metabolism of, 628
- SPCA. *See* Serum prothrombin conversion accelerator
- Specific acid/base catalysis, 51–52
- Specificity, enzyme, 49, 50f
- Spectrin, 615, 615f, 616f, 616t, 617
abnormalities of, 617
- Spectrometry
covalent modifications detected by, 27, 27f, 27t
for glycoprotein analysis, 514, 515t
- Spectrophotometry
for NAD(P)⁺-dependent dehydrogenases, 56, 56f
for porphyrins, 273–274
- Spectroscopy, nuclear magnetic resonance (NMR)
for glycoprotein analysis, 514, 515f
protein structure demonstrated by, 35–36
- Spermidine, synthesis of, 265–266, 266f
- Spermine, synthesis of, 265–266, 266f
- Spherocytosis, hereditary, 432t, 617, 617f
- Sphingolipidoses, 202–203, 203t
- Sphingolipids, 197
metabolism of, 201–202, 202f, 203f
clinical aspects of, 202–203, 203t
in multiple sclerosis, 202
- Sphingomyelins, 116, 116f, 201, 202f
in membranes, 417
membrane asymmetry and, 420
- Sphingophospholipids, 111
- Sphingosine, 116, 116f
- Spina bifida, folic acid supplements in prevention of, 494
- Spliceosome, 353, 414
- Spongiform encephalopathies, transmissible (prion diseases), 37
- Squalene, synthesis of, in cholesterol synthesis, 219, 221f, 222f
- Squalene epoxidase, in cholesterol synthesis, 220, 222f
- SR-B1. *See* Scavenger receptor B1
- SRC-1 coactivator, 472, 472t
- Src homology 2 (SH2) domains
in insulin signal transmission, 465, 466f, 467
in Jak/STAT pathway, 467, 467f
- SRP. *See* Signal recognition particle
- SRS-A. *See* Slow-reacting substance of anaphylaxis
- ssDNA. *See* Single-stranded DNA
- Staphylococcus aureus* V8 protease, for polypeptide cleavage, 25, 26t
- STAR. *See* Steroidogenic acute regulatory protein
- Starch, 107, 108f
glycemic index of, 474
hydrolysis of, 474
- Starling forces, 580
- Starvation, 80
clinical aspects of, 236
fatty liver and, 212
ketosis in, 188
metabolic fuel mobilization in, 232–234, 234f, 234t
triacylglycerol redirection and, 208
- Statin drugs, 229
- STATs (signal transducers and activators of transcription), 467, 467f
- Stearic acid, 112t
- Steely hair disease (Menkes disease), 588
- Stem cells, differentiation of to red blood cells, erythropoietin in regulation of, 610, 611f
- Stereochemical (-sn-) numbering system, 114, 115f
- Stereoisomers. *See also* Isomerism of steroids, 117, 118f
- Steroid nucleus, 117, 117f, 118f
- Steroid receptor coactivator 1 (SRC-1 coactivator), 472, 472t
- Steroid sulfates, 201
- Steroidogenesis. *See* Steroids, synthesis of
- Steroidogenic acute regulatory protein (STAR), 442
- Steroids, 117–118, 117f, 118f, 119f. *See also* specific type
adrenal. *See also* Glucocorticoids; Mineralocorticoids
synthesis of, 438–442, 440f, 441f
calcitriol as, 484
receptors for, 436
stereoisomers of, 117, 118f
storage/secretion of, 453, 454t
synthesis of, 123f, 124, 438, 438–445, 439t, 440f, 441f
transport of, 454–455, 455t
vitamin D as, 484
- Sterol 27-hydroxylase, 226
- Sterols, 117
in membranes, 417
- Stickler syndrome, 553

- Sticky end ligation/sticky-ended DNA, 299, 398, 400f, 401f, 414
- "Sticky foot," 527
- "Sticky patch," in hemoglobin S, 46, 46f
- Stoichiometry, 60
- Stokes radius, in size exclusion chromatography, 21
- Stop codon, 369f, 370
- Stop-transfer signal, 506
- Strain, catalysis by, 52
- Streptokinase, 605, 605f, 606t
- Streptomycin, 106
- Striated muscle, 556, 557, 557f. *See also* Cardiac muscle; Skeletal muscle
- actin-myosin interactions in, 572t
- Stroke, with mitochondrial encephalopathy and lactic acidosis (MELAS), 100–101
- Strong acids, 9
- Strong bases, 9
- Structural proteins, 535
- Stuart-Prower factor (factor X), 599f, 600, 600t
- activation of, 599–600, 599f
- coumarin drugs affecting, 604
- Substrate analogs, competitive inhibition by, 67–68, 67f
- Substrate level, phosphorylation at, 94
- Substrate shuttles
- coenzymes as, 50
- in extramitochondrial NADH oxidation, 99, 100f
- Substrate specificity, of cytochrome P450 isoforms, 627
- Substrates, 49
- competitive inhibitors resembling, 67–68, 67f
- concentration of, enzyme-catalyzed reaction rate affected by, 64, 64f, 65f
- Hill model of, 66–67, 67f
- Michaelis-Menten model of, 65–66, 66f
- conformational changes in enzymes caused by, 52, 53f
- multiple, 69–70
- Succinate, 131–133, 132f
- Succinate dehydrogenase, 87, 132f, 133
- inhibition of, 67–68, 67f
- Succinate semialdehyde, 267, 268f
- Succinate thiokinase (succinyl-CoA synthetase), 131, 132f
- Succinic acid, pK_a value of, 12t
- Succinyl-CoA, in heme synthesis, 270–273, 273f, 274f, 275f, 276f
- Succinyl-CoA:acetoacetate-CoA transferase (thiophorase), 133, 186, 186f
- Succinyl-CoA synthetase (succinate thiokinase), 131, 132f
- Sucrose-isomaltase complex, 475
- Sucrose, 106–107, 107f, 107t
- glycemic index of, 474
- Sugars. *See also* Carbohydrates
- amino (hexosamines), 106, 106f
- glucose as precursor of, 169, 171f
- in glycosaminoglycans, 109, 169, 171f
- in glycosphingolipids, 169, 171f
- interrelationships in metabolism of, 171f
- classification of, 102, 102t
- deoxy, 106, 106f
- "invert," 107
- isomerism of, 102–104, 103f
- nucleotide, in glycoprotein biosynthesis, 516–517, 516t
- "Suicide enzyme," cyclooxygenase as, 194
- Sulfate
- active (adenosine 3'-phosphate-5'-phosphosulfate), 289, 289f, 629
- in glycoproteins, 515
- in mucins, 520
- Sulfatide, 116
- Sulfation, of xenobiotics, 629
- Sulfo(galacto)-glycerolipids, 201
- Sulfogalactosylceramide, 201
- accumulation of, 203
- Sulfonamides, hemolytic anemia precipitated by, 613
- Sulfonylurea drugs, 188
- Sulfotransferases, in glycosaminoglycan synthesis, 543
- Sunlight. *See* Ultraviolet light
- Supercoils, DNA, 306, 332, 333f
- Superoxide anion free radical, 90–91, 611–613, 613t. *See also* Free radicals
- production of in respiratory burst, 622
- Superoxide dismutase, 90–91, 119, 611–613, 613t, 622
- Supersecondary structures, 33
- Suppressor mutations, 363
- Suppressor tRNA, 363
- Surfactant, 115, 197
- deficiency of, 115, 202
- SV40 viruses, cancer caused by
- Swainsonine, 527, 527t
- Symport systems, 426, 426f
- Syn conformers, 287, 287f
- Synaptobrevin, 511
- Syntaxin, 511
- Synthesis, rate of (k_s), control of, 74
- $t_{1/2}$. *See* Half life
- T_3 . *See* Triiodothyronine
- T_4 . *See* Thyroxine
- T_m . *See* Melting temperature/transition temperature
- T lymphocytes, 591
- t-PA. *See* Tissue plasminogen activator
- T Ψ C arm, of tRNA, 310, 312f, 360, 361f
- t-SNARE proteins, 509, 511
- T (taut) state, of hemoglobin
- 2,3-bisphosphoglycerate stabilizing, 45, 45f
- oxygenation and, 43, 43f, 44f
- T tubular system, in cardiac muscle, 566
- T-type calcium channel, 567
- TAFs. *See* TBP-associated factors
- Talin, 540, 541f
- Tandem, 414
- Tandem mass spectrometry, 27
- Tangier disease, 228t
- TaqI, 399t
- Target cells, 434–435, 435t
- receptors for, 435, 436f
- Targeted gene disruption/knockout, 412
- Tarui's disease, 152t
- TATA binding protein, 346, 349f, 350, 351
- TATA box, in transcription control, 345, 345f, 346, 347f, 348, 348f, 351t
- Taurochenodeoxycholic acid, synthesis of, 226f
- Taut (T) state, of hemoglobin
- 2,3-bisphosphoglycerate stabilizing, 45, 45f
- oxygenation and, 43, 43f, 44f
- Tay-Sachs disease, 203t
- TBG. *See* Thyroxine-binding globulin
- TBP. *See* TATA binding protein
- TBP-associated factors, 346, 350, 351
- T Ψ C arm, of tRNA, 310, 312f, 360, 361f
- TEBG. *See* Testosterone-estrogen-binding globulin
- Telomerase, 318
- Telomeres, 318, 319f
- Temperature
- chemical reaction rate affected by, 62, 62f
- enzyme-catalyzed reaction rate affected by, 63
- in fluid mosaic model of membrane structure, 422
- Temperature coefficient (Q_{10}), enzyme-catalyzed reactions and, 63
- Template binding, in transcription, 342, 342f
- Template strand DNA, 304, 306, 307f
- transcription of in RNA synthesis, 341–343, 342f
- Tenase complex, 600–601
- Terminal transferase, 400t, 414
- Termination
- chain
- in glycosaminoglycan synthesis, 543
- in transcription cycle, 342, 342f
- of protein synthesis, 369f, 370
- of RNA synthesis, 342, 342f, 344, 344f
- Termination signals, 359
- for bacterial transcription, 346, 346f
- for eukaryotic transcription, 349–350

- Tertiary structure, 33–35, 35f
stabilizing factors and, 35
- Testes, hormones produced by, 437, 442, 443f. *See also specific type*
- Testosterone, 439f, 440f
binding of, 455, 455t
metabolism of, 442, 444f
synthesis of, 442, 443f
- Testosterone–estrogen-binding globulin (sex hormone-binding globulin), 455, 455t, 583t
- Tetracycline (tet) resistance genes, 402, 403f
- Tetrahedral transition state intermediate, in acid-base catalysis, 52, 53f
- Tetrahydrofolate, 492, 493–494, 493f
- Tetraiodothyronine (thyroxine/T₄), 438, 447
storage/secretion of, 453, 454t
synthesis of, 447–449, 448f
transport of, 454, 454t
- Tetramers
hemoglobin as, 42
histone, 314–315, 315
- Tetroses, 102, 102t
- Tf. *See* Transferrin
- TFIIA, 350
- TFIIB, 350
- TFIID, 346, 350, 351
in preinitiation complex formation, 352
- TFIIE, 350
- TFIIF, 350
- TFIIH, 350
- TFPI. *See* Tissue factor pathway inhibitor
- TfR. *See* Transferrin receptor
- Thalassemias, α and β , 47, 610t
recombinant DNA technology in
detection of, 408f, 409, 409t
- Thanatophoric dysplasia, 551t
- Theca cells, hormones produced by, 442
- Theobromine, 289
- Theophylline, 289
hormonal regulation of lipolysis and, 215
- Thermodynamics
biochemical (bioenergetics), 80–85. *See also* ATP
glycolysis reversal and, 153–155
laws of, 80–81
hydrophobic interactions and, 7
- Thermogenesis, 217, 217f
diet-induced, 217, 478
- Thrombin, 217, 217f
- Thrombomodulin, 482t, 488–489, 489f
in citric acid cycle, 133
cofactors derived from, 51
deficiency of, 482t, 489
pyruvate metabolism affected by, 140, 143, 489
- Thiamin diphosphate, 140, 166, 488–489, 489f
- Thiamin pyrophosphate, 50
- Thiamin triphosphate, 489
- Thick (myosin) filaments, 557, 558f
- Thin (actin) filaments, 557, 558f, 559f
- Thioesterase, 173
- 6-Thioguanine, 290, 291f
- Thiokinase (acyl-CoA synthetase)
in fatty acid activation, 180, 181f
in triacylglycerol synthesis, 199, 214f, 215
- Thiol-dependent transglutaminase. *See* Transglutaminase
- Thiol ester plasma protein family, 590
- Thiolase, 181, 182f, 184
in mevalonate synthesis, 219, 220f
- Thiophorase (succinyl-CoA-acetoacetate-CoA transferase), 133, 186, 186f
- Thioredoxin, 294
- Thioredoxin reductase, 294, 297f
- Threonine, 15t
catabolism of, 253f, 255
phosphorylated, 264
requirements for, 480
- Thrombin, 601, 602, 603f
antithrombin III affecting, 603–604
circulating levels of, 602–603
conserved residues and, 55t
formation of fibrin and, 601–602, 603f
in platelet activation, 606, 606f
- Thrombolysis
laboratory tests in evaluation of, 608
t-PA and streptokinase in, 605, 605f, 606t
- Thrombomodulin, in blood coagulation, 600t, 603, 607, 607t
- Thrombosis, 598–608. *See also* Coagulation
antithrombin III in prevention of, 603–604
circulating thrombin levels and, 602–603
endothelial cell products in, 607, 607t
hyperhomocysteinemia and, folic acid supplements in prevention of, 494
phases of, 598
in protein C or protein S deficiency, 603
t-PA and streptokinase in management of, 605, 605f, 606t
types of thrombi and, 598
- Thromboxane A₂, 113f
in platelet activation, 606f, 607
- Thromboxanes, 112, 113f, 190, 192
clinical significance of, 196
cyclooxygenase pathway in formation of, 192, 193f
- Thymidine, 288t
base pairing of in DNA, 303, 304, 305f
Thymidine monophosphate (TMP), 288t
Thymidine-pseudouridine-cytidine (TPC)
arm, of tRNA, 310, 312f, 360, 361f
- Thymidylate, 303
- Thymine, 288t
- Thyroglobulin, 447, 449
- Thyroid-binding globulin, 454, 583t
- Thyroid hormone receptor-associated proteins (TRAPs), 472t, 473
- Thyroid hormone response element, 459t
storage/secretion of, 453, 454t
- Thyroid hormones, 437, 438
in lipolysis, 215, 216f
receptors for, 436, 471
synthesis of, 447–449, 448f
transport of, 454, 454t
- Thyroid-stimulating hormone (TSH), 437, 438, 439f, 449
- Thyroperoxidase, 449
- Thyrotropin-releasing hormone (TRH), 438, 439f
- Thyroxine (T₄), 438, 447
storage/secretion of, 453, 454t
synthesis of, 447–449, 448f
transport of, 454, 454t
- Thyroxine-binding globulin, 454, 454t
- TIF2 coactivator, 472, 472t
- Tiglyl-CoA, catabolism of, 261f
- TIM. *See* Translocase-of-the-inner membrane
- Timnodonic acid, 113t
- Tin, 496t
- Tissue differentiation, retinoic acid in, 483
- Tissue factor complex, 601
- Tissue factor (factor III), 599f, 600t, 601
- Tissue factor pathway inhibitor, 601
- Tissue plasminogen activator (alteplase/t-PA), 604–605, 605, 605f, 606t, 607t
- Tissue-specific gene expression, 385
- Tirin, 566t
- TMP (thymidine monophosphate), 288f, 288t
- Tocopherol, 482t, 486, 486f. *See also* Vitamin E
as antioxidant, 91, 119, 486, 487f
deficiency of, 482t
- Tocotrienol, 486, 486f. *See also* Vitamin E
- Tolbutamide, 188
- TOM. *See* Translocase-of-the-outer membrane
- Topogenic sequences, 506
- Topoisomerases, DNA, 306, 328t, 332, 332f
- Total iron-binding capacity, 586
- Toxemia of pregnancy of ewes, ketosis and, 188
- Toxic hyperbilirubinemia, 283
- Toxoperoxyl free radical, 486
- TpC. *See* Troponin C
- TpI. *See* Troponin I
- TpT. *See* Troponin T
- TR activator molecule 1 (TRAM-1 coactivator), 472, 472t
- TRAM (translocating chain-associated membrane) protein, 504

- TRAM-1 coactivator, 472, 472t
- Trans fatty acids, 113–114, 192
- Transaldolase, 166
- Transaminases. *See* Aminotransferases
- Transamination, 124, 124f
- in amino acid carbon skeleton catabolism, 249–250, 249f, 250f, 251f
- citric acid cycle in, 133–134, 134f
- in urea biosynthesis, 243–244, 243f
- Transcortin (corticosteroid-binding globulin), 454–455, 455t
- Transcript profiling, 412
- Transcription, 306, 350–352, 351t, 414
- activators and coactivators in control of, 351, 351t
- bacterial promoters in, 345–346, 345f
- control of fidelity and frequency of, 344–350
- eukaryotic promoters in, 346–349, 347f, 348f, 349f
- in gene expression regulation, 383–387, 391, 392t. *See also* Gene expression
- hormonal regulation of, 457, 458f, 468–473, 470f, 471f, 472t
- initiation of, 342–343, 342f
- NF- κ B in regulation of, 468, 469f
- nuclear receptor coregulators in, 471–473, 472t
- recombinant DNA technology and, 397, 398f
- retinoic acid in regulation of, 483
- reverse, 414
- in retroviruses, 308, 332–333
- in RNA synthesis, 306, 307f, 341–343, 342f
- Transcription complex, eukaryotic, 306, 350–352, 351t
- Transcription control elements, 351, 351t
- Transcription domains, definition of, 387
- Transcription factors, 351, 351t
- nuclear receptor superfamily, 469–471, 471f, 472t
- Transcription start sites, alternative, 393–394
- Transcription unit, 342, 345f
- Transcriptional intermediary factor 2 (TIF2 coactivator), 472, 472t
- Transcriptome information, 412, 414
- Transfection, identification of
- enhancers/regulatory elements and, 386
- Transfer RNA (tRNA), 308, 310, 312f, 341, 342t, 360–361, 361f. *See also* RNA
- aminoacyl, in protein synthesis, 368
- anticodon region of, 359
- processing and modification of, 355, 356
- suppressor, 363
- Transferases, 50
- Transferrin, 478, 583t, 584–586, 585f, 585t
- Transferrin receptor, 586
- Transfusion, ABO blood group and, 618
- Transgenic animals, 385, 411–412, 414
- enhancers/regulatory elements identified in, 386
- Transglutaminase, in blood coagulation, 600, 600t, 602, 603f
- Transhydrogenase, proton-translocating, as source of intramitochondrial NADPH, 99
- Transient insertion signal. *See* Signal peptide
- Transition mutations, 361, 361f
- Transition state intermediate, tetrahedral, in acid-base catalysis, 52, 53f
- Transition states, 61
- Transition temperature/melting temperature (T_m), 305, 422
- Transketolase, 163–166, 165f, 170
- erythrocyte, in thiamin nutritional status assessment, 489
- thiamin diphosphate in reactions involving, 166, 170, 488–489
- Translation, 358, 414
- Translocase-of-the-inner membrane, 499
- Translocase-of-the-outer membrane, 499
- Translocating chain-associated membrane (TRAM) protein, 504
- Translocation, protein, 499
- Translocation complexes, 499
- Translocon, 504
- Transmembrane proteins, 419
- ion channels as, 423–424, 425f, 426t
- in red cells, 615–616, 615f, 616f, 616t
- Transmembrane signaling, 415, 431
- in platelet activation, 606, 606f
- Transmissible spongiform encephalopathies (prion diseases), 37
- Transport proteins, 454–456, 454t, 455t, 583t
- Transport systems/transporters. *See also specific type*
- active, 423, 423t, 424f, 426–427, 427–428, 428f
- ADP/ATP, 95, 98f
- ATP-binding cassette, 210, 211f
- in cotranslational insertion, 506, 506f
- disorders associated with mutations in genes encoding, 512t, 513
- exchange, 98–100, 98f, 99f
- facilitated diffusion, 423, 423t, 424f, 426–427, 427, 427f
- glucose. *See* Glucose transporters
- in inner mitochondrial membrane, 98–100, 98f, 99f
- membrane, 426–431, 426f
- for nucleotide sugars, 517
- Transport vesicles, 498, 508–511, 509t, 510f
- Transposition, 324–325
- retrotransposons/retrotransposons and, 321, 637
- Transthyretin, 583t, 590
- Transverse asymmetry, 511
- Transversion mutations, 361, 361f
- TRAPs, 472t, 473
- Trauma, protein loss and, 480
- TRE. *See* Thyroid hormone response element
- Trehalase, 475
- Trehalose, 107t
- TRH. *See* Thyrotropin-releasing hormone
- Triacylglycerols (triglycerides), 114, 115f, 205
- digestion and absorption of, 475–477, 476f
- excess of. *See* Hypertriglycerolemia
- interconvertability of, 231
- in lipoprotein core, 205, 207f
- metabolism of, 123, 123f, 125–126, 126f
- in adipose tissue, 214–215, 214f
- fatty liver and, 212, 213f
- hepatic, 211–212, 213f
- high-density lipoproteins in, 209–211, 211f
- hydrolysis in, 197
- reduction of serum levels of, drugs for, 229
- synthesis of, 198f, 199
- transport of, 207, 208f, 209f, 210f
- Tricarboxylate anions, transporter systems for, 98–99
- lipogenesis regulation and, 178
- Tricarboxylic acid cycle. *See* Citric acid cycle
- Triglycerides. *See* Triacylglycerols
- Triiodothyronine (T_3), 438, 447
- storage/secretion of, 453, 454t
- synthesis of, 447–449, 448f
- transport of, 454, 454t
- Trimethoprim, 494
- Trinucleotide repeat expansions, 322
- Triokinase, 167, 169f
- Triose phosphates, acylation of, 123
- Trioses, 102, 102t
- Triphosphates, nucleoside, 287, 287f
- Triple helix structure, of collagen, 38, 38f, 535–539, 536f
- Triplet code, genetic code as, 358, 359t
- tRNA. *See* Transfer RNA
- Tropocollagen, 38, 38f
- Tropoelastin, 539
- Tropomyosin, 557, 559f, 562
- in red cell membranes, 616t
- as striated muscle inhibitor, 563
- Troponin/troponin complex, 557, 559f, 562
- as striated muscle inhibitor, 563
- Troponin C, 562